TWI243210B - A quality control method for assessing herbal compositions - Google Patents

A quality control method for assessing herbal compositions Download PDF

Info

Publication number
TWI243210B
TWI243210B TW089104268A TW89104268A TWI243210B TW I243210 B TWI243210 B TW I243210B TW 089104268 A TW089104268 A TW 089104268A TW 89104268 A TW89104268 A TW 89104268A TW I243210 B TWI243210 B TW I243210B
Authority
TW
Taiwan
Prior art keywords
herb
array
batch
composition
herbal
Prior art date
Application number
TW089104268A
Other languages
Chinese (zh)
Inventor
Patric C Kung
Young Chi Cheng
Original Assignee
Univ Yale
Phytoceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/024851 external-priority patent/WO2000024934A1/en
Application filed by Univ Yale, Phytoceutica Inc filed Critical Univ Yale
Application granted granted Critical
Publication of TWI243210B publication Critical patent/TWI243210B/en

Links

Abstract

The present invention provides the tools and methodologies necessary to guide the standardization of herbal compositions, to determine which specific components of an herbal composition are responsible for any particular biological activity, to predict the biological activities of a particular herbal composition, and for the development of improved herbal therapeutics. This invention provides the tools and methodologies for creating, maintaining, improving and utilizing Herbal BioResponse Arrays (HBR Arrays), wherein the HBR Arrays constitute data sets associated with particular herbal compositions. The HBR Arrays of the present invention may include information on the plant-related parameters of the herbal constituents, marker information collected following the exposure of a biosystem to the herbal composition, and biological response information collected following the exposure of a biosystem to the herbal composition.

Description

1243210 A7 五、發明說明( 經 濟 部 智 慧 財 產 局 員 工 消 費 合 作 社 印 製 整的理論。 西方醫藥一般係使用純化的化合物(無論是天然的或 口成的)’其大部分針對—單_的生理標的。但是,傳統 中醫藥所採用的組成物通常係由基於獨立和整體觀針對體 〃的I的之複方的草藥和化合物所組成。傳統中醫藥 要係以不同的組合和配方來運用加工過的原始天然產物 ,在引起較少的副作用之下治療不同的證候。傳統中醫藥 的強大潛力尚待被大多數的世人所了解。 在-典型傳統中醫處方中的草藥係被委以主藥、次藥 (含臣藥、佐藥和使藥)之職。主藥係於治療一疾病的病因 或主症時產生主要治療作用的藥物。臣藥協助加強主藥的 作用並於兼症的治療中起主要的治療作用。佐藥有三種. 1)加強主藥和臣藥之治療作用或治療第三種兼症者;2)減 低或排除主藥和臣藥之毒性或其他副作用者;3)作用於非 議主藥所影響之互補標的組織者。使藥係引導其他諸 藥直達病所和/或協同和調和處方中或配方中其他藥物的 作用:相反於大部分之由單一植物的一或多個部位所構成 的草某或外加物者,傳統中醫藥的預期效果係針對於多 的組織。 m 著名的中醫藥方,用於治療氣喘的麻黃湯, 係由麻黃、桂枝、㈣仁和甘草所組成。麻黃係為主藥, 其散寒、發汗、促it肺氣之運行以平主證氣喘。桂枝為纪 藥’以助麻黃發汗之力,並可溫經絡以通陽氣以減輕頭】 和體痛。苦杏仁為佐藥,有助於肺氣之肅降並加強麻黃平 臣 本紙張尺度適用中國國家標準[NS)A4規格(210 x 297公爱)1243210 A7 V. Description of the invention (Theories printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs. The western medicine generally uses purified compounds (whether natural or oral). However, the composition used in traditional Chinese medicine is usually composed of herbal medicines and compounds based on the independent and holistic view of body I. Traditional Chinese medicine is processed by different combinations and formulations. The original natural products treat different symptoms with fewer side effects. The powerful potential of traditional Chinese medicine has yet to be understood by most people in the world. The herbal medicine department in the typical traditional Chinese medicine prescription is entrusted with the main medicine, Secondary medicines (including ministerial medicines, adjuvant medicines, and medicines). The main medicine is the medicine that produces the main therapeutic effect in the treatment of the cause or main disease of a disease. The medicine helps to strengthen the role of the main medicine and treat the comorbidities It plays the main therapeutic role. There are three kinds of adjuvants. 1) Strengthen the therapeutic effect of the main medicine and the minister medicine or treat the third comorbidity; 2) Reduce or exclude the main medicine and the minister The toxicity or other side effects are; 3) Effect of the action of the non-complementary to the target meeting organizer main drug. Make the drug system direct other medicines to the disease center and / or synergize and reconcile the role of other medicines in the prescription or formula: in contrast to most grasses or additives that are composed of one or more parts of a single plant, The expected effect of traditional Chinese medicine is targeted at multiple organizations. m The famous Chinese medicine prescription, Mahuang Decoction for the treatment of asthma, is made up of ephedra, osmanthus, coix seed and licorice. Ephedra is the main medicine, and its function of dispersing cold, sweating, and promoting lung qi is to relieve asthma. Guizhiweiji's medicine helps ephedra sweat, and can warm the meridians to relieve yang and relieve body pain]. Bitter almond is an adjuvant, which helps to reduce lung qi and strengthen ephedra. This paper size applies Chinese national standard [NS) A4 (210 x 297 public love)

裝----l· — (請先閱讀背面之注意事項再填寫本頁) 訂---------Loading ---- l · — (Please read the notes on the back before filling this page)

1243210 五、發明說明(6 ) 生理功能所需之能量係來自氣、血和津液,而氣血、津液 之生成和代謝亦賴於斯。傳統中醫藥之處方考慮及藥草對 氣和血之治療上的效用。 傳統中醫藥主張經脈、絡脈和其附屬部分係分布於全 身。藥草於病理標的上發生作用並達成病情之改善係經由 此。例如··麻黃作用於肺和膀胱之經絡以發汗而止咳和利 尿。如上所述,針灸之臨床亦受經絡理論之指導。 簡言之,儘管傳統中醫藥中,任一藥草的天性和性質 皆可被歸於陰或陽及五行中之一行,其經由經脈和絡脈作 用並藉由氣血和津液轉輸俾以在標的(如臟和腑)上獲致療 效。致病因子可假扮而成病媒,經由相同的經脈和絡脈對 五臟和六腑的功能造成負面的影響並因而造成疾病。 經由以上的討論,很清楚的是,傳統中醫藥術語是哲 學性的觀念與解剖學的觀念一樣多。例如:心代表在傳統 中醫藥中所描述之功能有所貢獻的人體中許多組織、器官 和系統。因此,心的觀念需要多重方面的資料組合以描述 傳統中醫藥之每一觀念。一旦此事被完成之後,一種分子 整體觀醫學可能被發展出來。 美國管制程序 在美國,膳食補充物(如植物產品、維他命和礦物質 、月女基酸及組織萃取物)係被1994年之膳食補充物健康及 教育法案(DSHE法案)所管制。此法案將膳食補充物的成 分自聯口口、藥斗勿及化粧品法案之下視為食品添加物的 管制中抽離。此外,DSHE法案要求食品和藥物管理局 ) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -Τ--I J ----3^^農* ---L----訂----I---I - (請先閱讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 9 12432101243210 V. Description of the Invention (6) The energy required for physiological functions comes from Qi, blood and body fluid, and the production and metabolism of Qi, blood and body fluid also depend on this. The traditional Chinese medicine takes into account the therapeutic effects of herbs on qi and blood. Traditional Chinese medicine advocates that the meridians, collaterals, and their subordinates are distributed throughout the body. It is through this that herbs work on pathological targets and achieve improvement in the condition. For example, ephedra acts on the meridians of the lungs and bladder to sweat and relieve cough and diuresis. As mentioned above, the clinical practice of acupuncture is also guided by meridian theory. In short, although in the traditional Chinese medicine, the nature and nature of any herb can be attributed to one of the yin or yang and the five elements. Such as viscera and pupae). The pathogenic factors can be disguised as vectors, and through the same meridians and collaterals, they negatively affect the functions of the five internal organs and the six organs and thus cause disease. From the above discussion, it is clear that traditional Chinese medicine terminology is as philosophical as anatomical. For example, the mind represents many tissues, organs, and systems in the human body that contribute to the functions described in traditional Chinese medicine. Therefore, the concept of mind requires a multifaceted combination of data to describe each concept of traditional Chinese medicine. Once this is done, a molecular holistic medicine may be developed. US Regulatory Procedures In the United States, dietary supplements (such as plant products, vitamins and minerals, menstrual acid, and tissue extracts) are regulated by the Dietary Supplement Health and Education Act of 1994 (DSHE Act). This bill separates the ingredients of dietary supplements from the control of food supplements under the Linked Foods, Drugs and Cosmetics Act. In addition, the DSHE Act requires the Food and Drug Administration) This paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) -T--IJ ---- 3 ^^ 农 * --- L-- --Order ---- I --- I-(Please read the phonetic on the back? Matters before filling out this page) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 9 1243210

請 先 閱 讀 背 面 之 注 意 I 4 項 再 填 I裝 頁 I ί 訂Please read the note on the back I 4 before filling in the page I I order

Γ 經濟部智慧財產局員工消費合作社印製 l2432l〇 A7 ' ---------— —____ 五、發明說明(11 ) 利用氣相層析一質譜儀和原子吸收光譜等法,加州健 康科學、食品及藥品部分(Calif0rnia Department of 汕Γ Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs, 2424l0A7 '---------—— —____ V. Description of the Invention (11) Using gas chromatography-mass spectrometry and atomic absorption spectrometry, California Health Science, Food and Drugs (Calif0rnia Department of Shantou

Sciences,Food and Drug Branch)最近檢測了由藥草店所獲 得之亞洲藥品的污染物[R.j·郭,1998年新英格蘭醫學= 諸第 339 期第 847 頁(R.J· κ〇5 1998, N. Engl· j· Med 339.847)]。在他所檢測之260樣品中,至少有83個(百分之 32)含有不明藥物或重金屬,且23個具有至少一種摻雜物 。利用高效液相層析、氣相層析和質譜儀法,一種市面上 可獲得之8種藥草的組合物(pC-SpES)被發現含有雌性素 生成性有機物[狄寶拉等人,1998年,新英格蘭醫學雜誌 (DiPaola et al.,1998, N. Engl. J. Med. 339:785-791)]。研 究者結論認為:PC-SPES具有潛在的雌性素生成活性,並 且服用PC-SPES之前列腺癌患者可能會授亂了標準治療的 結果並可能經歷臨床上有顯著性的負作用。不同樣本之傳 統中藥“威靈仙,,之氣相層才斤資料亦被收集且亦探討這些樣 品之抗發炎活性的相關性[魏等人,化學型式之辨識應用 於傳統中藥“威靈仙,,的品質評估之研究,藥學學報 26(10):772-772(1991)]。此研究並未提供相關的藥草生物 反應陣列資料,如時程、劑量依賴反應、控管樣品以證實 生物標識物之區分能力,其亦未採用再反覆式資料建立程 序’以建立-用於鑑別藥草組成物之作用的易理解的資料 庫。 蛋白質濃度之改變亦已被用來鑑別藥草組成物或藥草 特疋成刀的作用。例如:來自周邊血液單核球對顆粒球 本紙張尺錢财目國家標準(CNS)A4規格^7297公釐) 裝---------訂--------- (請先閱讀背面之注意事項再填寫本頁) 14 A7 1243210 B7_ 五、發明說明(12) 細胞株刺激因子(G-CSF)之產生被發現係依何種特定的中 藥草被加入培養而改變[Yamashiki等人,1992年臨床實驗 免疫學雜誌37(2)83-90 (Yamashiki et al·,1992, J. Chin· Lab. Immunol· 37(2):83-90)]。以人工培養的人類上皮角質細胞 被以曰本最常用的草藥小柴胡湯處理後,間白素-1 α受體 之係顯著地被正向調控[松本等人,1997年,日本藥理學 雜諸 73(4):333-336 (Matsumoto et al.9 1997,Jph. J. Pharmacol. 73(4):333-336)] 〇 巨嗤細胞之Fc gamma 11/111 受體和補體受體3之表現被以Toki-shakuyakusan (TSS)處 理後係被提高者(J.C. Cyong 1997,Nippon Yakurigaku Zasshillo (Suppl. 1):87-92)。漢防己鹼,一種分離自一天 然中國藥草的生物鹼,抑制老鼠肺泡巨噬細胞中之訊息誘 發性NF-kappa B活化作用[陳等人1997年,生化生物物理 研究通訊 231(1):99-102 (Chen et al.,1997,Biochem. Biophys. Res. Commun. 231(1):99-102)]。藥草賽雷多 (Sairei-to)、澤篇(alismatis rhizoma)(目名 “Takusha”)和茯茶( 目名“Bukuryou”)以抗腎小球基底膜腎炎抑制大鼠中内皮素 -1之合成和表現(Hattori等人,1997年,曰本藥理學雜誌 第39期第9卷第121-128頁)。 信息核糖核酸水平之增加或減少亦已被用作為不同藥 草及藥草成分之作用的指示物。青洋參(QYS)(—種具有抗 顛癎性質的傳統中藥)以及二苯海因鈉之腹膜内注射降低 了大鼠在紅藻胺酸所誘發的慢性顛癇性質之阿爾發和貝他 管蛋白信息核糖核酸及海馬c-fos信息核糖核酸(郭等人, 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 裝Sciences, Food and Drug Branch) recently tested contaminants in Asian medicines obtained from herb stores [Rj · Guo, 1998, New England Medicine = Various Issues No. 339, p. 847 (RJ · κ〇5 1998, N. Engl J Med Med 339.847)]. Of the 260 samples he tested, at least 83 (32%) contained unknown drugs or heavy metals, and 23 had at least one dopant. Using commercially available high-performance liquid chromatography, gas chromatography, and mass spectrometry, a commercially available composition of 8 herbs (pC-SpES) was found to contain estrogen-producing organic compounds [Dibaola et al., 1998 , New England Journal of Medicine (DiPaola et al., 1998, N. Engl. J. Med. 339: 785-791)]. Researchers have concluded that PC-SPES has potential estrogen-generating activity, and that patients with prostate cancer who take PC-SPES may confuse the results of standard treatments and may experience clinically significant negative effects. Different samples of traditional Chinese medicine "Wai Ling Xian," and gas phase layer data were also collected and the correlation of the anti-inflammatory activity of these samples was also explored. [Wei et al. Identification of chemical types was applied to traditional Chinese medicine "Wai Ling Xian Research on the Evaluation of Quality, Chinese Journal of Pharmacy 26 (10): 772-772 (1991)]. This study did not provide relevant herb bioresponse array data, such as time course, dose-dependent response, and control samples to verify the ability to distinguish between biomarkers. It also did not use a repetitive data creation process' to establish-for identification An easy-to-understand database of the effects of herbal compositions. Changes in protein concentration have also been used to identify the effect of herb composition or herb-specific knives. For example: from the surrounding blood mononuclear ball to particle ball paper rule (CNS) A4 specifications ^ 7297 mm) installed --------- order --------- ( (Please read the precautions on the back before filling this page) 14 A7 1243210 B7_ V. Description of the invention (12) The production of cell line stimulating factor (G-CSF) was found to be changed depending on which specific Chinese herb was added to the culture [ Yamashiki et al., 1992 Journal of Clinical Experimental Immunology 37 (2) 83-90 (Yamashiki et al., 1992, J. Chin. Lab. Immunol. 37 (2): 83-90)]. After artificially cultured human epithelial keratinocytes were treated with the most commonly used herbal herb Xiao Chai Hu Tang, the melanin-1 alpha receptor system was significantly positively regulated [Matsumoto et al., 1997, Japanese Pharmacology Zhu 73 (4): 333-336 (Matsumoto et al. 9 1997, Jph. J. Pharmacol. 73 (4): 333-336)] 〇 Fc gamma 11/111 receptors and complement receptors 3 of macrophage cells The performance was improved after being treated with Toki-shakuyakusan (TSS) (JC Cyong 1997, Nippon Yakurigaku Zasshillo (Suppl. 1): 87-92). Tetrandrine, an alkaloid isolated from a natural Chinese herb, inhibits message-induced NF-kappa B activation in mouse alveolar macrophages [Chen et al. 1997, Biochemical Research Letters 231 (1): 99 -102 (Chen et al., 1997, Biochem. Biophys. Res. Commun. 231 (1): 99-102)]. Herbs Sairie-to, alismatis rhizoma (Takusha) and 茯 茶 (Bukuryou) inhibit glomerular basement membrane nephritis and inhibit endothelin-1 synthesis in rats And performance (Hattori et al., 1997, Japanese Journal of Pharmacology, Vol. 39, No. 9, pp. 121-128). Increases or decreases in information RNA levels have also been used as indicators of the effects of different herbs and herb ingredients. Green ginseng (QYS) (a traditional Chinese medicine with anti-turning properties) and intraperitoneal injection of sodium diphenylhein reduce the alfa and beta of chronic eclampsia induced by kainic acid in rats Tubulin information ribonucleic acid and hippocampal c-fos information ribonucleic acid (Guo et al., This paper size applies Chinese National Standard (CNS) A4 specification (210 X 297 mm) (Please read the precautions on the back before filling in this page) Hold

*. ml· ϋ ϋ I Jr、 ϋ «ϋ ·ϋ I I 經濟部智慧財產局員工消費合作社印製 15 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(13) 1993年,傳統中國醫學雜誌第13期第4卷第281-286頁;郭 等人’ 1995年,傳統中國醫學雜誌第15期第4卷第292_296 頁;郭等人,1996年,傳統中國醫學雜誌第16期第1卷第 48-51頁)。以黃蓍皂苷(一種由黃蓍所純化的成分)對培養 的人類臍靜脈内皮細胞(HUVECs)之處理降低了胞漿素元 活化因子抑制因子第丨型(PAM)專一性的信息核糖核酸表 現且增加組織型胞漿素元活化因子(t-PA)專一性的信息核 糖核酸[章等人,1997年,血管研究期刊第34期第4卷第 273-280 頁(Zhang et al.,1997, J· Vase. Res. 34(4):273-280)] 。一由人蔘之根所分離的成分被發現為一由人類單核細胞 和由人類單核細胞系THP-1所產生之間白素-8(IL_8)的有 效的誘發劑,此誘發伴隨著提高的IL-8信息核糖核酸表現 (Sonoda等人,1998年,免疫藥理學第38期第287-294頁) 〇 目前在互補去氧核糖核酸(cDNA)微陣列科技方面之 進步使基因表現上訊息之大量平行採集成為可能。此種程 序已被用來研究細胞周期、生化途徑、酵母菌中之基因組 級表現、細胞生長、細胞分化、對於一單一化合物之細胞 反應’以及遺傳疾病(包含疾病之肇始和進行)[M.徐納等 人,1998年,生物科技趨勢 16:301 (M. Schena et al.,1998, TIBTECH 16:301)]。現今並無研究者已經試圖應用這些新 科技來研究全藥草處理和添加之分子作用。 某些研究者已經試圖特徵化由所擇定之藥草所分離之 主要活性成分之作用。例如:以自三七(panax n〇t〇ginseng) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 16 —I,—;—· I —^— II 訂——— (請先閱讀背面之注咅?事項再填寫本頁) A7 B7 1243210 五、發明說明(Η) 所純化之三七苷(NR1)對組織型胞漿素元活化因子合成產 生-劑量-和時間-依賴性升高[張等人,1994年,動脈硬化 和血栓 14(7): 1040-1046 (Zhang et al.,1994, Arteriosclerosis and Thrombosis 14(7):1040-1046)]。以三七菩(NR1)處理 並未改變尿激酶型胞漿素元活化因子和胞漿素元活化因子 抑制因子-1抗原合成,也不會影響胞漿素元活化因子抑制 因子-1在細胞外基質中的堆積。當人類臍靜脈内皮細胞 (HUVECs)被以NR1處理時,組織型胞漿素元活化因子訊 息核糖核酸(mRNA)升高為兩倍,而胞漿素元活化因子抑 制因子-1特定訊息核糖核酸(mRNA)之表現並未顯著地被 三七苷(NR-1)影響。由於針對三七(P· notoginseng)之大部 分的研究係涉及其與其他藥草之混合物,研究者注意到當 治療性地被使用於人時,欲評估其結果如何與生體内之狀 況相關聯實為困難。(Id·,at 1045,second volume,first paragraph)。此外,由於研究者只有研究藥草中之一主要 成分,欲由此研究確定全藥草之分子作用或藥草之成分間 的交互作用係為不可能。*. ml · ϋ ϋ I Jr, ϋ ϋ ϋ ϋ II Printed by the Consumers ’Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs 15 1243210 Printed by the Employees’ Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 B7 V. Invention Description (13) 1993, Traditional Chinese Medical Journal, Vol. 13, Vol. 4, pp. 281-286; Guo et al., 1995, Traditional Chinese Medical Journal, Vol. 15, Vol. 4, pp. 292_296; Guo et al., 1996, Traditional Chinese Medical Journal, No. 16 Volume 1 pp. 48-51). Treatment of cultured human umbilical vein endothelial cells (HUVECs) with baicalin (a component purified from baicalone) reduces cytoplasmin activation factor inhibitor-type (PAM) -specific information RNA performance And increase the specific RNA of tissue type cytoplasmin activation factor (t-PA) [Zhang et al., 1997, Journal of Vascular Research, Vol. 34, No. 4, pp. 273-280 (Zhang et al., 1997 J. Vase. Res. 34 (4): 273-280)]. A component isolated from the roots of human cormorants was found to be a potent inducer of interleukin-8 (IL_8) produced by human monocytes and produced by the human monocyte cell line THP-1. This induction was accompanied by Improved IL-8 information RNA performance (Sonoda et al., 1998, Immunopharmacology, 38, pp. 287-294) o Current advances in complementary DNA (cDNA) microarray technology have enabled gene performance Mass collection of information is possible in parallel. Such procedures have been used to study the cell cycle, biochemical pathways, genomic expression in yeast, cell growth, cell differentiation, cellular response to a single compound ', and genetic diseases (including the onset and progression of the disease) [M. Xu Na et al., 1998, Biotechnology Trends 16: 301 (M. Schena et al., 1998, TIBTECH 16: 301)]. No researcher has attempted to apply these new technologies to study the molecular effects of all-herb treatment and addition. Some researchers have attempted to characterize the effects of the main active ingredient isolated from the chosen herb. For example: since Panax n0toginseng, this paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 16 —I, —; — · I — ^ — II Order ——— (Please read the note on the back? Matters before filling out this page) A7 B7 1243210 V. Description of the invention (i) Purified notoginsenoside (NR1) produces tissue-type cytosolic element activating factor synthesis-dose-and time -Increased dependence [Zhang et al., 1994, Arteriosclerosis and Thrombosis 14 (7): 1040-1046 (Zhang et al., 1994, Arteriosclerosis and Thrombosis 14 (7): 1040-1046)]. Treatment with Panax notoginseng (NR1) did not change the synthesis of urokinase-type cytoplasmin-activating factor and cytoplasmin-activating factor-inhibitory factor-1 antigen, nor did it affect cytoplasmin-activating factor-inhibitory factor-1 in cells. Accumulation in the outer matrix. When human umbilical vein endothelial cells (HUVECs) were treated with NR1, tissue-type cytoplasmin activation factor message ribonucleic acid (mRNA) increased twice, while cytoplasmin activation factor inhibitor-1 specific message ribonucleic acid (MRNA) performance was not significantly affected by notoginsenoside (NR-1). Since most of the research on P. notoginseng involves mixtures with other herbs, researchers have noticed that when used therapeutically in humans, they want to assess how the results relate to conditions in the body. It's really difficult. (Id ·, at 1045, second volume, first paragraph). In addition, since the researcher only studies one of the main components of the herb, it is impossible to determine the molecular effect of the whole herb or the interaction between the components of the herb through this study.

Dobashi等人(1995年,神經科學通訊第197期第235-238 頁[Dobashi et al·,(Neuroscience Letters 197:235-238)] 研究柴胡劑(一種用來治療腎病徵候群、支氣管性氣喘及 慢性風濕性關節炎之中草藥)之主成分中之兩種的作用。 SS-d之投予以劑量依賴方式提升了血漿促腎上腺皮質激素 (ACTH)水平,腦下腺前葉中胜肽族信息核糖核酸(mRNA) 水平以及老鼠下視丘中促腎上腺皮質激素釋放因子信息核 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -17 - (請先閱讀背面之注咅?事項再填寫本頁)Dobashi et. And chronic rheumatoid arthritis), which are two of the main ingredients. The dose of SS-d in a dose-dependent manner increases plasma adrenocorticotropic hormone (ACTH) levels, and the peptide family information ribose in the anterior gland Nucleic acid (mRNA) levels and information on adrenocorticotropic hormone release factor in mouse inferior colliculus. The paper size applies to Chinese National Standard (CNS) A4 (210 X 297 mm). (Fill in this page again)

裝-----r---訂--------- I 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 1243210 A7 --—---2Z______ 五、發明說明(17) 之生物反應資訊。 本發明對於為了特定的藥草組成物建立標準化的藥草 生物反應陣列提供所需要的工具和方法學,其中該標準化 的藥草生物反應陣列係被用作基準標識,藉此以評估相似 或不同批次的藥草組成物。本發明進一步對更新和維持該 藥草生物反應陣列提供所需的工具和方法學。本發明之特 別的實施例係涉及反覆式程序,其中追加的批次之藥草組 成物之資料、追加的植物相關的資料、追加的標識物資訊 和/或追加的生物反應資訊係定期地被追加至該標準化的 藥草生物反應陣列。因此,本發明係在一前瞻性的基礎上 對創造、維持、更新提供工具和方法學。 本發明係對於指導藥草組成物之標準化、判定藥草組 成物之何種特定的成分係相對應於特別的生物活性、預測 藥草組成物之生物活性、改良式藥草治療術之開發、調整 或修飾一藥草組成物、鑑定保有所需之生物活性之批次藥 草組成物中之特定的分子、判定一已知的藥草組成物之何 種藥草成分可以從該已知的藥草組成物中被排除而保持或 促進該已知的藥草組成物之所需的生物活性、為批次藥草 組成物鑑定新的用途和先前未知的生物活性以及利用批次 藥草組成物之所預測的生物活性來協助包含藥草成分和合 成化學樂物之治療術的設計(包含使用組合化學之方法的 治療術之設計)提供所需的工具和方法學。 更特別地,本發明係為了藥草組成物提供建立標準化 藥草生物反應陣列(HBR陣列)之方法,其中該方法包含: 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 20 ----*5----r----裝-----^----訂--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 l2432l〇 ____^__ 五、發明說明(l〇 1) 以至少一種已知的生物反應擇定一藥草組成物; 2) 將一生物系統暴露於一批次之藥草組成物並針對2 或更多種標識物收集資料; 3) 將步驟2)之標識物資料儲存為一 HBR陣列; 4) 使用2或更多種與步驟2)中所使用之相同或不同的 標識物對一或更多附加批次之藥草組成物重覆步驟 2)和 3)。 5) 連結在步驟3)和4)中所獲得的HBR陣列;以及 6) 分析步驟5)之連結過的HBr陣列的對藥草組成物產 生一標準化的HBR陣列,其中該標準化的HBR陣列 具有與至少一種該藥草組成物之已知的生物反應相 關聯的2或更多種標識物之資料。本發明進一步提 供進一步包含將一生物系統暴露於一或更多批次之 藥草組成物、、收集針對一或更多種生物反應之資料 以及將所收集的生物反應資料追加至該藥草組成物 之標準化的HBR陣列中之諸等方法。 本發明提供評估藥草組成物之諸方法,其中該等方法 匕S將生物系統暴露於一批次之藥草組成物且針對二或 更多種標識物收集資料;以及將所收集的標識物資料與一 作為该批次藥草組成物之標準化HBR陣列之相同或實質上 相同之標準化HBR陣列相比較。 本务明提供一用於預測一藥草組成物之生物活性的系 統,其包含: 1)一包含一或更多不同型式之細胞、組織、器官或生 本紙張尺度適用中g家標準(CNS)A4規格(21G χ 297公釐) -------- —— IJ——丨—h 丨丨丨訂-------1 (請先閱讀背面之注音?事項再填寫本頁) 1243210 A7 ____B7 五、發明說明(l9) 體外檢驗物之生物系統; 2) —批次藥草組成物; (請先閱讀背面之注意事項再填寫本頁) 3) 二或更多種分子標識物; 4) 一種用於將該生物系統暴露於該批次藥草組成物且 測量該分子標識物之分化性反應的方法; 5) —用於分析及儲存該分子標識物之分化性反應測量 資料,俾以創造一該批次藥草組成物之藥草生物反 應陣列(HBR陣列)資料組之電腦處理器(包含記憶 體); 6) —用於將該批次藥草組成物之HBR陣列與一或更多 的先前儲存的HBR陣列相比較,俾以預測該藥草組 成物之生物活性的電腦處理器(包含記憶體),其中 該被用來產生一或更多的先前儲存的HBR陣列之藥 草組成物之生物活性係為已知者。 圖示說明 第1圖 經濟部智慧財產局員工消費合作社印製 第1圖係提供一用於建立一任何擇定的藥草組成物之 標準化藥草生物反應陣列(HBR陣列)的基本方法步驟之流 程圖。該圖為了便於了解,係以其最基本的形式被表示。 如此處所討論者,流程圖中之任一途徑皆可被重覆進行。 此外,包含於一方框中之任何資訊皆可被用來引導有關為 任何其它方框收集資料的決定。以此方式,貫串該流程, 為數甚多的回饋迴路亦為可能者。 本紙張尺度適用中國國豕4示準(CNS)A4規格(210 X 297公璧) 22 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(20 ) 第2圖 第2圖k供一用於為了任何批次藥草組成物建立一藥 草生物反應陣列(HBR陣列)以及用於將此批次hbr陣列與 一由標準化HBR陣列所擇定之資訊次組相比較之基本方法 步驟流程圖。此圖為了易於了解係以其最基本的型式被呈 現。如此處所論及者,該流程之任一途徑皆可被重覆進行 。進一步s之,包含於一方框中之任何資訊皆可被用來引 導有關為任何其它方框收集資料的決定。以此方式,貫串 該流程’為數甚多的回饋迴路亦為可能者。 第3圖 第3圖提供一用於建立和使用一主資料組之基本方法 步驟的流程。此圖為了易於了解,係以其最基本的形式被 呈現。如此處所論及者,該流程之任一途徑皆可被重覆進 行。進-步言之,包含於-方框中之任何資訊皆可被用來 引導有關為任何其他方框收集資料的決定。以此方式,貫 串該流程,為數甚多的回饋迴路亦為可能者。 第4圖 用於不同的藥草組成物之西方轉印圖。 A·無藥草組成物 B. 黃芩湯A (HQTA) (0.2毫克/毫升) C. 黃芩湯A (4毫克/毫升) D. 黃芩湯Β (0·2毫克/毫升) Ε·黃芩湯Β (4毫克/毫升) F·黃芩(0.2毫克/毫升) ---I L--—丨訂---------_ (請先閱讀背面之注音?事項再填寫本頁)Packing ----- r --- Order --------- I Printed by the Employees 'Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs Printed by the Employees' Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 1243210 A7 -------- 2Z______ Fifth, invention description (17) biological response information. The present invention provides the necessary tools and methodologies for establishing a standardized herb bio-reaction array for a specific herb composition, wherein the standardized herb bio-reaction array is used as a reference mark to evaluate similar or different batches of Herbal composition. The invention further provides the tools and methodologies needed to update and maintain the herb bioreactor array. A special embodiment of the present invention relates to a iterative process in which additional batches of herbal composition information, additional plant-related information, additional identifier information, and / or additional biological response information are added periodically. To this standardized herb bioreaction array. Therefore, the present invention provides tools and methodologies for creation, maintenance, and renewal on a forward-looking basis. The present invention is directed to the standardization of the herbal composition, to determine which specific composition of the herbal composition corresponds to a particular biological activity, to predict the biological activity of the herbal composition, to develop, adjust or modify an improved herbal therapy. Herbal composition, identification of specific molecules in a batch of herbal composition that retains the required biological activity, determination of which herbal ingredient of a known herbal composition can be excluded from the known herbal composition and maintained Or to promote the required biological activity of the known herb composition, to identify new uses and previously unknown biological activities for the batch herb composition, and to use the predicted biological activity of the batch herb composition to assist in the inclusion of the herb component The design of therapies for synthetic and musical chemistry (including the design of therapies that use combinatorial chemistry) provides the tools and methodologies needed. More specifically, the present invention provides a method for establishing a standardized herb bio-response array (HBR array) for a herbal composition, wherein the method includes: The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 20 ---- * 5 ---- r ---- install ----- ^ ---- order --------- (Please read the notes on the back before filling this page) Economy Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Commerce 1224l10 ____ ^ __ 5. Description of the Invention (101) Select a herb composition based on at least one known biological response; 2) Expose a biological system to a batch Herb composition and collect data for 2 or more identifiers; 3) store the identifier information of step 2) as an HBR array; 4) use 2 or more of the same as those used in step 2) or Different markers repeat steps 2) and 3) for one or more additional batches of herb composition. 5) concatenating the HBR array obtained in steps 3) and 4); and 6) analyzing the concatenated HBr array in step 5) to produce a standardized HBR array for the herb composition, wherein the standardized HBR array has Information on at least one known biological response associated with the herb composition of two or more markers. The invention further provides further comprising exposing a biological system to one or more batches of the herb composition, collecting data for one or more biological responses, and adding the collected biological response data to the herb composition. Various methods in a standardized HBR array. The present invention provides methods for evaluating herb compositions, wherein the methods expose biological systems to a batch of herb compositions and collect data for two or more identifiers; and the collected identifier data and A standardized HBR array that is the same or substantially the same as the standardized HBR array of the herb composition is compared. The present invention provides a system for predicting the biological activity of a herb composition, which includes: 1) A standard containing Chinese Standards (CNS) containing one or more different types of cells, tissues, organs or raw paper A4 specification (21G χ 297mm) -------- ---- IJ—— 丨 —h 丨 丨 丨 Order ------- 1 (Please read the note on the back? Matters before filling out this page ) 1243210 A7 ____B7 V. Description of the invention (l9) Biological system of in vitro test substance; 2) — Batch herb composition; (Please read the notes on the back before filling this page) 3) Two or more molecular identifiers 4) a method for exposing the biological system to the batch of herb composition and measuring the differentiation response of the molecular marker; 5)-for analyzing and storing the differentiation response measurement data of the molecular marker, (2) A computer processor (including memory) of the Herbal Bioreactor Array (HBR Array) data set of the batch of herb composition; 6) — used to combine the HBR array of the batch of herb composition with one or more Comparison of many previously stored HBR arrays to predict the herb The biologically active substance into a computer processor (including memory), which is used to generate the one or more previously stored drug grass HBR arrays consisting of a biologically active homologue of those known. Illustrated Figure 1. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. Figure 1. Provides a flow chart of the basic method steps for establishing a standardized herbal bioreactor array (HBR array) for any selected herb composition. . This figure is shown in its most basic form for easy understanding. As discussed herein, any of the approaches in the flowchart can be repeated. In addition, any information contained in one box can be used to guide decisions about collecting information for any other box. In this way, a number of feedback loops are possible through the process. This paper size is applicable to China National Standard 4 (CNS) A4 (210 X 297 public) 22 1243210 Printed by the Consumers ’Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 B7 V. Description of the invention (20) Figure 2 Figure 2 A flow chart of the basic method steps for establishing a herb bioreactor array (HBR array) for any batch of herbal composition and comparing this batch of hbr array with a subgroup of information selected by a standardized HBR array. This figure is presented in its most basic form for easy understanding. As discussed here, either way of this process can be repeated. Furthermore, any information contained in one box can be used to guide decisions about collecting information for any other box. In this way, numerous feedback loops running through this process are also possible. Figure 3 Figure 3 provides a flow of basic method steps for creating and using a master data set. This figure is presented in its most basic form for easy understanding. As discussed here, any one of these processes can be repeated. Further, any information contained in the box can be used to guide decisions about collecting information for any other box. In this way, a number of feedback loops are possible through the process. Figure 4 Western transfers for different herb compositions. A. Herb-free composition B. Huang Zhi Tang A (HQTA) (0.2 mg / ml) C. Huang Zhi Tang A (4 mg / ml) D. Huang Zhi Tang B (0.2 mg / ml) Ε Huang Zhi Tang B ( 4 mg / ml) F · Scutellaria baicalensis (0.2 mg / ml) --- I L --- 丨 order ---------_ (Please read the note on the back? Matters before filling out this page)

23 l2432l〇 A7 五、 發明說明(21 ) G·黃芩(4毫克/亳升) 第5圖 經濟部智慧財產局員工消費合作社印製 白芍(Paeonie lactiflora pallus)之高效液相層析圖。 第6圖 大棗(Ziziphi fructus)之高效液相層析圖。 發明之詳細說明 除非另有定義,此處所使用之所有的技術和科學術語 具有與任一習知本發明所屬之技藝者所共同了解之相同的 意義。雖然類似或等同於此處所描述之任何方法和材料可 以被使用於本發明之實施或測試,較佳之方法及材料係為 所被描述者。 發明總覽 如上所述,本發明係為針對有用於預測一藥草組成物 之生物反應的工具和方法。更特別的是,本發明提供建立 藥草生物反應陣列(HBR陣列)資料庫以及用來運用此等資 料庫俾以增進有效的以藥草為主的治療術之設計的方法二 本發明之目的係為用於藥草組成物之製備、測試和投藥之 藥草生物反應陣列之總體的設計、創立、改良和利用,以 及指引新藥草組成物之開發和現存的藥草組成物之新穎的 用途。 、、 植物測定法 就此處所使用者言之,視其所被使用處之上下文而定 ,植物測定法係指利用生物資訊技術和統計學的方法以提 示出藥草組成物之成分之錢和定量狀況或者係指為了提 2清先閱讀背面之>i音?事項再填寫本頁} 裝 —訂---------· 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 24 _ 1243210 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(22 ) 示此等狀況而被開發的實際的資料庫。 藥草生物反應陣列 就此處所使用者而言,一藥草生物反應陣列包含與一 藥草組成物相關之二或更多種觀察或測量之資料組。此藥 草生物反應陣列可包含在組成物中針對其植物之定性和定 量資料(植物相關資料),在將一生物系統暴露至此藥草組 成物(包含一劑量依賴性研究)後所得到的標識物資訊以及 在將一生物系統暴露於此藥草組成物後所得到的生物反應 資料。在任何特別的藥草生物反應陣列中之資料皆可以在 2或3維空間被統計分析。 藥草生物反應陣列可被設計為批次藥草生物反應陣列 和標準化生物反應陣列。批次藥草生物反應陣列係為與一 藥草組成物之特定的批次有關之資料的陣列。標準化藥草 生物反應陣列係為與一標準化藥草組成物相關之資料的陣 列。 主資料組 就此處所使用者而言,主資料組一詞係指作為基準組 資料之資料組,藉此為了相同或不同的藥草組成物不同的 其它組資被比較抑或分析。通常,主資料組係利用生物科 技技術而被建立,以確定藥草組成物之某些遺傳或蛋白質 狀況。因此,主資料組經常,但非總是以一基因組或蛋白 質組之資料組為主。例如··去氧核糖核酸Dna微陣列結 果可以為被用來與其他,從屬性或次要資料組相化。 次要或從屬資料組 ^紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公髮) 裝-----^—訂--------- (請先閱讀背面之注意事項再填寫本頁) 25 1243210 A7 智 慧 財 產 局 員 工 消 作 社 印 製 五、發明說明(23 ) 就此處所使用者而言,“次要資料組,,或“從屬資料組,, 係指一或更多種被用於與主資料相化比較的資料組。經常 ’但非說是,此次要資料組將包含藉由更多的信號方法所 收集的針對一藥草組成物的資料。例如:次要或從屬資料 組可包含-組由更多的傳統手段所獲得之植物相關的資料 。植物相關資料的例子包含,但不限於,藥草組成物中之 藥草的屬名/種名,在該組成物中藥草之特別的植物部份 以及藥草所分布的地理位置。另一次要資料組的例子可以 包含在以一或多種不同量之藥草組成物處理後,一組細胞 、組織、器官或有機體之生物反應。此等生物反應或一完 整有機體的例子可以包含,但不限定於:細胞毒性研究、 酵素處理研究、生長速度、體重增或減、運動技能上的變 化和心智能力上的改變。 藥草 技術面而言,一藥草係為一小型、非木質化(即肉質 莖)、一年生或多年生之種子植物,而每一生長季之尾聲 其所有地上部枯死。藥草係以其藥用、香氣或芳香品質2 被珍視。由於此字眼係更被普遍地使用,且由於此字眼係 被用於此處,一 “藥草,,係指具有一食品添加物、醫療、藥 物、治療或延長生命用途的任何植物或植物部位。因此, 就此處所使用者而言,一藥草並非被限定於藥草之植物學 上的定義,而是指用於此等目的之任何植物產物、植物或 植物部份,包含植物界(包含草、灌木、亞灌木和樹木)= 任何植物種或亞種之任何植物或植物部位。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐 1243210 經濟部智慧財產局員工消費合作社印製 A7 五、發明說明(24 用於藥草組成物中之植物部位包含,但不限於··種子 、葉、莖、樹枝、樹幹、芽、花、鱗莖、球莖、塊莖、根 莖、蔓、根、果實、毬果、漿果,形成層和樹皮。 藥草組成物 就此處所使用者言之,一,,藥草組成物,,係指包藥草、 草本植物或藥草植物部位之任何組成物。因此,就此處所 使用者而言,一藥草組成物係為包含藥草食物補充劑、草 藥、藥草類藥物和醫用食品之任何藥草配製劑。藥草組成 物之例子包含但不限於以下之成份:一單一植物種之全株 植物或植物部位,多種植物種之全株植物或植物部份,由 一單一植物種所衍生之多種成分,由多種植物種所衍生之 多種植物成分或這些不同的成分之任何組合。為了對不同 的藥草組成物作一完全的回顧,參見,例如:基張黃,中 國藥草之藥理學,CRC出版社(1993年)[Kee Chang Huang23 l2432l0 A7 V. Description of the invention (21) G. Scutellariae (4 mg / ml) Figure 5 High performance liquid chromatography chart of Paeonie lactiflora pallus printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. Figure 6. High-performance liquid chromatography of Ziziphi fructus. Detailed Description of the Invention Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by any person skilled in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are those described. Summary of the Invention As described above, the present invention is directed to tools and methods for predicting the biological response of a herb composition. More specifically, the present invention provides a method for establishing a herb bioresponse array (HBR array) database and a method for using these databases to enhance the design of an effective herb-based therapy. The purpose of the present invention is to The overall design, creation, improvement, and utilization of herbal bioreactor arrays for the preparation, testing, and administration of herbal compositions, as well as directing the development of new herb compositions and novel uses of existing herb compositions. Phytometry is based on the words used by the users here, depending on the context in which it is used. Phytometry refers to the use of bioinformatics and statistical methods to indicate the money and quantitative status of the components of the herb composition. Or is it to read > i on the back for the sake of clarity? Please fill in this page again for matters} Binding-binding --------- · This paper size is applicable to China National Standard (CNS) A4 (210 X 297 mm) 24 _ 1243210 A7 B7 Employees ’Intellectual Property Bureau, Ministry of Economic Affairs The cooperative prints V. Invention Description (22) An actual database developed to show these conditions. Herbal Bioreactor Array For the purposes herein, a Herbal Bioreactor Array contains a data set of two or more observations or measurements related to a herb composition. The herb bio-response array may contain qualitative and quantitative data (plant-related data) on the plant in the composition, and information about the identifier obtained after exposing a biological system to the herb composition (including a dose-dependent study) And biological response data obtained after exposing a biological system to the herb composition. The data in any particular herb bioreactor array can be analyzed statistically in 2 or 3 dimensions. Herb bioreactor arrays can be designed as batch herb bioreactor arrays and standardized bioreactor arrays. A batch herb bio-reaction array is an array of data related to a particular batch of a herb composition. Standardized Herbal Bioreactor Array is an array of information related to a standardized herbal composition. Master Data Set For the purposes of this user, the term master data set refers to the data set that serves as the baseline set of data, in order to compare or analyze other sets of data for the same or different herb composition. Generally, master data sets are established using biotechnological techniques to determine certain genetic or protein conditions of the herb composition. Therefore, master data sets are often, but not always, data sets of a genomic or proteomic group. For example ... DNA microarray results can be used to phase with other, secondary or secondary data sets. Secondary or subordinate data group ^ The paper size is applicable to China National Standard (CNS) A4 (210 X 297). Packing ----- ^-Order --------- (Please read the note on the back first Please fill out this page again for details) 25 1243210 A7 Printed by the Consumers' Club of Intellectual Property Bureau V. Invention Description (23) For the users here, "secondary data group, or" subordinate data group, "means one or More data sets are used for comparison with master data. Often, but not to say, this time the primary data set will contain data for a herb composition collected by more signalling methods. For example: secondary or subordinate data sets may contain-sets of plant-related data obtained by more traditional means. Examples of plant-related information include, but are not limited to, the genus / species name of the herb in the herb composition, the particular plant part of the herb in the composition, and the geographical location where the herb is distributed. Another example of a secondary data set may include the biological response of a group of cells, tissues, organs or organisms after treatment with one or more different amounts of the herbal composition. Examples of such biological responses or a complete organism may include, but are not limited to: cytotoxicity studies, enzyme treatment studies, growth rate, weight gain or loss, changes in motor skills, and changes in mental capacity. Herbs Technically, a herb is a small, non-lignified (ie, fleshy stalk), annual or perennial seed plant, and at the end of each growing season, all its parts die up. Herbs are prized for their medicinal, aromatic or aromatic qualities2. As this term is more commonly used, and because it is used here, a "herb" refers to any plant or plant part that has a food additive, medical, pharmaceutical, therapeutic or prolonged life use. Therefore, for the users here, a herb is not limited to the botanical definition of the herb, but refers to any plant product, plant or plant part used for these purposes, including the plant kingdom (including grass, shrubs) , Subshrubs and trees) = any plant species or any plant or plant part of the subspecies. This paper size applies to China National Standard (CNS) A4 specifications (210 X 297 mm 1243210, printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs, A7) V. Description of the invention (24 Plant parts used in herbal compositions include, but are not limited to, seeds, leaves, stems, branches, trunks, buds, flowers, bulbs, tubers, rhizomes, vines, roots, fruits, Capsules, berries, forming layers and bark. Herbal composition, as used herein by the user, refers to a medicinal herb, herb, or herb Any composition of a plant part. Therefore, for the purposes of this application, a herb composition is any herb formulation that includes herb food supplements, herbs, herbs and medical foods. Examples of herb compositions include but Not limited to the following components: whole plants or plant parts of a single plant species, whole plants or plant parts of multiple plant species, multiple ingredients derived from a single plant species, multiple plants derived from multiple plant species Ingredients or any combination of these different ingredients. For a complete review of different herbal compositions, see, for example: Ke Zhang Huang, Chinese Herbal Pharmacology, CRC Press (1993) [Kee Chang Huang

The Pharmacology 〇f Chinese Herbs,CRC Press(1993)], 此處截有其全貌。各種不同的藥草組成物之代表性例子係 被提供於以下之段落。 從18世紀中葉起在英國包含有柳樹皮的藥草組成物已 被用來治療發熱。在柳樹皮中之活性成分係為一苦味的糖 苷’稱為水楊素,當其水解時產生糖和水楊酸醇。阿斯匹 靈(乙醯水楊酸)和似阿斯匹靈類藥物(如ibupr〇fen)此等常 被統稱為非固醇類抗發炎藥物(NASAIDs)常常被用來治療 疼痛’發熱和發炎。繡線菊是另一種含有水楊酸之藥草。 以柳樹皮或繡線菊對風濕性及類風濕性症狀之治療需要消 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 27 裝----l·! (請先閱讀背面之注意事項再填寫本頁) tr---------ΜΨ, 經濟部智慧財產局員工消費合作社印製 1243210 A7 _____B7 五、發明說明(25 ) 耗大量的由這些植物所製成的藥草茶。整個白楊種(即白 楊樹和灌木)亦含有水楊酸之先質且白楊木芽已被使用於 抗發炎、抗發熱和麻醉之醫藥用途。 美國專利已經發給用於不同疾病以及其他侵犯人類和 動物等與健康相關的問題之治療的藥草組成物。例如,美 國專利第5,417,979號揭露一包含一藥草之混合物(含千金 藤(Stephania)和甘草(Glycyrrhiza)等物種)及此等物之萃取 物的組成物’其被用做一食欲刺激劑和用於疼痛之治療。 包含甘草(Glycyrrhiza uralensis)之藥草組成物已被發現對 於濕疹、乾癬、搔癢、和皮膚之發炎反應有用(美國專利 第5,466,452號)。美國專利第5,595,743號揭露含有甘草 (Glycyrrhiza)、和豬簽草、槐花、百部和防己,用於不同 的哺乳類動物疾病之治療(包含炎症和風濕性關節炎)之不 同的藥草組成物。眼睛發炎可以用一含有植物鹼一漢防己 鹼之藥學組成物治療(美國專利第5,627,195號)。美國專利 第5,683,697號揭露一具有抗發炎、抗發熱、袪痰或鎮咳 作用之藥學組成物,其中該組成物包含楝(Meiia)、白芷 (Angelica)石斛:鳳仙花、桔柑、桑寄生、青葙、自前 (Cynanchum)和珊瑚菜等物種之植物部位。一包含山姜、 菝窫、青牛胆、疾藜、睡茄、和薑之根、根莖和/或植株 之萃取物藥草組成物已被發現可降低或緩解與風濕性關節 炎、骨關節、活動性關節炎有關之症狀和用於降低前發炎 性細胞激素(美國專利第5,683,698號)。 藥草組成物係適用於許多形式,包含膠囊、錠劑或膜 本紙張尺度適用中國國豕標準(CNS)A4規格(21〇 x 297公董) 28 ---τ----r ----- I---^--11 訂--------- (請先閱讀背面之注意事項再填寫本頁) 1243210 A7 經濟部智慧財產局員工消費合作社印製 五、發明說明(26 衣錠、丸劑、萃取液或酊劑、粉末、新鮮或乾燥物植物或 植物部位、製備好的煎劑、藥汁、藥霜或藥膏、精油戋此 等形式之任何的組合。草藥係藉由不同的方法中之任何一 種被投藥,&含:口服、直腸投帛、非經腸投藥、經腸投 藥、經皮投藥、靜脈注射、經餵食管投藥和局部投藥。 由本發明所涵蓋已藥草組成物包含亦含有非藥草成分 之藥草組成物。此種非藥草成分包含,但不限於:全昆蟲 和昆蟲部位、蟲類、動物或昆蟲排泄物、天然或原油、氨 之石炭酸鹽、酒石酸鹽 '酒、水、甘油、固醇類、藥學品、 維他命、營養萃取物、乳漿、鹽類和膠質。 、為了要口服投#,所揭露之藥草組成物可以採取的形 式,如:以傳統方法,與普遍可接受的賦形劑如枯合劑( 如預膠質化玉米澱粉、聚乙烯基料_或㈣基甲基纖 維素)、填充劑(如乳糖、微結晶纖維素或磷酸鈣)、潤滑 劑(如硬脂酸鎂’滑石或二氧化矽)、崩散劑(如馬鈐薯澱 粉或澱粉羥乙酸鈉)或濕潤劑(如硫酸月桂酸鈉)、增滑劑 二人工和天然香料及甜味劑、人工或天然色素和染料以及 安定劑。此藥草組成物可進一步被配製成以一此項技藝中 所熟知且如美國專利第4,69〇,825號和第5,〇55,3〇〇號中所 :及之時間釋放方式釋於其活性劑。其㈣可藉由此項技 ☆中所熟知的方法被膜覆。 用於口服投藥之液體製劑可以採取的形式,如溶液、 糖漿、懸浮液或糊劑(如被截述於馬爾乾丹尼等人 (Mulchandanietal),1992年美國專利第 5,i〇8,76^ 中之液 Μ氏張尺度顧+咖家鮮(CNS)A4規格(21〇 x 297公釐) 裝-----^----訂---------. (請先閱讀背面之注意事項再填寫本頁) 29 經濟部智慧財產局員工消費合作社印製 1243210 五、發明說明(27) 體營養補充劑),或者它 它適合的溶媒還原之乾燥錢用前用水或其 及礦物質之液體製财以 和其他維他命 Γ筚=的形成。此等液體製劑可藉由傳統的方法 、甲美:維辛成”添加劑如:懸浮劑(如:山梨醇糖漿 拉伯:二 用油脂)、乳化劑(如:_旨或阿 拉伯膠)非水〉谷性溶媒(如·木A、1 ’、·杏仁油、油性酯或乙醇)、 防腐劑(如甲基或丙基對一 、 T L本甲酸或山梨酸)以及人工或 天然色素和/或甜味劑而被製備。 至於局部投藥,為了提供一最適於局部投藥的組成物 ,如-藥霜、凝踢、固體、藥糊、軟膏、粉末、乳液、液 體、噴霧治療等,藥草組成物可被與至少-種包含一可接 受的載體、稀釋劑或賦形劑之其他成分合併混合。無菌蒸 餾水本身及單純的藥霜、軟膏和凝膠基劑可被採用為料 成分之載體。防腐劑和緩衝劑亦被添加。此配方可被應用 於用於局技藥的热端帶、生物可分解性 '可吸收性的 貼布或繃帶,或應用於具有一高速初始釋放衰退至慢速釋 放之慢速釋放注入系統。 關於以藥草為主的組成物之一更完整的總覽和討論, 參見··義耳敏代爾,義耳敏代爾藥草聖經,赛門及史卡斯 特出版社,1992年(Earl Mindel卜 Earl Mindell,s Herb Bible,The Pharmacology 〇f Chinese Herbs, CRC Press (1993)], here is a complete picture. Representative examples of various herbal compositions are provided in the following paragraphs. Herbal compositions containing willow bark have been used in the UK since the mid-18th century to treat fever. The active ingredient in willow bark is a bitter-flavored glycoside 'called salicin, which produces sugar and salicyl alcohol when hydrolyzed. Aspirin (acetylsalicylic acid) and aspirin-like drugs (such as ibuprofen) are often collectively referred to as non-steroidal anti-inflammatory drugs (NASAIDs) are often used to treat pain, fever and inflammation. Spiraea is another herb containing salicylic acid. The treatment of rheumatism and rheumatoid symptoms with willow bark or spiraea requires the elimination of this paper. The paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm). 27 Pack ---- l ·! (Please first Read the notes on the back and fill out this page) tr --------- ΜΨ, printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 1243210 A7 _____B7 V. Description of the invention (25) Consumption made by these plants Made of herbal tea. The entire poplar species (ie poplars and shrubs) also contain precursors of salicylic acid and poplar buds have been used for anti-inflammatory, anti-pyretic and anesthetic purposes. U.S. patents have been issued to herbal compositions for the treatment of different diseases and other health-related problems that infringe upon humans and animals. For example, U.S. Patent No. 5,417,979 discloses a composition comprising a mixture of herbs (including species such as Stephania and Glycyrrhiza) and extracts thereof, which are used as an appetite stimulant and used For the treatment of pain. Herbal compositions containing Glycyrrhiza uralensis have been found to be useful for eczema, psoriasis, pruritus, and skin inflammation (U.S. Patent No. 5,466,452). U.S. Patent No. 5,595,743 discloses different herb compositions containing licorice (Glycyrrhiza), and weeds, locust flower, hydrangea, and dysentery for the treatment of different mammalian diseases, including inflammation and rheumatoid arthritis. Inflammation of the eyes can be treated with a pharmaceutical composition containing phytochloride and tetrandrine (U.S. Patent No. 5,627,195). U.S. Patent No. 5,683,697 discloses a pharmaceutical composition with anti-inflammatory, anti-pyretic, expectorant or antitussive effects, wherein the composition includes Meiia and Angelica Dendrobium: Impatiens, Citrus, Mulberry Parasitic, Barley , Cynanchum and coral plant species. An herbal composition containing ginger, coriander, green ox gall, quinoa, sleeping eggplant, and ginger roots, rhizomes, and / or plants has been found to reduce or alleviate rheumatoid arthritis, bones, joints, Active arthritis-related symptoms and for reducing pro-inflammatory cytokines (US Patent No. 5,683,698). Herbal composition is suitable for many forms, including capsules, tablets, or films. The paper size is applicable to China National Standard (CNS) A4 (21 × x 297). 28 --- τ ---- r --- -I --- ^-11 Order --------- (Please read the precautions on the back before filling out this page) 1243210 A7 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 26 Coated tablets, pills, extracts or tinctures, powders, fresh or dried plants or plant parts, prepared decoctions, herbs, creams or ointments, essential oils, any combination of these forms. Herbs are made by Any one of different methods is administered, including: oral, rectal, parenteral, enteral, transdermal, intravenous, feeding tube, and topical administration. Herbs covered by the present invention The composition includes a herb composition that also contains a non-herb component. Such non-herb components include, but are not limited to: whole insects and insect parts, insects, animal or insect excreta, natural or crude oil, ammonia carbonic acid salts, tartaric acid Salt 'wine, water, glycerin, sterols, medicine Products, vitamins, nutrient extracts, serums, salts and gums. For oral administration, the disclosed herbal composition can take forms such as traditional methods, and generally acceptable excipients such as cumin. Mixtures (such as pre-gelatinized corn starch, polyethylene-based or fluorenylmethyl cellulose), fillers (such as lactose, microcrystalline cellulose, or calcium phosphate), lubricants (such as magnesium stearate, talc, or two Silicon oxide), disintegrating agents (such as potato starch or starch sodium glycolate) or wetting agents (such as sodium laurate sulfate), slip agents, artificial and natural flavors and sweeteners, artificial or natural pigments and dyes, and stability This herb composition can be further formulated to be released at a time well known in the art and as described in U.S. Pat. Nos. 4,69,825 and 5,055,300. It can be released into its active agent. It can be covered with a film by the method well known in this technique. Liquid preparations for oral administration can take forms such as solutions, syrups, suspensions or pastes (such as As described in Mulchandanietal et al., 1 992 U.S. Patent No. 5, i0,76 ^ Liquid M Zhang scale Gu + Kajia Xian (CNS) A4 specification (21〇x 297 mm) Pack ----- ^ ---- Order ---------. (Please read the notes on the back before filling this page) 29 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 1243210 V. Description of the Invention (27) Body Nutrition Supplements), or it It is suitable for solvent-reduced drying of money before use. It is used to make money with water or its mineral liquid to form other vitamins Γ 液体 =. These liquid preparations can be added by traditional methods, Jiamei: Weixincheng "additives such as : Suspending agent (such as sorbitol syrup Laber: dual-purpose oil), emulsifier (such as: _ purpose or Gum Arabic) non-aqueous> cereal solvents (such as wood A, 1 ', almond oil, oily ester or Ethanol), preservatives (such as methyl or propyl para-one, TL formic acid or sorbic acid), and artificial or natural pigments and / or sweeteners are prepared. As for topical administration, in order to provide a composition that is most suitable for topical administration, such as-creams, gels, solids, pastes, ointments, powders, emulsions, liquids, spray treatments, etc., the herb composition can be combined with at least one species An acceptable carrier, diluent or other ingredients of the excipient are combined and combined. Sterile distilled water itself and simple creams, ointments and gel bases can be used as carriers for ingredients. Preservatives and buffers are also added. This formulation can be applied to hot-end tapes for local medicines, biodegradable 'absorbable patches or bandages, or to slow-release injection systems with a high-speed initial release decay to slow-release. For a more complete overview and discussion of one of the medicinal-based compositions, see... Yi Ermindale, Yier Mindale Herb Bible, Simon and Scaster Press, 1992 (Earl Mindel and Earl Mindell , S Herb Bible,

Simon & Schuster (1992))、史耳培伯氏藥草全書,w佛 爾仙有限公司(原出版取十六世紀中葉)(Culpeper,s Complete Herb,W. Foulsham & Co· Ltd.)及羅代耳氏圖解 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 30 ^ -----r---t--------- <請先閱讀背面之注意事項再填寫本頁) 1243210 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(28) 為草百科’羅代耳出版社’ 1987年(Rodale’s Illustrated Encyclopedia of Herbs, Rodale Press(1987))。 標準化藥草組成物 就此處理所使用者言之,一“標準化藥草組成物,,係指 一被用於評估具有與標準化藥草組成物之成分相同或不同 的成分之批次藥草組成物之被擇定為標準藥草組成物的特 別的藥草組成物。有時在此亦指“母藥草組成物”。 才示準化樂卓組成物係為已被良好地特徵化且在一特別 的生物系統中展現所需要的生物反應之共通性藥草組成物 。才示準化藥草組成物通常係為被以熟習此項技藝者所習知 的化學試驗所標準化且為了長期的使用和對照被妥善保存 者。此標準化藥草組成物係被用來建立一基於對植物(即 植物相關資料)、標識物和生物反應的觀察和測量俾以特 徵化此藥草組成物的標準化藥草生物反應陣列。 批次藥草組成物 就此處所使用者而言,一“批次藥草組成物,,係指被用 來建立一基於對植物和標識物的觀察和測量,俾以特徵化 該藥草組成物的藥物生物反應陣列的任何受測藥草組成物 。有時在此亦指一“受測,,或“批次,,藥草組成物。生物反應 之視察和測量可以或不可以被包含在内。被用來建立標準 化藥草組成物之藥草組成物在被指空為“標準化藥草組成 物’’前亦可被稱為“批次藥草組成物,,。 批次 就此處所使用者而言,一“批次,,係指可依某一特別的 (請先閱讀背面之注咅?事項再填寫本頁) .1 _1 I —^1 ^1 ^1 >1 I ϋ ϋ 1 I— I - 31 1243210 可 物 A7 B7 五、發明說明(29) 屬f生而被鑑疋,俾以將#與任何其他特定量之相同的藥草 、、且成物區刀之-特定量之_草本組成物。例如··—批次之 -藥草、组成物可在諸批次之一係於異於其它批次之時間或 不同的地理位置被採收方面與另一批次之此相同的藥草組 成物作區分。其它區分特地批次之差異可包含,但不限於 下列·· 1)所使用的特定植物部份(如在一批次中,一藥草 之根被使用’而在一不同的批次中,相同的藥草之葉被使 用)’,2)個別藥草或藥草組成物之採收後處理(如一批次 係以蒸餚水處理,而一不同的批次可被可氯化氮處理以刺 激人類胃之酸度);以及在一藥草組成物中個別藥草之相 對的比例(如一批次可能具有等重疊或體積比率之三種不 同的藥草,而另一批次具有比其它兩種藥草佔更多比例之 一藥草)。 就此處所使用者而言,一‘‘生物系統,,係指生物反應」 被觀察或測量之任何生物實質。因此,一生物系統包含但 不限於:任何細胞、組織、器官、全生物或生體外試驗 -丨丨丨 · — — — — I 訂1111 — * (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 用 生物活性 就此處所使用者而言,一藥草之“生物反應,,係指針對 特定的生物系統,一藥草組成物所特有之特定的生物作 植物相關資料 就此處所使用者而言,“植物相關資料,,係指針對藥 草 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 32 1243210 經濟部智慧財產局員工消費合作社印製 A7 五、發明說明(3〇 ) 組成物所收集的資料,包含但不限於:關於植物之資料, 二生長條件和採收時及採收後此植物的處理。植物相關資 料亦包合一藥草組成物中其成分之相對比例,其中該成分 可為不同的植物部位、不同的植物物種、其它非植物成分 (如此触σ卩位、化學藥物)或這些變項之任何組合。 為了 一藥草組成物而可被收集的資料,包含但不限於 下述· 1)植物物種(以及,如果可獲得的話,特定的植物 變種、栽培種、繁殖株、品系等)和被使用於組成物中之 特疋植物邛位,2)藥草之地理來源,包含經度/緯度和海 拔同度,3)藥草的生長條件,包含肥料種類和數量、降兩 和灌就之量和時間、每天所接收之微愛因斯坦、殺蟲劑的 使用(包含殺草劑、殺昆蟲劑、殺螨劑和殺黴菌劑)以及耕 耘方法,4)用於處理藥草之方法和條件,包含藥草之株齡 /成熟度、浸泡時間、乾燥時間、萃取方法和研磨方法; 以及5)藥草成分和最終藥草組成物之儲存方法和條件。 此外,私準化藥草組成物可被化學分析。化學特性可 以藉由廣被熟習此項技藝者所習知之任何化學分析方法而 被兀成。可應用之化學分析的例子包含,但不限於高效液 相層析HPLC、薄層層析TLC、化學指紋、質量光譜儀分 析和汽相色層分析。 生物資訊術 就此處所使用者而言,‘‘生物資訊術,,係指具有生物意 義之資讯的利用和組織。生物資訊術其中涵義下述:丨)資 料獲得和分析;2)資料庫發展;3)整合和連結;以及句所 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ^ i I I l· I--訂--I I I I---- (請先閱讀背面之注意事項再填寫本頁) 33 經濟部智慧財產局員工消費合作社印製 1243210 A7 -------— _B7__ 五、發明說明( 產生之貧料庫之進一步分析。直到1990年早期之前,幾乎 所有的生物資訊術資源皆被開發為公共領域免費軟體,且 有許多透過網路仍可免費獲得。有些公司已開發有所有權 的資料庫或分析軟體。 基因組成基因組學 就此處所使用者而言,“基因組學,,一詞係指基因及其 功能之研究。基因組學強調在比較基因圖譜、分子選殖、 大規杈限制酶圖譜和去氧核糖核酸DNA定序與電腦化分 析方面基礎和應用研究之整合。遺傳資訊係利用基礎的技 術(如DNA疋序、蛋白質定序和聚合酶連鎖反應pcR,而 被提取。 运傳功能係藉由1)分析基因中DNA突變 細胞、組織、器官或生物體之健康= DNA序列中之不同的信息,以及3)研究由一基因或相關基 因之體系所產生的蛋白質而被判定。 蛋白質組成蛋白質組學 就此處所使用者而言,“蛋白質組學,,一詞,亦被稱為 “蛋白質研究”或“表現組學”係指在所限定的條件下,一基 口、、且之疋畺蛋白質表現型式。就一般所使用者而言,蛋白 質組術係指利用蛋白質生物化學高單位時間輸出, 分析的方法。 為了許多的理由,除了基因組研究外再進行蛋白質組 研究係有其需要。第一,基因表現的水平未必代表在一細 胞中之活性蛋白質的量。同時,基因序列並未描述為一蛋 本紙張尺度適用中國國豕標準(CNS)A4規格(21〇 X 297公复) 34 Μ-----r---t---------. (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1243210 A7 ___B7 五、發明說明(32) 白質之功能和活性所必需的轉譯後修飾。此外,基因組本 身並未描述改變蛋白質水平上升或下降之動態細胞程序。 蛋白質研究尋求特徵化在一細胞中之所有的蛋白質, 鑑定一被分離的蛋白質之至少部分的胺基酸序列。一般, 蛋白質先被用2維2D凝膠或高效液相層析HPLC分離,然 後胜肽或蛋白質利用高單位時間輸出質譜儀定序。利用一 電腦,質譜儀的輸出可以被分析,以便連結一基因及其所 編碼之特定的蛋白質。此全部的程序有時被稱為“功能性 基因組學”。一些廠商目前提供蛋白質組學服務(如: Pharmaceutical Proteomics™ ; The Proteomics™ System form Ciphergen Biosystem ; PerSeptive Biosystems) o 有關蛋白質組研究之一般資料,參見,例如:J.S.富 魯頓,1999年,蛋白質、酵素、基因:化學和生物之交錯 ,耶魯大學出版部(J.S. Fruton,1999,Proteins,Enzymes, Genes : The Interplay of Chemistry and Biology, Yale Univ. Pr.)、威耳金基等人,1997年,蛋白質組研究:功能基因 組學之新領域(原理與操作),史布林格佛例(Wilkins et aL,1997, Proteome Research · New Frontier in Functional Genamics(Principles and Practice),Springer Verlag)、AJ· 林克,1999年,2維蛋白質組分析流程(分子生物學方法) ,112,人示出版社(A.J. Link,1999,2-D Proteome Analysis Protocols(Methods in Molecular Biology),112,Humana Pr.) 、坎普等人,1999年,蛋白質組與蛋白質分析,史布林格 佛列(Kamp et aL. 1999,Proteome and Protein Analysis, 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 35 ----I---------------:----訂----I--- (請先閱讀背面之注意事項再填寫本頁) 1243210 A7 五、發明說明(33 Μ 財 產 局 員 工 消Simon & Schuster (1992)), the entire book of Schöpper's Herbs, w. Fulxian Co., Ltd. (originally published mid-16th century) (Culpeper, s Complete Herb, W. Foulsham & Co. Ltd.) and Luo Daier's illustration This paper size is applicable to China National Standard (CNS) A4 (210 X 297 mm) 30 ^ ----- r --- t --------- < Please read first Note on the back, please fill out this page again) 1243210 A7 B7 Printed by the Consumers' Cooperative of Intellectual Property Bureau of the Ministry of Economic Affairs V. Invention Description (28) It is Rodale's Illustrated Encyclopedia of Herbs, Rodale Press (1987)). In this regard, standardized herbal compositions are treated by users. "A standardized herbal composition refers to a batch of herbal compositions that are used to evaluate a batch of herbal compositions that have the same or different components from those of a standardized herbal composition." It is a special herb composition that is a standard herb composition. Sometimes it is also referred to as the "parent herb composition". It is shown that the quasi-Lezo composition is well-characterized and exhibited in a special biological system. A common herbal composition that requires a biological response. It is shown that quasi-standardized herbal compositions are usually standardized by chemical tests familiar to those skilled in the art and are well preserved for long-term use and control. This standardized herb The composition system is used to establish a standardized herb bioresponse array based on observations and measurements of plants (ie plant-related information), markers, and biological responses to characterize the herb composition. Batch Herb Compositions are used herein In the case of a "batch herb composition," it is meant to be used to establish an observation and measurement based on plants and markers. Any tested herb bioreactor array serve to characterize the pharmaceutical composition herb composition. Sometimes also referred to herein as a "tested," or "batch," herb composition. Inspection and measurement of biological responses may or may not be included. A herb composition used to establish a standardized herb composition may also be referred to as a "batch herb composition" before being referred to as a "standardized herb composition '". As far as the users are concerned, a "batch" refers to a special (please read the note on the back? Matters before filling out this page) .1 _1 I — ^ 1 ^ 1 ^ 1 > 1 I ϋ ϋ 1 I— I-31 1243210 可 物 A7 B7 V. Description of the invention (29) It was identified as a genus of familiarity, so that # and any other specific amount of the same herb, and the product area Knife-a specific amount of _ herb composition. For example ...-batch-herb, composition can be harvested at a time when one of the batches is different from the other batches or at a different geographical location. One batch of this same herb composition is distinguished. The differences between other batches that specifically distinguish may include, but are not limited to, the following ... 1) The specific plant parts used (eg, the root of a herb in a batch Is used 'while the same herb leaf is used in a different batch)', 2) post-harvest treatment of individual herbs or herb compositions (eg a batch is treated with steamed water, and a different The batch can be treated with nitrogen chloride to stimulate the acidity of the human stomach); and the phase of individual herbs in a herb composition (Eg one batch may have three different herbs with equal overlap or volume ratio, while another batch has one herb with a greater proportion than the other two herbs). System refers to any biological substance that is "observed or measured". Therefore, a biological system includes, but is not limited to, any cell, tissue, organ, whole organism or in vitro test-丨 丨 丨 · — — — — I 1111 — * (Please read the precautions on the back before filling this page) For the users here, the "biological response of a herb" refers to a specific biological system and a specific organism unique to a herb composition as a plant-related information. For the users here, "Plant-related information refers to the application of Chinese National Standard (CNS) A4 (210 X 297 mm) to the size of medicinal herbs paper." 32 1243210 Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 Five 2. Description of the invention (30) The information collected by the composition includes, but is not limited to, information about the plant, the growth conditions and the treatment of this plant during and after harvesting. Plant-related information also includes the relative proportions of its components in a herb composition, which may be different plant parts, different plant species, other non-plant components (such as σ 卩, chemical drugs) or these variables Any combination. Information that can be collected for a herb composition, including but not limited to the following: 1) plant species (and, if available, specific plant varieties, cultivars, breeding plants, strains, etc.) and used in the composition The niche of the special plant, 2) the geographical origin of the herb, including longitude / latitude and the same altitude, 3) the growth conditions of the herb, including the type and quantity of fertilizer, the amount and time of the two drops and irrigation, and the daily Accepted micro-Einstein, use of pesticides (including herbicides, insecticides, acaricides and fungicides) and cultivation methods, 4) methods and conditions for treating herbs, including the age of the plants / Maturity, soaking time, drying time, extraction method and grinding method; and 5) storage methods and conditions of the herb ingredients and the final herb composition. In addition, privatized herb compositions can be chemically analyzed. Chemical properties can be created by any chemical analysis method widely known to those skilled in the art. Examples of applicable chemical analysis include, but are not limited to, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), chemical fingerprints, mass spectrometer analysis, and vapor phase chromatography. Bioinformatics For the users here, ‘bioinformatics’ refers to the use and organization of biologically meaningful information. The meanings of bioinformatics are as follows: 丨) data acquisition and analysis; 2) database development; 3) integration and linking; and the paper size of the sentence applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) ^ i II l · I--Order--III I ---- (Please read the notes on the back before filling out this page) 33 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 1243210 A7 --------- _B7__ 5. Explanation of the invention (Further analysis of the poor data base produced. Until the early 1990s, almost all bioinformatics resources were developed as free software in the public domain, and many were still available for free through the Internet. Some companies Owned database or analysis software has been developed. For the users here, "genomics," the term "genomics," refers to the study of genes and their functions. Genomics emphasizes comparison of genetic maps, molecular selection, Integration of large-scale restriction enzyme maps and DNA sequencing with DNA and basic and applied research in computerized analysis. Genetic information uses basic technologies (such as DNA sequencing, protein sequencing) It is extracted by chain reaction with polymerase pcR. Transport function is performed by 1) analyzing the health of DNA mutant cells, tissues, organs or organisms in a gene = different information in the DNA sequence, and 3) studying a gene by Or a system of related genes. Proteins Proteomics For the purposes of this document, the term "proteomics," also known as "proteomics," or "expressomics" means Under the defined conditions, a basal mouth, and the protein expression pattern. For the average user, proteomics refers to the method of using protein biochemical high unit time output and analysis. For many reasons, proteomics research is needed in addition to genomic research. First, the level of gene expression does not necessarily represent the amount of active protein in a cell. At the same time, the gene sequence has not been described as an egg paper size applicable to the Chinese National Cricket Standard (CNS) A4 specification (21 × X 297 public copy) 34 Μ ----- r --- t ------- -. (Please read the notes on the back before filling this page) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 1243210 A7 ___B7 V. Description of the invention (32) Post-translational modification necessary for the function and activity of white matter. Furthermore, the genome itself does not describe dynamic cellular programs that alter the rise or fall of protein levels. Protein research seeks to characterize all proteins in a cell and to identify the amino acid sequence of at least a portion of an isolated protein. Generally, proteins are first separated using a two-dimensional 2D gel or high performance liquid chromatography (HPLC), and then peptides or proteins are sequenced using a high unit time output mass spectrometer. Using a computer, the output of the mass spectrometer can be analyzed to link a gene and the specific protein it encodes. This whole program is sometimes called "functional genomics". Some manufacturers currently provide proteomics services (eg: Pharmaceutical Proteomics ™; The Proteomics ™ System form Ciphergen Biosystem; PerSeptive Biosystems) o For general information about proteomics research, see, for example: JS Fullerton, 1999, Proteins, Enzymes Genes: the intersection of chemistry and biology, Yale University Publishing Department (JS Fruton, 1999, Proteins, Enzymes, Genes: The Interplay of Chemistry and Biology, Yale Univ. Pr.), Wilkinki et al., 1997, Protein Group research: New field of functional genomics (principle and operation), Wilkins et aL (1997, Proteome Research · New Frontier in Functional Genamics (Principles and Practice), Springer Verlag), AJ Link , 1999, 2D Proteome Analysis Process (Molecular Biology Method), 112, Renshi Press (AJ Link, 1999, 2-D Proteome Analysis Protocols (Methods in Molecular Biology), 112, Humana Pr.), Kan Pu et al., 1999, Proteomics and Protein Analysis, Springer Fletcher (Kamp et aL. 1 999, Proteome and Protein Analysis, this paper size is applicable to China National Standard (CNS) A4 (210 X 297 mm) 35 ---- I ---------------:- --Order ---- I --- (Please read the notes on the back before filling out this page) 1243210 A7 V. Description of the invention (33 Μ Property Bureau employee consumption

Springer Verlag) 〇 訊號轉導 就此處所使用者而言,“訊號轉導,,,亦被習知為細胞 Λ號轉‘’係指細胞接受外來訊號,在内部傳遞、放大及 引導Λ號所經由的途徑。訊號傳遞途徑需要以逐步方式傳 L號的蛋白貝乂互通訊鏈。蛋白質激酶時常參與種反應 鏈,因為許多訊號轉導涉及接收一引發細胞質蛋白質之磷 酸化以放大訊號之細胞外化學訊號。 轉譯後修飾 就此處所使用者而言,“轉譯後修飾,,係為一用於涵 在其被合成為一初期聚胜肽後,發生於一蛋白質的改變 綜合名詞。此種轉譯後修飾包含,但不限於··糖化作用、 亂Ν-端甲硫胺酸(或氮Ν-端甲硫胺酸(或氮Ν·甲盤甲硫胺酸) 之去除、訊號胜肽去除、乙醯基化、f酸基化、胺基酸 飾、胜肽鏈之内部裂鮮以釋出較小的蛋白質或胜肽、磷 化及甲硫胺基酸之修舞。 陣列或微陣列 就此處所使用者而言,一“陣列,,或“微陣列,,係指一 標方格系統’其中任-位置或探針細胞被-定義好的核, 片斷所佔據。此等陣列本身亦被稱為“晶片,,、“生物晶片, 、“去氧核糖核酸DNA晶片”或“基因晶片,,。高密度去氧核 糖核酸DNA微陣列經常具有數以千計之 / 格型式之探針細胞。 ^ 旦此陣列被裝配好,-批次被添加且此批次與該陣 蓋 之 修 酸 酸 方 本紙張尺度適用中國國家標準(CNS)A4規格⑽x 297公£Springer Verlag) 〇Signal transduction For the users here, "signal transduction, also known as cell Λ transduction" refers to the process by which cells receive external signals, transmit, amplify, and guide Λ The signal transmission pathway requires the step-by-step communication of the protein chain of protein L. Protein kinases often participate in the species reaction chain because many signal transductions involve receiving an extracellular chemistry that triggers phosphorylation of cytoplasmic proteins to amplify the signal. Signal. Post-translational modification For the users here, "post-translational modification" is a general term used to describe a change in a protein that occurs after it is synthesized into an initial polypeptide. Such post-translational modifications include, but are not limited to, saccharification, messy removal of N-terminal methionine (or nitrogen N-terminal methionine (or nitrogen N-formine methionine), signal victory Peptide removal, acetylation, f-acidification, amino acid decoration, internal cracking of peptide chains to release smaller proteins or peptides, phosphating and repair of methionine. Array or Microarray For the purposes of the user herein, an "array," or "microarray," refers to a standard grid system in which any-position or probe cell is occupied by-defined nuclei, fragments. Such arrays Also known as "wafer," "biochip," "DNA DNA wafer," or "gene wafer." High-density DNA DNA microarrays often have thousands / lattice patterns. Probe cells. ^ Once the array is assembled, the batch is added and the batch and the cover cover are modified in acid paper. The paper size applies to the Chinese National Standard (CNS) A4 size x 297 kg.

I 1243210 五、發明說明(34) 列間產生某種形式之化學作用且該陣列產生對該陣列盘批 次為特定性之某種辨認型式。經放射性標定的批次之自動 放射顯影為-傳統的監測策略,但其它的選擇係為所用者 ’包含電子訊號轉導。 標識物 务就此處所使用者而言,“標識物,,一詞係指對一特定的 藥草組成物之任何以生物學為主的測量或觀察,其為一正 被暴露於-特定批次之一藥草組成物之特定的生物系統之 特性。“標識物,,-詞涵蓋—生物系統之定性和定量兩者的 測量和觀察。標識物資料庫包含一將相應於藥草治療的基 因,現型式特徵化之資料組,其中該型式顯示相應於特二 之藥草組成物某些基因被開啟、關閉、提高或降低。因此 ,“標識物’’係指任何以生物學為基礎的測量和觀察,其在 於生物系統中表現水平之提高和降低或暫時性調控或定 量或定性的改變係被用來特徵化一生物系統對一藥草組成 物之分化性生物反應。 經濟部智慧財產局員工消費合作社印製 生物系統所被暴露之特定批次之一藥草組成物可為一 未知的藥草組成物,一已知的藥草組成物或一標準化藥草 組草物。有用於完成本發明之標識物之例子,包含但不限 於:分子標識物、細胞遺傳學標識物、生化標識物或區分 子“ °戠物。巨分子標識物包含但不限於··酵素、聚胜肽、 胜肽、糖類、抗體、去氧核糖核酸DN A、核糖核酸rna 蛋白負(轉澤蛋白質和轉譯後蛋白)、核酸和多醣類。 任何滿足此處“標識物,,之定義的標識物係適於引領本 本紙張尺度翻+ _鮮(CNS)A4態—χ 29—- 37 1243210 A7 B7 五、發明說明(35 ) 發明者。‘‘標識物,,一詞包含相關的、不同類型的術語,如 :“生物標識物,,或“遺傳標識物,,或“基因標識物”。為了達 到提升一藥草生物反應HBR陣列的辨別能力之目的,可能 有一或更多種的初級標識物連同次級標識物或一系列的標 識物。因此,所擇定之分子標識物可能與不同的其它分子 、細胞遺傳、生化或巨分子標識物相結合,使一更加準確 、周延的藥草生物反應陣列成為可能。 一分標識物包含一或更多的來自一或更多級次之分孔 化合物的顯微分子,如:去氧核糖核酸DNA、核糖核酸RNA 、互補去氧核糖核酸cDNA、核酸片段、蛋白質、蛋白質 片段、脂肪、脂肪酸、醣類和糖蛋白。 可利用的分子標識物之建構、生成和利用係為熟習此 項技藝者所習知者。用於分子標識物之特徵化之特別有用 的科技之例子包含分化性表現、反轉錄酶聚合酶連鎖反應 PCR、表現序列標定物ESTs之大規模的定序、基因表現之 系列分析SAGE、西方免疫轉印或蛋白質之2維(2D)、3維(3D) 的研究及微陣列科技。一熟習分子標識物科技者係熟知此 種科技的方法和用途[參見如:伯納得R.格立克和傑克J.佩 斯特納克,重組DNA之分子生物科技、原理及應用,第2 版 ASM 出版社(1998 年)(Bernard R. Glick and Jack J. Pasternak, Molecnla Biotechnology, Principles and Application of Recombinant DNA, Second Edition,ASM Press (1998))、馬修R.沃克及洛夫雷普利,基因科技之圖 谱’布雷克威耳科學出版社(1997年)(Mathew R. Walker and 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注音?事項再填寫本頁) -----r---^ 1111111 . 經濟部智慧財產局員工消費合作社印製 38 1243210 A7 B7 五、發明說明(36)I 1243210 V. Description of the invention (34) A certain type of chemical interaction occurs between the columns and the array produces a certain type of identification for the array disk batch. Autoradiography of a radiolabeled batch is a traditional monitoring strategy, but other options are for the user's use including electronic signal transduction. For the purposes of this user, the term "identifier," means any biologically-based measurement or observation of a particular herb composition that is being exposed to a particular lot. The characteristics of a particular biological system of a herb composition. "Identifiers,-the term covers-measurement and observation of both qualitative and quantitative biological systems. The marker database contains a data set that characterizes the genes corresponding to the treatment of the herb, the current type, where the pattern shows that certain genes corresponding to the special herb composition are turned on, off, raised or lowered. Therefore, "identifier" refers to any biologically-based measurement and observation, which is used to characterize a biological system by increasing and decreasing the level of performance in a biological system or temporarily regulating or quantitatively or qualitatively changing. Differentiated biological response to a herb composition. One of the specific batches of the exposed biological system printed by the consumer cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs may be an unknown herb composition, a known herb composition Or a standardized herb group. There are examples of markers used to complete the present invention, including but not limited to: molecular markers, cytogenetic markers, biochemical markers, or molecular molecules. Macromolecular markers include, but are not limited to, enzymes, polypeptides, peptides, carbohydrates, antibodies, DNA DNA, RNA RNA negative (translated protein and post-translational protein), nucleic acids and polysaccharides . Any mark that satisfies the definition of "marker" here is suitable for leading the size of the paper + _fresh (CNS) A4 state-χ 29--37 1243210 A7 B7 V. Inventor (35) Inventor. ' 'Identifier,' the term includes related, different types of terms, such as: "biomarkers, or" genetic markers, or "gene markers." In order to improve the ability of a herb to respond to HBR arrays For the purpose, there may be one or more primary markers together with secondary markers or a series of markers. Therefore, the selected molecular marker may be different from other molecular, cytogenetic, biochemical or macromolecular markers. This combination makes it possible to make a more accurate and extended herbal bioreaction array. A marker contains one or more micromolecules from one or more sub-porous compounds, such as DNA, RNA, complementary DNA cDNA, nucleic acid fragments, proteins, protein fragments, fats, fatty acids, sugars and glycoproteins. Construction of available molecular markers, Generation and utilization are known to those skilled in the art. Examples of particularly useful technologies for the characterization of molecular markers include differentiation expression, reverse transcriptase polymerase chain reaction PCR, and expression sequence markers ESTs. Large-scale sequencing, sequence analysis of gene expression SAGE, Western immunotransfer or protein 2D (3D), 3D (3D) research and microarray technology. A person familiar with molecular marker technology is familiar with this technology Methods and uses [see eg Bernard R. Glick and Jack J. Pestnack, Molecular Biotechnology, Principles and Applications of Recombinant DNA, 2nd Edition ASM Press (1998) (Bernard R. Glick and Jack J. Pasternak, Molecnla Biotechnology, Principles and Application of Recombinant DNA, Second Edition, ASM Press (1998)), Matthew R. Walker and Lovrepuli, Maps of Genetic Technology 'Blakewell Scientific Publishing (1997) (Mathew R. Walker and this paper size applies to Chinese National Standard (CNS) A4 (210 X 297 mm) (Please read the note on the back? Matters before filling out this page) ----- r --- ^ 11 11111. Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economy 38 1243210 A7 B7 V. Description of Invention (36)

Ralph Rapley? Route Mapsin Geme Techhology, Blackwell Science (1997))、羅伊等人,DNA分離及定序,约翰威利 及尚司(1996年)(Roe et al,DNA Isolation and Sequencing, John Wiley & Sons (1996)詹姆士 D.華生等人,重組 DNA 第 2版’科學美國叢書(l992)(James D. Watson et al., Recombinant DNA? Second Edition, Scientific American Books(1992)]。 去氧核糖核酸DNA、核糖核酸RNA和蛋白質之分離 和定序方法係為熟習此項技藝者所習知者。此等習知技藝 之例子被發現於:分子選殖:實驗手冊第2版、山姆布魯 克等人,紐約冷泉港(1989)(Molecular Cloning : A Laborator Manual 2nd Edition, Sambrook et al.? Cold Spring Harbor, N.Y. (1989)、漢斯彼得薩魯茲和J.P.宙斯特,基因組定序 實驗室指南:原始未被選殖的DNA之直接定序(生物方法 第 1冊)伯克霍斯特(1998)(Hanspeter Saluz and J.P. Jost,A Laborator Guide to Genomic Sequencing ·· The Direct Sequencing of Native Uncloned DNA(Biomethods Vol, Birkhauster(1988)和B.羅伊等人,DNA分離和定序,威利 (1996)(B. Roe et al.9 DNA Isplation and Sequencing, Wiley (1996))。傳統分子生物學技術的例子包含但不限於:生 體外接合、限制核酸内切酶分解、聚合酶連鎖反應(PCR) 、細胞轉化、雜交、電泳、去氧核糖核酸DNA定序、細 胞培養等。用於本發明之市面上可獲得的特定的套組和工 具包含,但不限於:有用於核糖核酸RNA分離、聚合酶 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) _ 39 (請先閱讀背面之注意事項再填寫本頁) ϋ ammmw I— 1 ammf I i_i I 1 I _ 經濟部智慧財產局員工消費合作社印製 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(37) 連鎖反應PCR互補去氧核糖核酸cDNA貯庫構築、反病毒 表現貯庫、載體、基因表現分析、蛋白質抗體純化、細胞 毒性檢驗、蛋白質表現和純化及高單位時間輸出質體純化 [參見如:選擇技術產品目錄XIII(3),1-32(1988年) (CLONTEniques product catalog,XIII(3),1-32(1998)或 www. clontect.com .AtlasTM互補核糖核酸表現檢驗產品目錄 (1998年)(AtlasTM cDNA Expression Assay product catalog (1998)、SIGMA® 產品目錄(1997)年]。 有關寡核苷酸陣列、微陣列、去氧核糖核酸DNA晶 片或生物晶片之討論、方法學和應用,參見如:美國專利 第 5,445,934號、第 5,605,662號、第 5,631,134號、第 5,735,257 號、第 5,741,644號、第 5,744,305號、第 5,795,714號;西 恩納等人,平行人類基因組分析:1000基因之以微陣列為 基礎的表現監控,美國國家研究院報告第93期,第10614-10619 頁(1996 年)(Schera et al,Pareller Human Genome Analysis : Microarray-based expression monitoring of 1000 gehes,Proc Natl. Acad,Sci U.S.A. 93,10614-10619(1996)) •,廸瑞西等人,在一基因組規模上探索基因表現之代謝和 遺傳控制,科學第278期、第680-686頁(1997年)(DeRisi et al·,Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale, Science 278,680-686(1997)) •,在廸卡等人,酵母菌(Saccharomyces cerevisiae)之基因 組級表現監控,自然生物科技第15期,第1359-1367頁(1997 年)(Wodicka et al.,Genome-Wide Expression Monitoring in 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 40 ---J-----------I l· I--訂----I---- (請先閱讀背面之注意事項再填寫本頁) 1243210 A7 B7 五、發明說明(38)Ralph Rapley? Route Mapsin Geme Techhology, Blackwell Science (1997)), Roy et al., DNA Isolation and Sequencing, Roe et al, DNA Isolation and Sequencing, John Wiley & Sons (1996) James D. Watson et al., Recombinant DNA 2nd Edition 'Science American Series (l992) (James D. Watson et al., Recombinant DNA? Second Edition, Scientific American Books (1992)]. Deoxygenation Methods for isolating and sequencing RNA, RNA, and protein are known to those skilled in the art. Examples of these techniques are found in: Molecular Selection: Experimental Manual, 2nd Edition, Sambrook Et al., Molecular Cloning: A Laborator Manual 2nd Edition, Sambrook et al.? Cold Spring Harbor, NY (1989), Hans Peter Saruz and JP Zeist, Guidelines for Genomic Sequencing Laboratories : Direct Sequencing of Original Unselected DNA (Biological Methods Volume 1) Burkhorst (1998) (Hanspeter Saluz and JP Jost, A Laborator Guide to Genomic Sequencing ·· The Direct Sequencing of Native Uncloned DNA (Biomethods Vol, Birkhauster (1988) and B. Roy et al., DNA isolation and sequencing, Wiley (1996) (B. Roe et al. 9 DNA Isplation and Sequencing, Wiley (1996)). Examples of traditional molecular biology techniques include, but are not limited to, in vitro conjugation, restriction endonuclease digestion, polymerase chain reaction (PCR), cell transformation, hybridization, electrophoresis, DNA sequencing of DNA, cell culture, and the like. The specific kits and tools available on the market for the present invention include, but are not limited to: useful for RNA isolation and polymerase. This paper is sized to the Chinese National Standard (CNS) A4 (210 X 297 mm). _ 39 (Please read the precautions on the back before filling this page) ϋ ammmw I— 1 ammf I i_i I 1 I _ Printed by the Employees ’Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 123210 Printed by the Employees’ Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 B7 V. Description of the invention (37) Construction of a chain reaction PCR complementary DNA cDNA repository, antiviral performance repository, vector, gene expression analysis, protein and antibody purification, cytotoxicity test, protein Performance and purification and high unit time output plastid purification [see eg: Select Technology Product Catalog XIII (3), 1-32 (1988) (CLONTEniques product catalog, XIII (3), 1-32 (1998) or www. clontect.com. AtlasTM cDNA Expression Assay Product Catalog (1998) (AtlasTM cDNA Expression Assay product catalog (1998), SIGMA® Product Catalog (1997)). For discussions, methodologies and applications of oligonucleotide arrays, microarrays, DNA DNA wafers or biochips, see, for example, U.S. Patent Nos. 5,445,934, 5,605,662, 5,631,134, 5,735,257, No. 5,741,644, No. 5,744,305, No. 5,795,714; Sienna et al., Parallel Human Genome Analysis: Microarray-Based Performance Monitoring of 1000 Genes, National Research Institute Report No. 93, pp. 10614-10619 (1996) (Schera et al, Pareller Human Genome Analysis: Microarray-based expression monitoring of 1000 gehes, Proc Natl. Acad, Sci USA 93, 10614-10619 (1996)) • Direci et al., In a genome Exploring Metabolism and Genetic Control of Gene Performance on a Large Scale, Science No. 278, 680-686 (1997) (DeRisi et al., Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale, Science 278,680-686 ( (1997)) • In Dica et al., Genome-level performance monitoring of yeast (Saccharomyces cerevisiae), Natural Biotechnology Issue 15, Issue 1 Pp. 359-1367 (1997) (Wodicka et al., Genome-Wide Expression Monitoring in This paper size applies to China National Standard (CNS) A4 specification (210 X 297 mm) 40 --- J ------ ----- I l · I--Order ---- I ---- (Please read the notes on the back before filling this page) 1243210 A7 B7 V. Description of the invention (38)

Saccharomyces cerevisiae, Nature Biofechnology 15,1359-1367(1997));帕廸,全基因組表現監控:人類,自然生 物科技,第 15期,第 1343-1344 頁(1997 年)(Pardee,Complete Genome Expression Monitoring : The Human Race, Nature Brotechnology 15,1343-1344(1997));薛佛等人,DNA變 異和人類遺傳學的未來,自然生物科技,第16期,第33-39 頁(1998年)(Schafer et al·,DNA Variation and the fature of human Gentics,Nature Biotechnology 16,33-39(1998)); 迪瑞西等人,一 cDNA微陣列對分析人類癌症基因表現型 式之用途,自然遺傳學,第14期,第457-460頁(1996年 )(DeRisi et al, Use of a cDNA Microarray to Analyze Gene Expression Patterns in Human Cancer, Nature Genetic 14, 457-460(1996));贺勒等人,利用cDNA微陣列對發炎性疾 病相關基因之發明和分析,美國國家科學院研究報告第94 期,第 2150-2155 頁(1997年)(Heller et al·,Discorery and Analdysis of Infammatory Disease-Related Genes Using cDNA Microarrays, Proc? Natl. Acad. Sci. USA 94 : 2150-2155(1997));馬修等人,DNA晶片:一具有可能性之陣 歹|J,自然生物科技第16期,第27-31頁(1998年)(Marshallet al·,DNA Chips : An Array of Possibilites,Nature Biotechnology 16,27-31(1998));布恩納等人,微陣列: 用於功能基因組學之生物科技的發現抬,生物科技趨勢第 16期’第 301-306頁(1998年)(Schena et al·,Microarrays : Biotechnology^ Discovery Platform for Function Genomics, 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ϋ Hi in i_i _1 11 ϋ 1· 1 in I . 經濟部智慧財產局員工消費合作社印製 41 1243210 A7 B7 五、發明說明(39)Saccharomyces cerevisiae, Nature Biofechnology 15, 1359-1367 (1997)); Paddy, Genome-wide Performance Monitoring: Human, Natural Biotechnology, No. 15, pp. 1343-1344 (1997) (Pardee, Complete Genome Expression Monitoring: The Human Race, Nature Brotechnology 15, 1343-1344 (1997)); Schaeffer et al., DNA Variation and the Future of Human Genetics, Natural Biotechnology, No. 16, pp. 33-39 (1998) (Schafer et al. al., DNA Variation and the fature of human Gentics, Nature Biotechnology 16, 33-39 (1998)); Di Ruixi et al., The use of a cDNA microarray for the analysis of human cancer gene phenotypes, Natural Genetics, 14 Issue, pp. 457-460 (1996) (DeRisi et al, Use of a cDNA Microarray to Analyze Gene Expression Patterns in Human Cancer, Nature Genetic 14, 457-460 (1996)); Heller et al. Array invention and analysis of inflammatory disease-related genes, National Academy of Sciences Research Report, 94, 2150-2155 (1997) (Heller et al., Scorery and Analdysis of Infammatory Disea se-Related Genes Using cDNA Microarrays, Proc? Natl. Acad. Sci. USA 94: 2150-2155 (1997)); Matthew et al., DNA Chips: A Possibility Array | J, Natural Biotechnology No. 16 Issue, pp. 27-31 (1998) (Marshallet al., DNA Chips: An Array of Possibilites, Nature Biotechnology 16, 27-31 (1998)); Boehner et al., Microarrays: For Functional Genomics Discovery of Biotechnology, Biotechnology Trends No. 16 ', pp. 301-306 (1998) (Schena et al ·, Microarrays: Biotechnology ^ Discovery Platform for Function Genomics, This paper size applies to China National Standard (CNS) A4 specifications (210 X 297 mm) (Please read the notes on the back before filling out this page) ϋ Hi in i_i _1 11 ϋ 1 · 1 in I. Printed by the Intellectual Property Bureau Staff Consumer Cooperatives 41 1243210 A7 B7 V. Invention Instructions (39)

Tibtech 16, 301-306(1998));藍赛,DNA晶片;科技現狀 ’自然生物科技第16期,第4〇-44頁(1998年);奇異 等人’以高密度DNA陣列接近遺傳資訊,科學第274期, 第610 614頁(1996年);和陳等人,用比色計债測藉由cdna U陣列系統剖析表現型式和離分化性表現的基因,基因組 學第50期,第1-12頁(1998年);ρ ·安德魯奥迪南等人,高 半胱胺酸之逆境誘導效應的特徵,生物化學期刊第332期 ,第213-221頁(1988年);以及傑伯特等人,遺傳學將會 對新藥發現過程產生革命嗎,Curr,〇pin Bi〇techn()1 816), 699-674(1997)。 可應用於本發明之其它更特定的參考文獻包含,但不 限於:提出表現科技者,如ESTS(參見如:麥可I費能, 正名和病悲中之基因表現_治療標的之鑑^,生物科技趨 勢第Μ期,第Μ298頁(⑽年…蛋白質綜覽之生成(參 見如:羅賓森等人,-前列肺癌之赂胺酸激酶綜覽,美國 國家科學院研究報告93期,第洲-侧頁(觸年))、用 於鐘定藥草組成物之成分的化學和光譜學方法(小島等人 來自⑹邮仙咖⑽)之Μ,植物化學第48期第5卷第 885-888頁(刪年))、功能抗原之判定(參見如阿力士任 西迪士、功能抗原’自然生物科技第16期,第305-307頁 (⑽年》、高效液相層析(參見如:米耳頓tw•希恩(編者) 、蛋白質、胜肽及聚核誓酸之高效液相層析··當代之主題 和應用(臨床化學之分析技術及實驗室手冊,VCH出版, (1991年)、電冰(參見如··咸斯頓梅耳等人,電泳操作: 本紙張尺度過用t國國家標準(CNS)A4規格⑵Q χ挪公^· 1243210 A7 B7 五、發明說明(40) 部 智 慧 財 產 局 員 工 消 作 社 印 製 二舰和蛋白質分離的方法和應用之指$,約輪威利及 尚司(1997年))、及交互反應性標識物檢試(參見如:艾耳 ' )、 卓人伍德恰可肝炎病毒··實驗性感染與自然發 生,肝病學第4期第5卷,第817-823頁(1984年))。結構基 因組學對於解開—已完成的基因組所編碼之所有蛋白質的 結構(其巾其方法學包含單位時間輸出直接結構判定及電 腦運算方法)之用途係被泰利賈恩特蘭,結構基因組學: 生物資訊術上路,自然生物科技第16期,第625-627頁所 討論。有關生物資訊術··一基因和蛋白質之分析的操作指 南=翰烕利與尚司(1998年)以及魯克阿耳飛,DNA定序 •從貫驗方法至生物資訊術(生物科技系列簡介卜史普林 佛雷格(1997年)。 細胞生物參數包含,但不限於··核型分析(如相對染 色伸長度、著絲點位置、存在或沒有次級緊縮)、核型示 思圖(即-生物之核型之一種圖示)、在有絲分裂和無絲分 裂期間染色體之行為、染色體染色和色帶型式、DNA-蛋 白夤父互作用(亦被涊為是核酸分解酶保護檢測)、中子散 射研究、滾動圓⑽ling circles)(AM·代傑曼及紅庫耳, 核酸研究第26期第13卷,第3235_3241頁(1998年)、貝克 特等人,分子細胞生物學第16期第丨丨卷,第628弘6294頁 (1996年)、史給力特等人,病毒學期刊第7〇期第2卷 1132· 1136頁(1996)、A.費艾耳和S q蘇,美國國家科學 研九報告第92期、第1〇卷、第4641_4645頁(1995年), 及隨著與放射標定過的核糖核菩酸反應後,全核酸之自動 第 院 以 本紙張尺度適用中國國家標準(CNS)A4 ^格⑵G X 297公爱)" [243210 A7 B7 導 解 五、發明說明(41) 放射顯影。 生化參數包含,但不限於:特定途徑研定,如訊號轉 蛋白質合成和運送、核糖核酸轉錄、胆固醇合成和分 糖生成和糖分解。 定紋 就此處所使用者而言,用於此處之“定紋,,一詞係指製 作一物質,特別是一藥草之特徵輪廓,以便於鑑定之的方 法。如此處所使用之“指紋,,一詞係指用於定紋之特定方法 其結果之呈現。 各種不同的定紋方法之例子,包含,但不限於:dna 定紋、蛋白質定紋、化學定紋和足跡定紋。 DNA定紋,或輪廓,係指一種由特定生物來源(如: 一特定植物、植物物種、植物屬、植物部位或植物組織) 之DNA製作一單一樣式的方法。此dna指紋,或輪廓, 可被用來區分該特定生物來源與—不同的生物來源。藉由 利用微陣列、寡核苷酸陣列、DNA晶片或生物晶片分析 一批次檢體所得到的樣式亦被稱為“指紋,,。 蛋白為定紋係指在一細胞、組織、器官或生物體(如 植物)衣作一蛋白質之樣式,其即時提供該細胞、組織 w s或生物體之一完全特徵化的“指紋”。 化學定紋係指在-細胞中低分子量化學物質之分析以 及mu細胞、組織、器官或生物體(如一植物)之最 、、的樣式。其分析通常被以氣相色層分析(GC)、高效液 相層析(HPLC)或質譜儀完成。 (請先閱讀背面之注音?事項再填寫本頁} -----r---^---------A_vl. 經濟部智慧財產局員工消費合作社印製Tibtech 16, 301-306 (1998)); Lansay, DNA chips; Current status of science and technology 'Natural Biotechnology No. 16, pp. 40-44 (1998); Strange and others' approach genetic information with high-density DNA arrays , Science No. 274, p. 610 614 (1996); and Chen et al., Using a colorimeter to measure genes for phenotypic patterns and dissociative expression by the cdna U array system, genomics No. 50, p. Pp. 1-12 (1998); p. Andrew Audin et al., Characteristics of the stress-inducing effects of homocysteine, Journal of Biochemistry No. 332, pp. 213-221 (1988); and Jebert et al. Humans, will genetics revolutionize the process of new drug discovery, Curr, Opin Biotechn () 1 816), 699-674 (1997). Other more specific references that can be applied to the present invention include, but are not limited to, those who propose expression technology, such as ETS (see, for example, Michael I Feineng, Gene Expression in Rectification and Sickness _ Therapeutic Target's ^, Biotechnology Trends Issue M, page M298 (lean year ... general overview of protein generation (see, for example: Robinson et al.-Overview of Proteomic Kinases in Forefront Lung Cancer, National Academy of Sciences Research Report No. 93, Chau-Side Page (touching the year)), chemical and spectroscopic methods for the ingredients of the Zhongding herb composition (Kojima et al. From ⑹post Xiancai), Phytochemistry No. 48, Vol. 5, pp. 885-888 ( (Deleted years)), the determination of functional antigens (see, for example, Alix Rensidis, Functional Antigens' Natural Biotechnology No. 16, pages 305-307 (leap year), high performance liquid chromatography (see eg: Miller Twinn Sheen (editor), High Performance Liquid Chromatography of Proteins, Peptides, and Polynuclear Acids. · Contemporary Themes and Applications (Analytical Techniques and Laboratory Manuals for Clinical Chemistry, VCH Publishing, (1991), Electric ice (see, for example, · Hunston Mel et al., Electrophoresis Operation: This paper uses the national standard (CNS) A4 specification, Q χ No. 1243210 A7 B7 V. Description of the invention (40) The method of printing the second ship and protein separation by the staff of the Intellectual Property Bureau of the Ministry of Intellectual Property and Application refers to $, Yolanda Willie and Shangsi (1997)), and interactive reactive marker test (see eg: Ail '), Zhuoren Wood Chaco hepatitis virus · experimental infection and natural occurrence, Hepatology No. 4, Vol. 5, pp. 817-823 (1984)). Structural genomics is unraveling—the structure of all proteins encoded by the completed genome (its methodology includes direct output per unit time structure Judgment and computer algorithms) were discussed by Terry Jentland, Structural Genomics: The Road to Bioinformatics, Natural Biotechnology No. 16, pp. 625-627. About Bioinformatics · Genes and Proteins Analytical Guidelines for Operational Analysis = Hanley and Shangsi (1998) and Luke Alfie, DNA Sequencing • From Methodology to Bioinformatics (Introduction to Biotechnology Series) ). Cell biological parameters include, but are not limited to, karyotype analysis (such as relative staining elongation, position of centromere, presence or absence of secondary contraction), karyotype map (ie, a type of karyotype of the organism) (Shown), chromosomal behavior during mitosis and mitosis, chromosome staining and ribbon patterns, DNA-protein-parent interaction (also known as nuclease protection detection), neutron scattering research, rolling circles ) (AM Degerman and Red Coul, Nucleic Acid Research, Vol. 26, No. 13, pp. 3235_3241 (1998), Beckett et al., Molecular Cell Biology, No. 16, vol. 丨, p. 628, Hong 6294 (1996), Shi Ge Li et al., Journal of Virology No. 70, Vol. 2 1132 · 1136 (1996), A. Fayle and S. Su, National Scientific Research Report No. 92, No. 1 Volume 〇, pages 4641_4645 (1995), and after reacting with radiolabeled riboribonic acid, the automatic first house of the whole nucleic acid applies the Chinese National Standard (CNS) A4 ^ Grid G X 297 Love) " [243210 A7 B7 Explanation V. Invention Description (4 1) Radiography. Biochemical parameters include, but are not limited to, specific pathway studies, such as signal transduction, protein synthesis and delivery, ribonucleic acid transcription, cholesterol synthesis, and glycogen production and glycolysis. For the users here, the term "fixing pattern," as used herein, refers to the method of making the characteristic outline of a substance, especially a herb, for easy identification. As used herein, the term "fingerprint," Refers to the presentation of the results of a particular method used to fix patterns. Examples of a variety of different texturing methods include, but are not limited to: DNA texturing, protein texturing, chemical texturing, and footprint texturing. DNA patterning, or contouring, refers to a method of making a single pattern from DNA from a specific biological source (eg, a particular plant, plant species, plant genus, plant part, or plant tissue). This DNA fingerprint, or profile, can be used to distinguish that particular biological source from—different biological sources. The pattern obtained by analyzing a batch of specimens using a microarray, oligonucleotide array, DNA chip, or biochip is also referred to as "fingerprint." A protein is defined as a cell, tissue, organ, or organism. A body (such as a plant) coats as a protein, which immediately provides a fully characterized "fingerprint" of the cell, tissue, or one of the organisms. Chemical texturing refers to the analysis of low-molecular-weight chemicals in cells and mu cells , Tissue, organ, or organism (such as a plant), the most common, and its style. The analysis is usually done by gas chromatography (GC), high performance liquid chromatography (HPLC) or mass spectrometer. (Please read the back first Phonetic notation? Please fill in this page again for matters} ----- r --- ^ --------- A_vl. Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs

經濟部智慧財產局員工消費合作社印製 1243210 A7 -------— B7_______ 五、發明說明(42 ) 足跡定紋係指-種發現兩分子如何枯在一起的方法。 在DNA的例子中,—蛋白質被結合至一段被標定的職 ^後此DNA藉由酵素或化學侵襲被分解。以程序產生 -含有所有大小之片段的“階梯,,。驗被所結合的蛋白質 =護的地方較少被分解,因此其“階梯,,顯得較模糊。足跡 定紋為一用於定位調控基因活性之蛋白質真與dna結合 的位置之通用技術. 用來完成任一定紋之工具和方法係被詳述於本文豆他 段落。 ^ 生物反應 就此處所使用者而言,一 “生物反應,,係指一生物系統 經過暴於一藥草組成物後之一生物反應的任何測量或觀察 。有時此處亦指一 “生物作用”。一生物反應係為針對一特 定藥草組成物之生物活性之定性或定量資料。生物反應資 料包含劑量和時間資訊二者,其中此種資訊係為熟習量測 生物系統對不同的處理之反應者所習知者。因此,生物反 應資料包含一特定的生物系統對一被以特定的方式投而經 過一段特定的時間之特定劑量的藥草組成物之特定生物反 應的資訊。 生物反應包含,但不限於,生理反應、型態學反應、 認知反應、動機反應、自主反應和轉譯後修飾(如訊息轉 導測量)。許多藥草組成物展現一種以上之生物反應(參見 ,如基張黃,中國藥草藥理學、CRC出版社(1993年))。某 些特定的生物反應可被包含於1種以之已劃定的族群或具 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 45 - I I I I I I I » — — — — — — — — (請先閱讀背面之注意事項再填寫本頁) -*1 ϋ «ϋ Β4.- 1243210Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 1243210 A7 ----------- B7_______ V. Description of the Invention (42) Footprint marking refers to a method to find out how two molecules wither together. In the case of DNA, a protein is bound to a labeled job and the DNA is broken down by enzymes or chemical attack. Generated by the program-the "steps," which contain fragments of all sizes. The bound proteins are less likely to be broken down, so the "steps," appear fuzzy. Footprinting is a general technique for locating where proteins that regulate gene activity actually bind to DNA. The tools and methods used to accomplish any of these lines are detailed in the other paragraphs of this article. ^ Biological response As used herein, a "biological response" refers to any measurement or observation of a biological system after a biological system has been exposed to a herb composition. Sometimes it is also referred to as a "biological effect" A biological response is qualitative or quantitative data on the biological activity of a particular herb composition. Biological response data includes both dose and time information, where such information is familiar with measuring biological system responders to different treatments Known. Therefore, the biological response data contains information about a specific biological response of a specific biological system to a specific dose of a herbal composition that has been cast in a specific manner over a specific period of time. Biological responses include, but do not Limited to physiological responses, morphological responses, cognitive responses, motivational responses, autonomic responses, and post-translational modifications (such as message transduction measurements). Many herbal compositions exhibit more than one biological response (see, for example, Ji Zhanghuang, Chinese Medicine Herbal Physiology, CRC Press (1993)). Some specific biological reactions can be included in one The specified ethnic group or paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm) 45-IIIIIII »— — — — — — — (Please read the precautions on the back before filling this page)- * 1 ϋ «ϋ Β4.- 1243210

(請先閱讀背面之注意事項再填寫本頁) 裝-----=----訂---------. 1243210 A7 -----------B7______ 五、發明說明(44 ) 之狀態(如:關節疼痛和發炎)、運動力、視力(如:近視 、眼盲)、肌肉張力(如:消耗性症候群、肌肉扭傷)、痛 覺之有無、表皮和真皮之健康(如··皮膚刺激、癢、皮膚 傷口)、内分泌系統之功能、心功能、神經協調、頭部相 關健康(如:頭痛、暈眩)、年齡(如:生命期、長壽)以及 呼吸(如:阻塞、呼吸疾病)。 一“型態學反應”係指一生物系統經過暴露於一藥草組 成物後’與其型怨學或形狀和結構有關之任何特性。形態 學反應’不管生物系統的種類,包含但不限於:大小、重 量、高度、寬度、顏色、發炎程度、一般外觀(如:不透 明、透明、蒼白)、潮溼或乾燥程度、癌化生長之有無以 及寄生蟲或害蟲之有無(如:老鼠、蝨子、跳蚤)。以一完 整生物為基準之形態反應包含,但不限於:毛髮生長的數 量和位置(如:多毛症、禿頭)、卷曲之有無、指甲和皮膚 生長之種類和程度、血液凝固的程度、潰爛或創傷之有無 以及痒瘡之有無。 一 έ忍知反應係指一生物糸統隨著暴露於一藥草組成 物後之與認知或心理狀態相關的任何特性。認知反應包含 ,但不限於:察覺、辨認、理解、判斷、認憶、推論和想 一“動機反應”係指一生物系統隨著暴露於一藥草組成 物後,與動機或誘發行動有關之任何特性。動機反應包含 ,但不限於:情感(如歡喜)、欲望、經後天學習的驅策力 、特殊的心理理虛求(如:食欲、性衝動)或作為對行為誘 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 裝 訂·--------幸 經濟部智慧財產局員工消費合作社印製 47 1243210 A7 五、發明說明(45 ) 因之類似衝動(如:精力、性衝動)。 一自主反應’’係指一生物系統隨著暴露於一藥草組成 物後之與自主反應有關的任何特性。自主反應與一生物系 統之自主神經系統有關。自主反應的例子包含,但不限於 :自主性功能(如:緊張、恐慌),或生理需求(如:呼吸 、心律、賀爾蒙釋放、免疫反應、失眠、麻醉)。 以各種不同的藥草組成物或藥草成分處理的細胞、組 、、我叩6和王生物體之生物反應係為藥草技藝中所習知者 。例如·藥草組成物賽雷多(Sairei-to)(TJ-114)、澤浮(目 名“T—,,)和茯茶(目名“触町⑽,,)任一皆被發現可抑 制老鼠内皮素-1之合成及表現(Hatt〇H等人,赛雷多 (Sairei-to)。可以抑制腎絲球中内皮素·丨的合成,曰本腎 藏學會諸第39期第2卷,第12Μ_ 〇997年))。間白素 (IL)-1阿_發生成藉由以草藥小柴胡湯對培養的人類皮角 貝細胞之處理被顯著地提高(松本等人,由於小柴胡湯培 養的人類角質細胞之由間白素-丨由“引介的自主分泌生長 之提升日本藥理學雜諸第37期第4卷,第333_336頁(DM 年將小柴胡湯添加至得自健康自願者之周圍也液單核 农、、、田胞之坨養中,造成顆粒球細胞株刺激因子(G-CSF) 生產之劑里依賴性提兩(山崎等人,草藥“小柴胡湯,,對周 圍血液單核球細胞誘發生體外顆粒球細胞株刺激因子生產 ,臨床實驗免疫學期刊第37期第2卷,第83_9〇頁(Η%年) 這4研九者結淪涊為小柴胡湯之投藥可能有用於 有其療效之慢性肝病、惡性疾病和急性感染疾病之治療。 本紙張尺度適用巾@ @家標準(CNS)A4規格⑵G X 297公着了 (請先閱讀背面之注咅?事項再填寫本頁) -----r---^---------. 經濟部智慧財產局員工消費合作社印製 48 1243210(Please read the precautions on the back before filling out this page) Install ----- = ---- Order ---------. 1243210 A7 ----------- B7______ Five State of the invention (44) (such as joint pain and inflammation), exercise, vision (such as: myopia, blindness), muscle tension (such as: wasting syndrome, muscle sprain), presence of pain, epidermis and dermis Health (such as skin irritation, itching, skin wounds), endocrine system function, heart function, neural coordination, head-related health (such as: headache, dizziness), age (such as life span, longevity), and breathing (Such as: obstruction, respiratory disease). A "morphological response" means any characteristic of a biological system after its exposure to a herb composition ' Morphological response 'Regardless of the type of biological system, including but not limited to: size, weight, height, width, color, degree of inflammation, general appearance (such as: opaque, transparent, pale), humidity or dryness, presence or absence of cancerous growth And the presence of parasites or pests (eg, mice, lice, fleas). Morphological responses based on a complete organism include, but are not limited to: the amount and location of hair growth (eg, hirsutism, baldness), the presence or absence of curl, the type and extent of nail and skin growth, the degree of blood clotting, ulceration or The presence of trauma and the presence of pruritus. One tolerance response refers to any characteristic of a biological system that is associated with a cognitive or psychological state following exposure to a herb composition. Cognitive responses include, but are not limited to: perception, recognition, understanding, judgment, recollection, inference, and thinking. A "motivational response" refers to any biological system that is associated with motivation or evoked actions following exposure to a herb composition. characteristic. Motivation reactions include, but are not limited to: emotions (such as joy), desires, driving forces for acquired learning, special psychological reasoning (such as appetite, sexual impulses), or the application of Chinese national standards on paper dimensions CNS) A4 size (210 X 297 mm) (Please read the precautions on the back before filling out this page) Binding · -------- Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs 47 1243210 A7 V. The invention (45) is similar to impulses (such as: energy, sexual impulses). An autonomous response ' ' refers to any characteristic of a biological system that is associated with an autonomous response following exposure to a herb composition. Autonomic responses are related to the autonomic nervous system of a biological system. Examples of spontaneous responses include, but are not limited to, autonomic functions (such as: tension, panic), or physiological needs (such as: breathing, heart rhythm, hormone release, immune response, insomnia, anesthesia). The biological response system of cells, cells, cells, and organisms treated with various herb compositions or herb ingredients is known in the art of herbs. For example, any of the herbal compositions Sairie-to (TJ-114), Zefu (head name "T- ,,"), and 茯 茶 (head name "Touchmachi ⑽,") were all found to inhibit mice Synthesis and expression of endothelin-1 (Hattoh et al., Sairai-to. Can inhibit the synthesis of endothelin · 丨 in glomerular silk. 12M_ 997))). Interleukin (IL) -1 A_genesis was significantly improved by the treatment of cultured human skin keratinocytes with the herb Xiaochaihu decoction (Matsumoto et al., Because of the human keratinocytes cultured by Xiaochaihu decoction Leukin- 丨 Improved the growth of spontaneous secretion induced by "Japanese Pharmacology Miscellaneous No. 37 Vol. 4, pp. 333_336 (DM year added Xiao Chai Hu Tang around healthy volunteers also single-nuclear agriculture, In the cultivation of field cells, it is dependent on the production of granulocyte cell line stimulating factor (G-CSF). (Yakizaki et al., Herbal "Xiao Chai Hu Tang," induces peripheral blood mononuclear cells Production of granulocyte cell line stimulating factors in vitro, Journal of Clinical Experimental Immunology, Vol. 37, Vol. 2, pp. 83-90 (Η% year) These 4 researchers who have been reduced to Xiaochaihu Decoction may be used for its efficacy Treatment of chronic liver disease, malignant disease and acute infectious disease. This paper is suitable for towels @ @ 家 标准 (CNS) A4 size ⑵G X 297. (Please read the note on the back? Matters before filling out this page)- --- r --- ^ ---------. Staff Consumption of Intellectual Property Bureau, Ministry of Economic Affairs Printed by Cooperatives 48 1243210

五、發明說明(46 ) 經濟部智慧財產局員工消費合作社印製V. Invention Description (46) Printed by the Consumer Cooperative of Intellectual Property Bureau of the Ministry of Economic Affairs

在以純化自中藥草黃蓍皂苷IV (AS-W)對人類臍帶靜脈内 皮細胞(HUVECs)之處理後,胞漿素原活性化因子抑制因 子第1型(PAI-1 )· —性汛息核糖核酸表現降低且組織型胞漿 素原活化因子(t-PA)-專一性訊息核糖核酸升高。(章等人 ,人工培養的人類臍靜脈内皮細胞之溶液纖維能力的調控 :黃蓍皂苷(IV)向下調控胞漿素原活化因子抑制因子_丨且 上调控組織型胞漿素原活化因子表現,血管研究期刊第Μ 期第4卷,第273_280頁(1997年))。分離自人蔘根的四種成 分中之一種成分被發現為一人類單核球和ΤΗΡ·!細胞之虬一 8生成的有效誘發劑,且此誘發係由升高的比_8訊息核糖 核酸表現所伴隨(園田等人,以來自人蔘根的酸性多糖類 對間白素-8-生產之刺激,免疫藥理學第%期第3卷,第 287 294頁(1998年))。藉由流動細胞計量分析,巨噬細胞 上以伽馬11/111受體和補體受體3(CR3)之表現,以漢方草 蕖Toki芍藥政(TSS)處理後禮發現提高(赛昂,來自漢方草 藥之新BRM,日本藥理學雜誌11〇期(附冊丨),第87_92頁 (1997年)。利用電腦影像分析,陳等人(用於MRI/lpr老鼠 中細胞間附著分子-丨表現之影像分析··中國草藥之作用, 中華醫學雜諸第75期第4卷,第2G4德頁(1995年))發現細 胞間附著分子-IdCAM])、免疫球蛋白和C3之分布強度 在以中國藥草天牛素(stragalin)處理後在MRI/lpr老鼠中被 顯著提高。西方轉印顯示,由一天然中國藥草分離之漢防 己素,抑制老鼠肺泡巨噬細胞中被訊號誘導的NF_卡巴B 活化鎮。(陳等人’漢防己素抑制老鼠肺泡巨嗤細胞中被 ^-----r---^---------_ (請先閱讀背面之注咅?事項再填寫本頁) 本紙張尺錢财關家標準(CNS)A4規格⑵〇x2m) 49 1243210 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(47 ) 訊號誘導的NF-卡巴B活化,生化生理研究通訊第231期第 1卷,第 99-102 頁(1997年))。 演算法 就此處所使用者而言,一“演算法,,係指一逐步的解決 問題程序,特別是一具有有限數目的步驟,已建構好之循 環式計算程序。用於植物相關的、標識物及生物反應資料 組之二和三維分析的適當的演算法係為熟習演算技藝者所 熟知。此等演算法係有用於構築本發明之藥草生物反應陣 列。有關演算法之一般資訊,參見如:傑若得H.扎耳,生 物統計分析,第二版,普廉提斯霍耳(1984年)、羅伯Α·修 溫傑特,遙感影像處理及分類,學術出版社(1983年)、、 史帝文高耳得等人,二維及三維點配合演算法:形勢估計 與相符,樣式辨認第31期第8卷,第1〇19_1031頁(1998年) 、伯克拉斯田,非線性程式設計與多目標判別演算法,威 利-跨學科系列(系統與最佳化),約翰威利與尚司(1998年) 、傑佛瑞H.金士敦,演算法與資料結構:設計、修正、分 析、國際計算機科學系列,愛迪生-威斯利出出版公^司09^ 年)、史帝文S_史乾納,演算法設計手冊,史普林格佛列 (1997年)以及馬梭!^.努兹,演算法機率:問題集伽心以 模型),I普曼與霍耳(1995年)。有關演算法對以遺傳為 主的資料之應用的更專門資訊,參見如:#賈斯斐得,群 、樹、序列演算法··計算機科學與計算機生物學,劍橋大 學出版部(1997年)、馬蘭尼米歇耳,遺傳演算法簡介(複 雜適應系統),麻省理工學院出版社(1996年)、大衛e.高耳 (請先閱讀背面之注意事項再填寫本頁) 裝 訂---------A9·.After treatment of human umbilical vein endothelial cells (HUVECs) with purified baicalin IV (AS-W) from Chinese herbal medicine, cytoplasmin activation factor inhibitor type 1 (PAI-1) Decreased RNA performance and increased tissue-type plasminogen activating factor (t-PA) -specific message RNA. (Zhang et al. Regulation of solution fiber capacity of artificially cultured human umbilical vein endothelial cells: baicalin (IV) down-regulates cytosinogen activating factor inhibitor _ 丨 and up-regulates tissue-type cytosinogen activating factor Performance, Journal of Vascular Research, Volume M, Volume 4, 273_280 (1997)). One of the four components isolated from human roots was found to be a potent inducer for the production of human mononuclear globules and THP ·! Cells, and this induction was caused by an increased ratio of _8 message RNA Accompanied by performance (Sonoda et al., Stimulation of melanin-8-production with acidic polysaccharides from the roots of mandarin duck root, Immunopharmacology Vol. 3, Vol. 3, p. 287 294 (1998)). Through flow cytometric analysis, the expression of gamma 11/111 receptor and complement receptor 3 (CR3) on macrophages was improved after treatment with Chinese herbal medicine Toki 芍 Pharmacy (TSS) (Saion, from New BRM of Chinese herbal medicine, Japanese Journal of Pharmacology, Issue 110 (Appendix 丨), pages 87_92 (1997). Using computer image analysis, Chen et al. (For intercellular adhesion molecules in MRI / lpr mice-丨 performance Image analysis ·· The role of Chinese herbal medicine, Chinese Medical Journal Vol. 75, Volume 4, 2G4 German page (1995)) found that the intercellular adhesion molecule-IdCAM]), the distribution strength of immunoglobulin and C3 Chinese herb stragalin treatment was significantly improved in MRI / lpr mice. Western transfer shows that tetrandrine, isolated from a natural Chinese herb, inhibits signal-induced NF_carbaba activated towns in mouse alveolar macrophages. (Chen et al. 'Anticotanin inhibits ^ ----- r --- ^ ---------_ in alveolar giant cell of mouse (please read the note on the back first? Matters before filling in this Page) This paper rule (CNS) A4 specification (0x2m) 49 1243210 A7 B7 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 5. Description of the invention (47) Signal-induced activation of NF-carbaba B Physiological Research Bulletin, No. 231, Vol. 1, pp. 99-102 (1997)). Algorithm For the users here, an "algorithm" refers to a step-by-step problem-solving program, especially a circular calculation program with a limited number of steps. It is used for plant-related, markers Suitable algorithms for biological response data sets two and three-dimensional analysis are well known to those skilled in algorithmic techniques. These algorithms are used to construct the herb biological response array of the present invention. For general information about the algorithms, see for example: Gerold H. Zaer, Biostatistical Analysis, Second Edition, Plenty Hall (1984), Rob A. Schwingert, Remote Sensing Image Processing and Classification, Academic Press (1983), Steve Golder, et al. Two-dimensional and three-dimensional point coordination algorithms: situation estimation and conformity, style identification No. 31, volume 8, page 1019_1031 (1998), Berklastian, nonlinear Programming and Multi-Objective Discriminant Algorithms, Wiley-Interdisciplinary Series (System and Optimization), John Wiley and Shang Si (1998), Jeffrey H. Kingston, Algorithms and Data Structure: Design, Correction, Minute Analysis, International Computer Science Series, Edison-Weasley Publishing Company (^^^^), Steven S. Steiner, Algorithm Design Manual, Springer Fletcher (1997), and Marshall! ^. Nutz, Probability of Algorithms: Problem Sets, Models and Models, Ipman, and Hall (1995). For more specific information on the application of algorithms to genetic-dominated data, see, for example, # 贾Fifield, Group, Tree, and Sequence Algorithms · Computer Science and Computer Biology, Cambridge University Press (1997), Maranne Mitchell, Introduction to Genetic Algorithms (Complex Adaptive Systems), MIT (1996), David E. Gaul (Please read the notes on the back before filling this page) Binding --------- A9 ·.

50 1243210 五、發明說明(48 ) =V::二算法於搜尋、最佳化和機器學習,愛迪生 算法+資料:構 〜4 構1化程式,史普林格佛列(1996年)、安 7威特林登與詹nDNA排序:基因 =,耶利斯霍伍得分子生物學系列,耶利斯霍伍得有 限公司⑽4年)以及皮耳保第與蘇廉布侖埋克,生物資訊 ★ •機③”法(適應性計算與機器”), 出版部(1998年)。 組合化學 就此處所使用者而言,“組合化學,,係指用來創造數以 百计或千計的化合物之諸等科技,其中任_化合物有一個 或更夕的不同特徵,如其形狀、電荷和/或厭水性特性。 組合化學可被用來產生屬於藥草或藥草成分的化學變異之 化合物。此等化合物可利用本發明的方法*被評估。 經 濟 部 智 慧 財 產 局 員 工 消 費 合 作 社 印 製 基本的組合化學觀念係為任一熟習化學技藝者所習知 ’且亦可被發現於尼可拉斯κ·特列得,組合化學(牛津化 學’專精門)’牛津大學出版部⑽8年)、安東尼w察尼 克與謝拉哈伯斯迪韋特(編者),組合化學操作指南,美國 化學會(㈣年)、史帝芬R•威耳遜(編者)與安東尼W.察尼 克(投稿人)’組合化學:合成與應用,約輪威利與尚司(1997 年)、艾利克M.高登與詹姆斯F•克文(編者),組合化學與分 子密度於新藥發現,威利.立斯(1998年)、徐謬飢比利(編 者),组合胜肽貯庫操作方法(分子生物學方法),修門出 版社(1997年)' 約翰P.狄弗林,高單位時間輸出筛選,馬50 1243210 V. Description of the invention (48) = V :: two algorithms in search, optimization and machine learning, Edison algorithm + data: structure ~ 4 structure 1 program, Springer Fletcher (1996), An 7Witlinden and Jen nDNA Sorting: Genes =, Yales Howard Molecular Biology Series, Yelles Howard Co., Ltd. (4 years) and Pierbodie and Surem Brunk, Bioinformatics ★ • Machine ③ "Method (Adaptive Computing and Machines)", Publishing Department (1998). Combinatorial chemistry For the users here, "combinatorial chemistry" refers to technologies used to create hundreds or thousands of compounds, where any compound has one or more different characteristics, such as its shape and charge And / or anaerobic properties. Combinatorial chemistry can be used to produce compounds that are chemical variations of herbs or medicinal ingredients. These compounds can be evaluated using the method of the present invention. The concept of combinatorial chemistry is known to anyone skilled in chemical arts' and can also be found in Nicholas K. Trede, Combinatorial Chemistry (Oxford Chemistry 'Professionalism', Oxford University Publishing Department ⑽8 years), Anthony W. Zanick and Sheila Haberth DeWitt (editor), Guide to Combinatorial Chemistry Operations, American Chemical Society (leap year), Stephen R. Wilson (editor) and Anthony W. Zhanick (contributor) ' Combinatorial Chemistry: Synthesis and Applications, Yolanda Willy and Shangsi (1997), Eric M. Gordon and James F. Kevin (Editor), Combinatorial Chemistry and Molecular Density In the discovery of new drugs, Willie Lies (1998), Xu Mu Heng Billy (editor), Combined Peptide Depot Operation Method (Molecular Biology Method), Shumen Press (1997), 'John P. Di Flynn, High Unit Time Output Screening, MA

51 124321051 1243210

五、發明說明(49 ) 經濟部智慧財產局員工消費合作社印製 梭德克(1998年)、賴瑞高耳得與約瑟夫艾耳伯,以組合化 學與基因組合學並行,自然生物科技第15期第297頁(1997 年);亞里士波西迪士,組合化學,自然生物科技第16期 ,第 691-693 頁(1998年)。 實施例 實施例1 :為擇定之藥草組成物建立一標準化藥草生物反 應陣列 建立一標準化藥草生物反應陣列之基本流程係被提供 於第1圖。流程之任一部分的定義係被提供於前述。 隨著感與趣的一藥草組成物之擇定後,與此藥草組成 物相關之不同的性狀之資料被收集,其包含,但不限於: 與植物有關的特徵及標識物與生物反應資訊。 與植物有關的資料包含,但不限於:植物物種、特定 的植物部位、藥草組成物中植物的地理來源、植物的生長 條件、用來製備藥草成分的加工方法、貯存方法及條件以 及此藥草組成物之不同的化學分析。標識物資訊包含一生 物系統暴露於此藥草組成物後,所被收集的有關標識物的 定性和定量資料。可應用的標識物包含,但不限於:分子 標識物、細胞遺傳學標識物、生化標識物和巨分子標識物 。生物反應資訊包含一生物系統暴露於藥草組成物後所被 收集之與生物反應有關的定性和定量資料。 任一類型之資料(如:化學物質、標識物、生物反應 ,可利用一或更多種對所感興趣的藥草組成物之相同、相 似、貫質上相似或不同批次所行的檢驗而被獲得。此等不 本紙張尺度適用中國國家標準(CNS)A4規格(21〇 X 297公釐) ^ ------^一^ 裝-----r---訂--------- (請先閱讀背面之注意事項再填寫本頁) 52 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(50) 同的檢驗可於同時或不同時被實施。相似地,生物反應資 料可於同時或不同時,針對相同或不同的生物反應被收集 。因此,對於藥草生物反應資料之收集係於一次被收集, 抑或以一進行中的基礎上被收集。其中一生物系統被暴露 於一藥草組成物,俾以收集資料,而針對被投予的藥草組 成物之劑量以及處理時間的資訊被收集。生物反應資料亦 可包含轉譯後修飾,如訊號轉導之測量。 經過二或更多種的資料(如有關二或更多種標識物及 一生物反應之資料、植物相關性狀之資料與一生物反應資 料)之收集,該資料利用演算法被分析,俾以建立2和/或% 維藥草生物反應陣列。 對於藥草生物反應陣列不同的統計參數可被計算且可 成為藥草生物反應資料組之-部分。這些統計參數可以包 含,但不限於:平均值、標準偏差、相關或相符(或不相 符)、矩陣、比例、迴歸係數以及轉換值(如:原始資料之 倒正弦百分比轉換)。因此,藥草生物反應陣列可包含原 始資料以及某些計算值、分布、地理表現和與原始資料相 關之其它資料操縱。此種資訊之特別的例子包含,但不限 於:數字影像、散播圖、集團分析和標識物資料大規模基 因表現輪廓。 全部被累積的資料和最終的分析構成—被用來建立藥 草生物反應陣列資料組的特定藥草組成物之標準化藥草生 物反應陣列。由於被用來建立及維護—藥草組成物之藥草 生物反應陣列的程序之反覆的特性’此等陣列可被視作在 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)V. Description of the invention (49) Printed by Sodek (1998), Lai Rui Gaoerde and Joseph Alber, in the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs, in parallel with combinatorial chemistry and genomics. 297 (1997); Aris Bosidis, Combinatorial Chemistry, Natural Biotechnology No. 16, 691-693 (1998). EXAMPLES Example 1: Establishing a standardized herb bio-reaction array for a selected herb composition The basic flow for establishing a standardized herb bio-reaction array is provided in FIG. 1. Definitions of any part of the process are provided above. With the selection of an interesting and interesting herb composition, information on different traits related to the herb composition is collected, which includes, but is not limited to, plant-related characteristics and identifiers and biological response information. Plant-related information includes, but is not limited to: plant species, specific plant parts, geographical origin of plants in herb compositions, plant growth conditions, processing methods used to prepare herb ingredients, storage methods and conditions, and the composition of the herb Different chemical analysis of things. The identifier information contains qualitative and quantitative information about the identifier that was collected after a biological system was exposed to the herb composition. Applicable markers include, but are not limited to: molecular markers, cytogenetic markers, biochemical markers, and macromolecular markers. Biological response information contains qualitative and quantitative data related to biological responses collected by a biological system after exposure to a herb composition. Any type of information (e.g., chemical substances, identifiers, biological reactions, can be tested using one or more of the same, similar, qualitatively similar, or similar batches of the herb composition of interest) Obtained. These paper sizes are applicable to the Chinese National Standard (CNS) A4 specification (21〇X 297 mm) ^ ------ ^ 一 ^ Packing ----- r --- Order ---- ----- (Please read the precautions on the back before filling out this page) 52 1243210 Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 B7 V. Description of the invention (50) The same inspection can be performed at the same time or at different times Similarly, biological response data can be collected for the same or different biological responses at the same time or at different times. Therefore, the collection of biological response data for herbs is collected at one time, or on an ongoing basis. One of the biological systems is exposed to a herb composition to collect data, and information on the dose and processing time of the administered herb composition is collected. Biological response data may also include post-translational modifications, such as signal transduction Its measurement. Collection of two or more kinds of data (such as data about two or more markers and a biological response, data about plant-related traits, and a biological response data), which is analyzed using algorithms to establish 2 And / or% dimensional herb bioresponse array. Different statistical parameters for the herb bioresponse array can be calculated and can be part of the herb bioresponse data set. These statistical parameters can include, but are not limited to: average, standard deviation, Relevant or matching (or not matching), matrices, proportions, regression coefficients, and conversion values (such as the inverse sine percentage conversion of the original data). Therefore, the herb bioresponse array can contain the original data and some calculated values, distributions, and geographic representations And other data manipulation related to the original data. Specific examples of such information include, but are not limited to: digital images, scatter plots, group analysis, and marker data. Large-scale gene expression profiles. All accumulated data and final analysis Composition—The composition of a particular herb used to create a herb bioresponse array data set Standardized Herbal Biological Response Arrays. Due to the repeated nature of the procedures used to create and maintain the Herbal Biological Response Arrays of Herbal Compositions' These arrays can be regarded as applying the Chinese National Standard (CNS) A4 specification at this paper scale (210 X 297 mm)

H------— β--------- (請先閱讀背面之注意事項再填寫本頁) 53 243210 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(51 ) 任一時間點為靜態,抑或在一段時間為動態。最終的分析 可鑑定與任何特定的藥草組成物之一或更多種特定的生物 活性相關(正或負)或有關(即顯示一共同趨勢)之標準化藥 草生物反應陣列的次組合。 實施例2 ·為批次藥草組成物建立一批次藥草生物反應陣列 用於一批次之一藥草組成物建立一藥草生物反應陣列 之基本流程係被提供於第2圖。流程之任一部分的定義係 被提供於前述。用於建立此一陣列的程序係於適前用於標 準化藥草生物反應陣列所提出者相同。 通常,為一批次藥草生物反應所收集的資料之數量將 少於為建立一標準化陣列所收集者。不過,為了一批次藥 草組成物而被收集的資料可被加至一已建立的藥草生物反 應陣列S被用來建立-新的標準化藥草生物反應陣列。 通Φ,為了 一批次藥草生物反應陣列而被收集之僅有 的資料係為被發現與該被測試中的藥草組成物之所需的生 物活性高度相關或有關的資料。例如:假如已經判定一特 疋次組合的植物相關與標識物資料係與一特定的藥草組成 物之一所需的生物活性高度相關(基於標準化藥草生物反 應陣列資料及之前所討論的分析),為了判定是否此批次 ,、有所而的生物活性,只須測試此批次組成物之該次組合 的性狀。為了該特定的藥草組成物,藉由比較得自此批次 之次組合性狀所獲得的資料(即其批次藥草生物反應陣列) 與標準化藥草生物反應陣列,熟習此項技藝者可判定該特 定的批次是否具有所需的生物活性。 ---J--------1-----r I--訂---------AVWI (請先閱讀背面之注意事項再填寫本頁) 54 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(52 ) 實施例3 :建立與利用一主資料組 用於建立與利用一藥草組成物的主資料組的基本流程 係被提供於第3圖。流程之任一部分的定義係被提供於前 述。 第一步為一擇定的藥草組成物或批次藥草組成物之一 主資料組的建立。此係藉由將一生物系統暴露於此藥草組 成物並收集所產生的將組成此主資料組的標識物資訊而被 完成,在大部分而非特例中,此主資料組係包含以一陣列 之形式的基因組學和/或蛋白組學資料,如一利用—dna 生物晶片所獲得的陣列。 其次,此主資料組被分析以探究是否分化性表現以吉 果已由被測試的藥草組成物被獲得。為了在下一步產生有 意義的演算法,分化性表現/結果係為所需者。此等分化 性表現/結果之例子包含,但不限於:相應於暴露於該藥 草組成物,某⑧基因被向上或向下調控或者相應於此暴露 某些蛋白質之濃度已被升高或降低之表徵。 如果沒有有意義的或有用的分化性表現/結果被獲得 ,那麼必須此暴露及標識物收集步驟。如果認為實驗錯誤 導致第一次缺乏足夠的結果,那麼此暴露/資料收集步驟 可以用與第-次相同之所有的變數(如:相同的生物系統 、相同的標識物組、相同的實驗操作步驟等)被重覆。然 而,可旎需要更改生物系統採樣(如··被利用的細胞類型 、細胞生長期別)、利用一不同的標識物組和/或改變實驗 操作步驟’俾以達到分化性表現/結果。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐了 M,-----r---tr---------· (請先閱讀背面之注意事項再填寫本頁) -Η- I I 4 _ 55 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(53 ) 實施例4 ··使用藥草生物反應陣列資訊 此處所討論之藥草生物反應陣列資訊可被使用於許多 不同的目的,包含但不限於下述·· 1}評估一藥草組成物之 成分、2)預測一藥草組成物之生物反應、3)判定何種標識 物資訊係與-藥草組成物之一特定生物反應最高度相關、 4)判定何種資料組之資訊(即植物相關資料、標識物資料 及生物反應資料)係與一藥草組成物之一特定生物反應最 相關、5)判定何種類型之生物系統最適於評估一藥草組成 物之生物活性、6)調整或改變一藥草組成物之成分,俾使 該藥草組成物之藥草生物反應陣列與一相同或實質上相同 的藥草組成物之標準化藥草生物反應陣列相對應、7)調整 或改變一藥草組成物之成分,俾使該藥草組成物將具有所 需要的生物活性、8)創造及更新標準化藥草生物反應陣列 、9)鑑定保有一藥草組成物之所需要的生物活性之特定成 分(如··植物部位、蛋白質、分子)、1〇)判定一藥草組成 物之何種成分可被排❺,而一方面保持或促進此藥草組成 物之所需要的生物活性、U)為一藥草組成物鑑定一或更 多之先前未知的生物活性、丨2)輔助治療學之設計,其包 含某草和非某草成分,如化學合成藥物或藥品以及13)利 用茱草生物反應資訊補充設計治療學之組合化學方法。本 發明之任一實施例可被熟習此應用技藝者利用此處所提供 的方法和工具所完成。 實施例5 :品質管制 本發明之藥草生物反應陣列科技係被用來將一實質上 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ^----------------- (請先閱讀背面之注意事項再填寫本頁) 56 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(Μ ) 等饧之-特定批次之一種藥草組成物(單位藥或一配方之 多广藥草)相關於或判定為一標準化或主批次之相同或實 質上相似的藥草組成物。被使用於此程序之藥草生物反應 陣列包含任一生物效應(即生物反應)之可接受的定量變異 範圍以及可旎上包含被指定於任一生物效應之重量值的 -種全體計分,其可包含來自—生物系統之多重生化途捏 之標識物。 “資料採掘,,係指用來判定或擇定何種組合之生物效應 為在任何特定的藥草生物反應陣列所需要的最少數目之生 物效應的一種程序。用於資料採掘的資訊係來自將一生物 系統(如一細胞系)以一劑量依賴性方式暴露於一標準化藥 草組成物以建立一標準化藥草生物反應陣列。此標準化藥 草生物反應陣列隨後可被與為了測試藥草組成物所建立之 不同的藥草生物反應陣列相比較。這些測試藥草組成物包 含’但不限於:不同的日期被製成之不同的批次、由不同 的時間被收集的粗藥草所製成的不同批次以及由不同地點 被收集的粗藥草所製成的不同批次。 實施例6 :改良一藥草組成物或為了 一藥草組成物鑑定新 的用途 藥草生物反應係藉由將生物系統暴露至來自一配方之 個別藥草的萃取物,抑或暴露至整個配方的萃取物,並檢 視此萃取物之生物效應。被觀察的生物效應可來自一生物 系統之多重生化途徑和/或來自一動物之多重組織,其中 不同的標識物係為了它們相應的定性和/或定量的改變而 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 57 _ 裝· · · · I —丨 I 訂·丨—··丨丨·_ · (請先閱讀背面之注意事項再填寫本頁) 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(55 ) 被估汁所產生的藥草生物反應陣列可被與新穎的藥草生 物反應陣列或來自不同的藥草組成物或以不同的程序所製 備的藥草組成物之相似的藥草生物反應陣列比較。此程序 係有用於擇定一指定組合之生物效應以及預測一指定的批 -人藥草組成物具有該指定組合之生物效應所需最少數目的 標識物。 為了建構藥草生物反應陣列,一熟習此項技藝者利用 不同的資料採掘工具,包含但不限於:統計分析、人工智 慧以及神經網路資料庫研究。可選擇的統計方法包含,但 不限於:基本搜尋式資料分析(EDA)、圖示搜尋式資料分 析[如拓荒(bushing)]以及多變異搜尋技術(如:集團分析 、硪別因子分析、逐步線性或非線性迴歸、分類樹)(參見 如:STATISTI CA™,出自StatSoft之套裝軟體,突耳沙 ,OK74104 ;電話·· 918-749-1119 ;傳真:918-749-2217 :^OQV^StatSoft rnm) 〇 資料採掘工具係被用來搜尋大量之藥草生物反應資料 ’以尋求建立一藥草生物反應陣列和各種不同的藥草生物 反應陣列内部,彼此間或之中的一致性型式。此程序包含 一藥草生物反應陣列的搜尋、建構,以及確認。此程序係 典型地一再重覆,直到一強固的藥草生物反應陣列或標準 化藥草生物反應陣列被蜂認。 上述之詳細描述係僅為了解的清晰而設而因此須了解 並沒有不必要的設限,因為對熟習此項技藝者而言變更的 方式是顯而易見的。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公餐) ---J--------- I I I L----訂--------- (請先閱讀背面之注意事項再填寫本頁) 58 1243210 經濟部智慧財產局員工消費合作社印製 A7 五、發明說明(56 ) 儘管本發明已連同此間之特別的實施例被載述,必須 被了解的是,本發明堪為進一步的變更且本發明意圖涵蓋 大體上遵循本發明之原理及包含諸如處在本發明所歸屬之 技藝中之習知或慣用的實務和可被應用於本文先前所載述 的必要特徵和遵行所提出申請的申請專利範圍之領域中之 來自本發明的新發展。 貫施例7 ·為人蔘建立一標準藥草生物反應陣列 為了此實施例之目的,標準人蔘係被選定為生長於東 北或於韓國之人蔘(panax Ginseng C.A· Meyer G115)。生H ------— β --------- (Please read the notes on the back before filling out this page) 53 243210 A7 B7 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 51) Any time point is static or dynamic over a period of time. The final analysis identifies subcombinations of standardized herb bioresponse arrays that are related (positive or negative) or related (ie show a common trend) to one or more specific biological activities of any particular herb composition. Example 2 • Establishing a Batch of Herbal Bioreaction Arrays for Batches of Herbal Compositions The basic flow for establishing a herb bioreaction array for a lot of herb compositions is provided in FIG. 2. The definition of any part of the process is provided above. The procedure used to create this array is the same as that previously proposed for standardizing herb bioreactor arrays. In general, the amount of data collected for a batch of herb biological responses will be less than that collected for the establishment of a standardized array. However, the data collected for a batch of herb composition can be added to an established herb bioreaction array S and used to create a new standardized herb bioreaction array. Through Φ, the only data collected for a batch of herbal bioreactor arrays are those found to be highly relevant or relevant to the biological activity required for the herb composition under test. For example, if it has been determined that a particular combination of plant-related and marker data is highly correlated with the biological activity required for a particular herb composition (based on standardized herb bioresponse array data and the analysis discussed earlier), In order to determine whether this batch has some biological activity, it is only necessary to test the properties of the combination of the batch composition. For this particular herb composition, by comparing the data obtained from the sub-combination traits of this batch (ie, its batch herb biological response array) with the standardized herb biological response array, those skilled in the art can determine that specific Does the batch have the required biological activity. --- J -------- 1 ----- r I--Order --------- AVWI (Please read the notes on the back before filling this page) 54 1243210 Ministry of Economic Affairs Printed by the Intellectual Property Bureau employee consumer cooperative A7 B7 V. Description of invention (52) Example 3: Basic process of establishing and using a master data set The master process of establishing and using a master data set is provided in Section 3. Illustration. Definitions of any part of the process are provided above. The first step is the creation of a master data set for a selected herb composition or batch of herb compositions. This is accomplished by exposing a biological system to the herb composition and collecting the generated identifier information that will form the master data set. In most, but not exclusively, the master data set consists of an array In the form of genomics and / or proteomics data, such as an array obtained using a DNA biochip. Second, this master data set was analyzed to investigate whether differentiated manifestations have been obtained from the tested herb composition. To produce meaningful algorithms in the next step, differentiated performance / results are needed. Examples of such differentiated manifestations / outcomes include, but are not limited to, those in which a certain gene is regulated up or down in response to exposure to the herb composition or that the concentration of certain proteins has been increased or decreased in response to this exposure Characterization. If no meaningful or useful differentiation manifestations / results are obtained, then this exposure and marker collection step must be performed. If it is considered that experimental errors lead to insufficient results for the first time, then this exposure / data collection step can use all the same variables as the first time (for example: the same biological system, the same set of markers, the same experimental operation steps Etc) was repeated. However, it may be necessary to change the sampling of the biological system (eg, the type of cell being used, the cell growth period), use a different set of markers, and / or change the experimental procedure ’to achieve differentiated performance / results. This paper size applies to China National Standard (CNS) A4 specifications (210 X 297 mm M, ----- r --- tr --------- · (Please read the precautions on the back before (Fill in this page) -Η- II 4 _ 55 1243210 Printed by the Consumers ’Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 B7 V. Description of Invention (53) Example 4 · Using Herbal Bioreactor Array Information Information can be used for many different purposes, including but not limited to the following: 1) Evaluating the composition of a herb composition, 2) Predicting the biological response of a herb composition, 3) Determining what kind of marker information is related to- A specific biological response of one of the herb components is most highly relevant, 4) The information of which data set (i.e. plant-related data, marker data and biological response data) is most relevant to a specific biological response of a herb component, 5 ) Determine what type of biological system is best for assessing the biological activity of a herb composition, 6) adjust or change the composition of a herb composition, so that the herb biological response array of the herb composition is the same or substantially the same Herb composition Corresponds to the standardized herb bio-response array, 7) adjusts or changes the composition of a herb composition so that the herb composition will have the required biological activity, 8) creates and updates a standardized herb bio-response array, 9) appraises Specific ingredients of biological activity required by a herb composition (such as plant parts, proteins, molecules), 10) determine which ingredients of a herb composition can be excreted, while maintaining or promoting the herb on the one hand The required biological activity of the composition, U) is the identification of one or more previously unknown biological activities of a herb composition, 2) the design of adjuvant therapy, which includes certain grass and non-some grass components, such as chemical synthesis Drugs or medicines and 13) combinatorial chemistry methods that complement the design of therapeutics using information from the biological response of the Chinese cornflower. Any of the embodiments of the present invention can be completed by those skilled in the art using the methods and tools provided herein. Example 5: Quality Control The herbal bioreactor array technology of the present invention is used to apply a substantially paper size to the Chinese National Standard (CNS) A4 specification (210 X 297 mm) ^ -------- --------- (Please read the notes on the back before filling out this page) 56 1243210 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 B7 V. Invention Description (M) etc.-Specific batches One of the herb compositions (a unit drug or a wide range of herbs) is related or determined to be a standardized or master batch of the same or substantially similar herb composition. The herb bioresponse array used in this procedure contains an acceptable quantitative variation range for any biological effect (ie, biological response) and a total score that can include the weight value specified for any biological effect, which May contain multiple biochemical markers from the biological system. "Data mining refers to a process used to determine or select which combination of biological effects is the minimum number of biological effects required in any particular herb biological response array. Information used for data mining is derived from the Biological systems (such as a cell line) are exposed to a standardized herb composition in a dose-dependent manner to establish a standardized herb bioresponse array. This standardized herb bioresponse array can then be used differently from herbs established to test the herb composition Comparison of bioreactor arrays. These test herb compositions include 'but are not limited to: different batches made on different dates, different batches made from crude herbs collected at different times, and Different batches of crude herbs collected. Example 6: Modification of a herb composition or identification of a new application for a herb composition. The biological response of the herb is by exposing the biological system to the extraction of individual herbs from a formula Or extracts that are exposed to the entire formula and examine the biological effects of the extract. Observed biological effects can come from multiple biochemical pathways of a biological system and / or multiple tissues of an animal, in which different identifiers are for their corresponding qualitative and / or quantitative changes, and this paper standard applies Chinese national standards (CNS ) A4 size (210 X 297 mm) 57 _ Installed Printed by the Consumer Cooperatives of the Bureau A7 B7 V. Description of the invention (55) The bioreactor array of the herb produced by the evaluated juice can be used with the novel bioreactor array of the herb or from different herb compositions or herbs prepared by different procedures Comparison of similar biologic response arrays of herbs. This procedure is used to select the biological effect of a specified combination and predict the minimum number of markers required for a specified batch-human herb composition to have the biological effect of the specified combination. In order to construct the herb bio-response array, a person skilled in the art uses different data mining tools, including but not limited to: statistical analysis, human Intelligence and neural network database research. Alternative statistical methods include, but are not limited to: basic search-type data analysis (EDA), graphical search-type data analysis [such as bushing], and multivariate search techniques (such as: Group analysis, identity factor analysis, stepwise linear or non-linear regression, classification tree) (see for example: STATISTI CA ™, packaged software from StatSoft, Tuersha, OK74104; Tel. · 918-749-1119; Fax: 918 -749-2217: ^ OQV ^ StatSoft rnm) 〇 Data mining tools are used to search for a large number of herb biological response data 'to seek to establish a herb biological response array and various different herb biological response arrays inside, among or among each other Consistent pattern. This procedure involves searching, constructing, and validating a herb bioresponse array. This procedure is typically repeated again and again until a robust herbal bioreactor array or a standardized herbal bioreactor array is recognized. The above detailed description is only for clarity of understanding, so it must be understood that there are no unnecessary restrictions, because the way of change is obvious to those skilled in the art. This paper size applies to China National Standard (CNS) A4 specification (210 X 297 meals) --- J --------- III L ---- Order --------- (Please Read the notes on the back before filling out this page) 58 1243210 Printed by A7, Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 5. Description of the Invention (56) Although the present invention has been described in conjunction with the specific embodiments here, it must be understood Yes, the present invention is a further change and the present invention is intended to cover generally following the principles of the present invention and including practices or customary practices, such as those in the art to which the present invention pertains, and may be applied to previously described herein The necessary features and areas of compliance with the scope of the patent application filed by the application are derived from new developments of the present invention. Example 7 • Establishing a standard herb bioreactor array for human pupae For the purpose of this example, the standard human pupae was selected as the human pupae growing in Northeast or South Korea (panax Ginseng C.A. Meyer G115). Raw

長氣候為-10至10C間,雨量50至100厘米(參見黃著中藥 藥理學(1993年)第21-45頁,CRC出版社,保卡雷頓,FL ,全權授權)。人蔘批次首先將以地理來源、物種、植物 部位(如根莖、根、葉皮、種子、芽和花)、生長條件、加 工方法和加工前後兩者之貯存條件被描述。這些批次化學 物含量的鑑定將藉由用於人蔘皂苷(如:R〇、Ral、Ra2、 RM、Rb2、Rb3、Rc、Rgh Rg2、Rd、Re、Rf、Rhi、Rh2 、NG-R2和Z-R1)之判定的定性高效液相層析分析被完成 ,其中亦包含對新脂性成分之薄層層析(參見葉耳金等人 ,中國藥理學報(1993年),第14期,第97_1〇〇頁和吉川等 人,藥理學雜誌(1993年)第113期,第46〇_467頁)。不同藥 草的皂菩含量視品種而定(參見表丨)必須為21和2〇6重量 百分比之間。這些資料然後將被貯存,最好存在一計算機 處理器之記憶體中,以備進一步之操作。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公爱) « . -----^----^--------- (請先閱讀背面之注意事項再填寫本頁) 59 1243210 A7 B7 五、發明說明(57 ) 經濟部智慧財產局員工消費合作社印製 表1·不同人蔘藥草之皂苷含量 ^___^種 人春 C.A. Meyer 西洋蔘 竹節蔘 大葉三七 總皂苷(重量百分比) 2.1-4.4% 4.9% 13.6-20.6% 9.34%The long climate is between -10 and 10C, and the rainfall is 50-100 cm (see Huang Zhu TCM Pharmacology (1993) pp. 21-45, CRC Press, Paul Carreton, FL, with full authority). The mandarin duck batch will first be described by geographical origin, species, plant parts (eg rhizomes, roots, leaf bark, seeds, buds and flowers), growth conditions, processing methods and storage conditions before and after processing. The chemical content of these batches will be identified by using human saponins (such as: R0, Ral, Ra2, RM, Rb2, Rb3, Rc, Rgh Rg2, Rd, Re, Rf, Rhi, Rh2, NG-R2 And Z-R1), a qualitative high-performance liquid chromatography analysis was completed, which also included thin-layer chromatography on neolipidic components (see Ye Erjin et al., Chinese Journal of Pharmacology (1993), No. 14, Pp. 97-100 and Yoshikawa et al., Journal of Pharmacology (1993), p. 113, p. 46-467). The soap content of different herbs depends on the species (see Table 丨) and must be between 21 and 206% by weight. This data will then be stored, preferably in the memory of a computer processor, for further operation. This paper size applies to China National Standard (CNS) A4 (210 X 297 public love) «. ----- ^ ---- ^ --------- (Please read the precautions on the back before (Fill in this page) 59 1243210 A7 B7 V. Description of the invention (57) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs. Total saponins (% by weight) 2.1-4.4% 4.9% 13.6-20.6% 9.34%

標準人蔘(即G115)之表現生物標識物包含下列··間白 素-8、間白素_2、GM_CSF、NfkB、ICAm_1、干擾素伽馬 、膽鹼醯轉移酶、trk A、神經生長因子(金等人,植物醫 學(1998年)第64期,第11(M15頁;園田等人,免疫藥理 學(1998年)第38期第如-綱頁;包等人,歐洲應用生理 學期刊(1997年)第76期第165-169頁;Iwangawa等人,自 由基生物醫學(1998年)第24期第1256-1268頁;萊得等人 ’歐洲應用生理學期刊(1996年)第74期第348_36〇頁)。另 外對較龐大批次大小,亞菲馬萃士(Affmatrix)之400000 寡核苷酸群/1.6厘米2晶片可被使用(美國專利第5,556,752 號)。標準人蔘之表現標識物將藉由採用光學石版圖、機 械微點或噴墨應用被製備(參見席納等人,生物科學趨勢 (1998年)第16期第301-306頁)。擇定組合之細胞將與標準 人蔘接觸一段不同的時間,在不同的條件以產生多重的微 陣列組合。此微陣列組合隨後將藉經由在微陣列之任一位 置上從螢光強度對穩定狀態信息核糖核酸(Mrna)濃度的推 測之生化萃取物的以雜交為基礎的監控被分析(席納等人 本紙張尺度適用中國國家標準(CNS)A4規格(21〇 χ 297公釐) ---J--------------^----^--------- (請先閱讀背面之注意事項再填寫本頁) 60 1243210The performance biomarkers of standard human 蔘 (ie G115) include the following: interleukin-8, interleukin_2, GM_CSF, NfkB, ICAm_1, interferon gamma, choline 醯 transferase, trk A, nerve growth Factors (Jin et al., Plant Medicine (1998) No. 64, page 11 (M15; Sonoda et al., Immunopharmacology (1998) No. 38 ru-gangue; Bao et al., European Applied Physiology Journal (1997) 76: 165-169; Iwangawa et al., Free Radical Biomedicine (1998) 24: 1256-1268; Ryder et al. 'European Journal of Applied Physiology (1996)' Issue 74, pages 348_36.) In addition, for larger batch sizes, Affmatrix's 400,000 oligonucleotide group / 1.6 cm2 wafer can be used (U.S. Patent No. 5,556,752). Performance markers will be prepared by using optical lithography, mechanical microspots, or inkjet applications (see Schiner et al., Bioscience Trends (1998) No. 16 pp. 301-306). Selecting a combination of cells Will be in contact with a standard person for a different period of time, under different conditions to produce multiple Array combination. This microarray combination will then be analyzed by hybridization-based monitoring of biochemical extracts of speculative steady-state information RNA (Mrna) concentrations from fluorescence intensity at any position on the microarray (Xi Na et al.'S paper size is applicable to Chinese National Standard (CNS) A4 (21〇χ 297 mm) --- J -------------- ^ ---- ^ --- ------ (Please read the notes on the back before filling this page) 60 1243210

經濟部智慧財產局員工消費合作社印製 ,科學(1995年)第·270期第467至470頁;席納等人,美國 國家科學院(1996年)第93期第10614至10619頁;羅克哈特 等人,自然生物科技(1996年)第14期第1675至1680頁;狄 瑞西等人,自然遺傳學(1996年)第14期第457至460頁;贺 勒等人,美國國家科學院報告(1997年)第94期第215〇至 2155頁)。陣列資料組隨後被輸入至演算法以產生標準人 蔘之統计表現生物標識物。標準人蔘之生物標識物包含: 環己醯胺敏感性[3氚]-白胺酸併入正比於蛋白質合成的增 加和[氚]-胸腺核苷相應於有絲分裂之併入的定量分析(參 見:山本等人,Arzneimittelforschung(1997年)第 27 期, 第1169至1173頁)。至於生化生物標識物,在不同的條件 下:存在[氚]-胸腺核苷(用於DNA合成)或存在和缺乏環己 醯胺和[氚]_白胺酸(用於蛋白質合成),骨髓細胞將與標準 人蔘接觸一段不同的時間,以完成生化生物標識物之定量 分析(即BBM測試)。生化生物標識物接著被輸入演算法以 產生標準人蔘之生化生物標識物值。統計資料隨後將被貯 存,最好存於一計算機處理器的記憶體中,以備進一步操 作。 一生物系統的生物反應(即生物反應)將採用細胞和整 個生物體而被測定。關於細胞,人蔘批次將被暴露於特定 的細胞類型,包含但不限於:纖維母細胞、巨噬細胞、單 核球、多形性有核白血球、LAK細胞、B16-F10黑色素瘤 細胞、THP-1細胞和海馬神經元(在〇·5毫克/亳升至1〇〇毫 克/毫升之濃度)。有關動物處理,0.5-100毫克/公斤之人 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 61 * -----^-----r---^--------- (請先閱讀背面之注意事項再填寫本頁) 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(59 ) 篆藥草卒取物將以口服、腹膜内注射或皮下注射的方式被 投予。 為了對標準人蔘判定一生物系統之一生物反應,人類 印巢癌細胞將被種入裸鼠中,造成可觸摸腫瘤的生成。在 腫瘤生成後’此老鼠被施以順_二氣二胺合鉑和標準人蔘 的共投藥。老鼠將被檢視腫瘤生長抑制、生存時間延長和 對血比容積值和體重之副作用的降低(NaKada等人,日本 癌症研究期刊(1998年)第89期第733至740頁)。其檢驗將 使用不同濃度的標準人蔘而被重覆進行,以產生對任一變 項之中間傾向、分散性和可變性之測量。 所產生的資料接著將被導入多維的分析,以產生多變 數常態分布組,作為判定生物活性和標準人蔘間一基準線 相關性之方法(參見札耳,j H·,於生物統計分析第2版(1984 年)第328至360頁,普廉提斯霍耳,安格伍德克里夫,NJ) 。一生物系統對標準人蔘之一生物反應的第二個獨立的判 定將為在運動時標準人蔘對身體表現的作用。大鼠將在不 同的濃度下(0.5-1〇〇亳克/公斤/天之間)被以標準人蔘處理4 天且動物將被測試其升高之血漿游離脂肪酸濃度和在約 70%最大食氧量(V〇2max)下運動時血糖濃度的維持(參見 王等人’植物醫學(1998年)第64期第13〇至133頁)。所產 生的資料將被收集,並隨後被導入多維分析以產生多變數 吊恶分布組,作為判定生物活性和標準人蔘間之基線相關 性的方法(參見札耳,JH.於生物統計分析第2版(1984年) ’第328至360頁,普廉提斯霍耳,安格伍德克里夫,Nj 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) _裝 L----訂---------. 62 1243210 A7 五、發明說明(6〇) 此處70王併為參考)。每一生物反應之分布組成物接著 被輸入至演#法,以i生標準人蔘之統計數值。、统計資料 隨後將被儲存,最好存於一計算機處理器之記憶體中,以 備進一步操作。 這些步驟之任一者(即化學分析、生物標識物之產生 和一生物系統之反應的判定)係被反覆,俾以產生一統計 數值之大資料庫。這些數值被編譯並輸入於一演算法中, 以產生標準人蔘之2_和3-維藥草生物反應陣列(HBR陣列) 。透過反覆,所產生的陣列(即標準化陣列)顯示有關標準 人篆在組成物(含生長條件)、生物標識物資訊和生物反應 之間最高的相關性。經由一測試批次在一藥草生物反應陣 列上之表現,藉著判定組成物和生物標識物資訊數值之2 或更多的已知相關的變數,生物反應變項數值藉由比較測 4值與標準人蔘標準化藥草生物反應陣列數值即可被預測 。所產生的預測將被用來評估一指定人蔘批次之品質,而 不須利用一生物系統之觀測的生物反應(參見實施例2)。 貫施例8 :利用與一特定的生物反應相關的一次組之變項 對一擇定的人蔘藥草組成物之評估 為了評估一測試批次之藥草組成物之品質,在所擇定 的藥草組成物中之藥草之有關植物相關資料的參數(如: 植物物種、植物部位、地理來源、生長條件、加工方法和 貯存條件)之資料先被收集。此被擇定之藥草組成然後被 施以如可被用來判定藥單之化學成分的化學分析之處置( 參見··葉耳金等人,中國藥理學報(1993年)第14期第97-100 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注咅?事項再填寫本頁) 裝 ----訂---------. 經濟部智慧財產局員工消費合作社印製 63 l2432l〇Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs, Science (1995) No. 270, pp. 467 to 470; Schenna et al., National Academy of Sciences (1996) No. 93, pp. 10614 to 10619; Rockha Special et al., Natural Biotechnology (1996) No. 14 pp. 1675-1680; Diriche et al., Natural Genetics (1996) No. 14 pp. 457-460; Holle et al., National Academy of Sciences Report (1997), Issue 94, pp. 215 to 2155). The array data set is then input to an algorithm to generate a statistical representation of a standard human biomarker. Biomarkers for standard human tadpoles include: Cyclohexamine susceptibility [3-]-leucine incorporation is proportional to an increase in protein synthesis and [氚] -thymidine corresponding to quantitative analysis of mitotic incorporation (see : Yamamoto et al., Arzneimittelforschung (1997), No. 27, pp. 1169 to 1173). As for biochemical biomarkers, under different conditions: the presence of [氚] -thymidine (for DNA synthesis) or the presence and absence of cyclohexamide and [氚] _leucine (for protein synthesis), bone marrow Cells will be in contact with standard human tadpoles for a different period of time to complete the quantitative analysis of biochemical biomarkers (ie, BBM testing). The biochemical biomarker is then input into an algorithm to generate a standard human biochemical biomarker value. The statistics will then be stored, preferably in the memory of a computer processor, for further manipulation. The biological response (ie, biological response) of a biological system will be measured using cells and the entire organism. Regarding cells, human cymbal batches will be exposed to specific cell types, including but not limited to: fibroblasts, macrophages, monocytes, polymorphic nucleated white blood cells, LAK cells, B16-F10 melanoma cells, THP-1 cells and hippocampal neurons (concentration increased from 0.5 mg / mL to 100 mg / mL). Regarding animal handling, the size of human paper of 0.5-100 mg / kg applies to Chinese National Standard (CNS) A4 (210 X 297 mm) 61 * ----- ^ ----- r --- ^- -------- (Please read the precautions on the back before filling out this page) 1243210 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 B7 V. Invention Description (59) Peony herb extracts will be taken orally, It is administered intraperitoneally or subcutaneously. In order to determine a biological response of a biological system to a standard human tadpole, human indica cells will be implanted in nude mice, causing the formation of a touchable tumor. After tumorigenesis, the mice were co-administered with cis-diagas diamine platinum and standard human thallium. Mice will be examined for tumor growth inhibition, prolonged survival, and reduced side effects on blood specific volume value and weight (NaKada et al., Japanese Journal of Cancer Research (1998) 89: 733-740). The test will be repeated using standard human salamanders of different concentrations to produce measurements of intermediate propensity, dispersion, and variability of any variable. The generated data will then be imported into a multi-dimensional analysis to generate a multivariate normal distribution group as a method of determining the correlation between biological activity and a standard baseline between humans (see Zhal, jH. 2nd edition (1984), 328-360, Plenty Hall, Anglewood Cliffs, NJ). A second independent determination of the biological response of a biological system to one of the standard humans will be the effect of the standard humans on physical performance during exercise. Rats will be treated with standard human radon at different concentrations (between 0.5 and 100 g / kg / day) for 4 days and animals will be tested for elevated plasma free fatty acid concentrations and a maximum of about 70% Maintenance of blood glucose concentration during exercise under oxygen consumption (VO2max) (see Wang et al. 'Plant Medicine (1998) No. 64, pp. 13-30). The data generated will be collected and then imported into multidimensional analysis to generate a multivariate distribution of havoc distributions as a method of determining the baseline correlation between biological activity and standard human tadpoles (see Zhal, JH. 2nd edition (1984) 'pp. 328-360, Plenty Hall, Anglewood Cliff, Nj This paper is sized for the Chinese National Standard (CNS) A4 (210 X 297 mm) (please first Read the notes on the back and fill out this page) _Install L ---- Order ---------. 62 1243210 A7 V. Description of the invention (60) Here 70 Kings are for reference). The distribution composition of each biological response is then input to the calculation method to generate statistical values of standard humans. The statistics will then be stored, preferably in the memory of a computer processor, for further operation. Any of these steps (ie chemical analysis, generation of biomarkers, and determination of the response of a biological system) are repeated to generate a large database of statistical values. These values are compiled and entered into an algorithm to generate standard 2D and 3-dimensional herb biological response arrays (HBR arrays). Through iteration, the resulting array (ie, standardized array) shows the highest correlation between the standard human tadpole among the composition (including growth conditions), biomarker information, and biological response. Based on the performance of a test batch on a herb bioresponse array, by determining 2 or more known related variables of the composition and biomarker information values, the biological response variable values are compared by measuring 4 values and Standard human 蔘 standardized herb bioresponse array values can be predicted. The resulting predictions will be used to evaluate the quality of a given human / batch without using the observed biological response of a biological system (see Example 2). Example 8: Evaluation of a selected human peony herb composition using a set of variables related to a specific biological response In order to evaluate the quality of a test batch of herb composition, the selected herb The parameters of plant-related data (such as: plant species, plant parts, geographical origin, growth conditions, processing methods, and storage conditions) of the herbs in the composition are collected first. This selected herb composition is then subjected to a treatment such as chemical analysis that can be used to determine the chemical composition of the drug list (see ·· Yerkin et al., Chinese Journal of Pharmacology (1993) No. 14 Issue 97-100 This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) (Please read the note on the back? Matters before filling out this page) Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs 63 l2432l〇

經濟部智慧財產局員工消費合作社印製 頁和Yoshikawa等人,藥理學雜誌(1993年)第113期第46〇_ 467頁)。先前已獲得的人參資料在有氧運動表現之耗氧量 和一次組之皂苷成分特別是Rgl和Rg2的存在之間已經顯 示一強大的相關性(王等人,植物醫學〇998年)第64期第 130至 133 頁)。 測試批次接著被暴露於測試細胞,包含但不限於··纖 維母細胞、巨噬細胞、單核球、多形性有核白血球、LAK 細胞、B16-F10黑色素瘤細胞、THpq細胞和海馬神經元( 以〇·5毫克/亳升至1〇〇亳升/毫升之濃度),以判定表現生物 才示識物數值。信息核糖核酸被由被暴露的細胞分離,其隨 後被用作為利用包含間白素_8、間白素_2和干擾素伽馬互 補去氧核糖核酸之微陣列之生化萃取物的以雜交為主的表 現監控之基質(席納等人,科學(1996年)第27〇期第467至 470頁;席納等人,美國國家科學院報告(1996年)第…期 第10614至1〇619頁;狄瑞西等人,自然遺傳學(^外年)第 14期第457至460頁;贺勒等人,美國國家科學院報告(1997 年)第94期第2150至2155頁)。先前所獲得的人參資料在有 氧運動耗氧量和表現生物標識物間白素-8、間白素_2之誘 發和測試細胞中干擾素伽馬之間已經顯示一強大的相關性 (凡卡杜拉門等人,運動醫藥科學(1997年)第29期第333至 334頁及王等人,植物醫學(1998年)第64期第13〇至η]頁) 。、有關生化生物標識物,大鼠骨髓細胞隨後將被暴露於測 忒批-人並檢測與有絲分裂相對的[氚卜胸腺核苷併入。先 前所獲得的人蔘資料已經顯示在大鼠骨趙細 Μ和 本紙張尺度適时目0家標準(CNS)A4規格(21Qx 297公爱) --------------裝-----:----訂--------- (請先閱讀背面之注意事項再填寫本頁) 64 1243210 A7 B7 五、發明說明(62 )Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs and Yoshikawa et al., Journal of Pharmacology (1993) No. 113 p. 46-467). Previously obtained ginseng data has shown a strong correlation between aerobic performance in aerobic performance and the presence of saponin components in the primary group, especially Rgl and Rg2 (Wang et al., Plant Medicine 998) 64th Issues 130-133). The test batch is then exposed to test cells including, but not limited to, fibroblasts, macrophages, monocytes, polymorphic nucleated white blood cells, LAK cells, B16-F10 melanoma cells, THpq cells, and hippocampal nerves Yuan (concentration of 0.5 mg / 亳 to 100 亳 L / ml) to determine the value of the object only when it is judged to be a manifesting organism. Information RNA was isolated from the exposed cells, which was subsequently used as a biochemical extract using a microarray containing melanin_8, melanin_2, and interferon gamma complementary DNA. The Matrix of Master's Performance Monitoring (Schenna et al., Science (1996) No. 27, pages 467-470; Schenna et al., National Academy of Sciences Report (1996), No.… pages 10614--10619 Diraci et al., Natural Genetics (^ Foreign Years) No. 14 pp. 457 to 460; Heller et al., National Academy of Sciences Report (1997) 94 pp. 2150-2155). Previously obtained ginseng data has shown a strong correlation between aerobic oxygen consumption and the induction of the biomarkers interleukin-8, interleukin_2, and interferon gamma in test cells (where Kaduramen et al., Sports Medicine Science (1997), 29th, pp. 333-334 and Wang et al., Plant Medicine (1998), 64th, pp. 13-30). 2. For biochemical biomarkers, rat bone marrow cells will then be exposed to test batches-humans and tested for [mitochondrial thymine incorporation as opposed to mitosis. The previously obtained human radon data has been shown in the rat bone Zhao Xi M and this paper size timely standard 0 CNS A4 specification (21Qx 297 public love) ------------- -Install ----- : ---- Order --------- (Please read the notes on the back before filling this page) 64 1243210 A7 B7 V. Description of the invention (62)

Rgi與去氧核糖核酸呈現一強大的相關性(山本等人Rgi shows a strong correlation with DNA (Yamamoto et al.

Arzneimitteelforschung(1978年)第 28期第 2238至 2241 頁) 經過反覆式分析後,來自任一檢驗的資料將被輸 入 /貞具法中’以產生基於數字化的植物相關資料(包含化學 分析和與生物標識物次組有關的資料)之被擇定的藥草組 成物之一測試藥草生物反應陣列。 一測試批次之品質將藉由針對上述的觀測和次組變項 之分析比較測試藥草生物反應陣列和標準人參標準化藥草 生物反應陣列被判定,其中生體外間白素_2、間白素_8和 干擾素伽馬之誘發和大鼠骨髓細胞中[氚]•胸腺核苷之併 入的升高(包含針對生長條件、來源和皂苷Rgl及RM之鑑 定所收集的資料)等的展現係可預測此測試批次在耗氧量 上之一等效價的生物反應效應係如同被標準人蔘所抑制者 基於此転序,可判定是否測試批次有關指定的生物反應 或所感興趣的生物反應係與標準之品質具有相似或不同的 品質。 實施例9:為黃連(HL)建立-標準化藥草生物反應陣列 經 濟 部 智 慧 財 產 局 員 工 消 費 合 作 社 印 製 為了此實施例之目的標準黃連係被擇定為採自西南亞 之味連(CGptis Chinesis Franee),其中生長條件係為孰習 此項技藝者所習知者(參見黃於中藥草藥理學⑽叫第 的頁及第287_288頁,CRC出版社,保卡雷頓,叫。 之乾燥根莖將藉由定量化學分析判定坤、小蒙♦、雨娃酸 、^州防己胺、黃連素、黃連切、黃連苷_!、連黃普_2 、頁連驗、柯諾辛胺、表小f驗、阿魏酸、綠地 本紙張尺度it用中關家標準(CNS)A4規格—χ挪公髮_ 素 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(63 ) (greenlanchcme)、異黃連鹼、光雨蛙酸、木蘭鹼、氧小蒎驗 、唐 ^ 草分定(thalifendine)、繳祕、爾伯素(urbenine)、 甲基頁連驗、巴馬亭、藥根驗和非洲防己胺被確認其化學 含量(亦參見中藥通報(1984年)第9期第仏料頁)。不同藥 草的小f驗之含量應介於7-9%(重量百分比)。這些資料將 被儲存,最好存於-計算機處理器之記憶體中,以利進一 步的操作。 ‘準κ連之表現生物標定物包含下述:Nfk B、bcl_2 類比物、A1、鋅手指蛋白、A2〇、間白素_2受體、細胞周 期楝針、C-Ki-ras2、生長調節因子探針以及糖類腎上腺 皮質素受體依賴性自體分解探針(參見齊等人,生命科學 (1994年)第54期第2009至2107頁;楊等人,遼寧史米得伯 格斯亞克藥理學(1996年)第354期第102-108頁);見浦等人 ,生化藥理學(1997年)第53期;張K.S·等人,台灣醫學協 會期刊(1991年)第90期第10-14頁)。另外,對於一較大的 批次大小’亞菲馬萃士(Affimatrix)之4〇〇〇〇〇寡核苷酸群 /1.6厘米2晶片可被使用(美國專利第5,556,752號)。標準黃 連之表現生物標識物將藉由如實施例〗所描述之微陣列被 製作’包含分析及統計資料生成。標準黃連之生化生物標 識物包含在黃連所被暴露之Hep G2細胞中之糖類腎上腺 皮質素增加及阿耳發胎兒蛋白分泌之抑制(參見:齊等人 ’生命科學(1994年)第54期第2099至2107頁)。生化生物 標識物被產生及分析(如實施例1中所敘述)。統計資料隨 後將被儲存,最好存於計算機處理器中,以備進一步操作。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公爱) 66 --------------裝-----:----訂------I--ASW1 (請先閱讀背面之注音?事項再填寫本頁) 1243210Arzneimitteelforschung (1978) No. 28, pages 2238 to 2241) After iterative analysis, data from any test will be entered into the chastity method 'to produce digitally-based plant-related data (including chemical analysis and biological analysis). Identifies the subgroup of the material) one of the selected herb components to test the herb bioresponse array. The quality of a test batch will be determined by comparing the test herb bioresponse array with the standard ginseng standardized herb bioresponse array by analyzing and observing the above-mentioned observations and subgroup variables. Among them, extracorporeal interleukin_2, interleukin_ 8 and interferon gamma-induced and [氚] • thymidine incorporation increase in rat bone marrow cells (including data collected for growth conditions, sources and identification of saponin Rgl and RM), etc. It can be predicted that the biological response effect of one equivalent of this test batch in terms of oxygen consumption is based on the sequence as if it was inhibited by standard humans. Based on this sequence, it can be determined whether the test batch is related to the specified biological response or the organism of interest. The response is similar or different from the standard quality. Example 9: Established for Coptis chinensis (HL)-Standardized Herbal Bioreactor Array Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs. Printed for the purpose of this example. The standard Coptis chinensis was selected to be harvested from CGptis Chinesis Franee. ), Where the growth conditions are known to those skilled in the art (see Huang Yu Chinese Medicine and Herbal Medicine Howling Pages and 287_288, CRC Press, Paul Carreton, called. The dried rhizomes will be borrowed Quantitative chemical analysis to determine Kun, Xiaomeng, Yuhua acid, tetrandrine, berberine, berberine cut, berberin _ !, lianhuangpu_2, page test, Kosinamine, table test , Ferulic acid, green paper This paper uses the Zhongguanjia Standard (CNS) A4 specification-χ Norwegian Gongfa _ prime 1243210 printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 B7 V. Description of the invention (63) (greenlanchcme) , Iso-berberine, light hyaluronic acid, magnolitine, oxygen test, Tang ^ thalifendine, Mi Se, urbenine, methyl-page test, Bamatine, medicine root test and African tetamine is confirmed for its chemical content See also Chinese Traditional Medicine Bulletin (1984) No. 9 page).) The content of micro-tests of different herbs should be between 7-9% (percent by weight). These data will be stored, preferably by computer processing In order to facilitate further operations, the bio-calibrators of the quasi-κ-connected cells include the following: Nfk B, bcl_2 analogs, A1, zinc finger protein, A2O, interleukin_2 receptors, cells Periodic needles, C-Ki-ras2, growth-regulatory factor probes, and probes for carbohydrate-dependent adrenocortin receptor-dependent autolysis (see Qi et al., Life Science (1994) No. 54, pp. 2009-2107; Yang et al., Pharmacology, Schmidberger Schiak, Liaoning (1996), No. 354, pp. 102-108); See Pu et al., Biochemical Pharmacology (1997), No. 53; Zhang KS, et al. , Journal of the Taiwan Medical Association (1991), 90th issue, pp. 10-14). In addition, for a larger batch size of 40,000 oligonucleotide groups / 1.6 cm2 wafers of Affimatrix (U.S. Patent No. 5,556,752) can be used. The performance biomarkers of the standard Coptis chinensis will be produced by microarrays as described in the Examples', including analysis and statistical data generation. Standard Coptis chinensis biochemical biomarkers include increased glucocorticoids in Hep G2 cells exposed to Coptis chinensis and inhibition of fetal protein secretion by Alfa (see: Qi et al. Life Science (1994) No. 54 No. 2099 to 2107). Biochemical biomarkers were generated and analyzed (as described in Example 1). The statistics will then be stored, preferably in a computer processor, for further manipulation. This paper size applies to China National Standard (CNS) A4 specifications (210 X 297 public love) 66 -------------- install -----: ---- order ---- --I--ASW1 (Please read the Zhuyin on the back? Matters before filling out this page) 1243210

五、發明說明(64) 生物系統之生物反應將利用細胞及整隻動物而被判 疋。所擇疋之藥草組成物之諸批次將被暴露於特定的細胞 類型,包含但不限於:人類11邛G2肝腫瘤細胞、人類胚 胎腫瘤細胞和胸腺母細胞(在〇·丨_ 1〇〇毫克/毫升之濃度下) 。對於動物處理,0.丨毫克-2克/公斤之黃連藥草組成物(即 黃連)將以口服、腹膜内注射或皮下注射被投藥。為了判 定一生物系統對標準化黃連的生物反應,人類胚胎腫瘤株 (NT2/D1)被暴露於不同,濃度之標準黃連且細胞將被檢視其 分化為具有神經元樣細胞型態的細胞之情形(張等人,台 灣醫學學會期刊(1991年)第90期第HM4頁)。此檢驗將被 重覆以產生測量值且如被描述於實施例中之人蔘之分析將 被完成。一生物系統對標準黃連之生物反應的一第二個獨 立的判定將為標準黃連對於因腸毒性大腸桿菌(ETEL)所 引起之下痢的作用。具有由於腸毒性大腸桿菌所引起的下 痢之患者將被以不同濃度的黃連(如2克/公斤)處理且糞便 體積將被判定(參見如Rabbani G H,Dan Med BuU (1996) 43:173-185)。此檢驗將被重覆以產生測量值且如在實施 例1中對人蔘所描述的分析將被實施。任一生物系統的分 布組隨後被輸入演算法中以對標準黃連產生一統計數值。 統計資料之後將被儲存,最好存在一計算機之處理器的記 憶體中’以便進一步的操作。 最後’如實施例1,這些步驟被重覆以產生標準黃連 的藥草生物反應陣列,其中所產生的藥草生物反應陣列隨 後將被用來預測生物活性及評估批次品質。利用此種方法 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公璧) (請先閱讀背面之注意事項再填寫本頁) -· I 丨丨 h I 丨—訂----I I I I . 經濟部智慧財產局員工消費合作社印製 67 1243210 A7 B7 五、發明說明(65 ) ,一標準化藥草生物反應陣列可被產生並定期更新。 實施例10 :利用一與一特定生物反應有關的變項次組對黃 連之一擇定的藥草組成物之評估 為了評估一被擇定之測試批次的黃連藥草組成物的品 質,有關植物相關的資料(如:植物品種、植物部位、地 理來源、生長條件、加工方法和貯藏條件)首先被收集。 該藥草組成物隨後被施以可作為判定此組成物之化學含量 之化學分析(亦參見:朱M·中藥通報(1984年)第9期第63_64 頁)。 先前所獲得的資料已經顯示人類胚胎惡性瘤細胞株變 為神經元葉細胞之分化係強烈地與小i鹼之存在相關(參 見張K.S.,台灣醫學學會期刊(1991年)第90期第1〇_14頁) 。此測試批次然後在由一非毒性毒濃度開始進行之濃度下 (其判定係屬習知的技藝)被暴露於包含人類胚胎惡性^瘤 細胞株,NT2/IM之測試細胞。信息核糖核酸從被暴露過 的細胞被分離,其隨後被當作利用包含間白素_2受體和Nfk B之微陣列基於生化萃取物之表現監控的雜交反應之受質( 參見:齊等人,生命科學(1994年)第54期第2〇99_21〇7)頁 ;揚等人,遼寧史米德伯格斯亞克藥理學(1996年)第354 期第102-108頁);Miura等人,生化藥理學(1997年)第”期 :張K.S.,台灣醫學學會期刊(1991年)第9〇期第1〇」4頁; 美國專利第5,556,752號),且可被用來判定在該細胞中c_ Ki-ras2基因表現的向下調控。先前所獲得的黃連資料已 經顯示人類胚胎惡性瘤細胞株變為神經元狀細胞之分化係 (請先閱讀背面之注意事項再填寫本頁) !IhI丨-訂丨丨-丨丨丨--· 經濟部智慧財產局員工消費合作社印製 用 適 度 尺 張 紙 本 格 規 A4 s) N (c 準 標 家 國 國 釐 公 97 68 經濟部智慧財產局員工消費合作社印製 1243210 A7 -------B7_ 五、發明說明(66 ) 與有絲分裂原探針之誘發和c-Ki-ras2基因表現之向下調控 強烈地相關(參見齊等人,生命科學(1994年)第54期第 2099-2017頁)。 至於生化生物標識物,Hep G2細胞被暴露於此測試 組成物且細胞被檢驗其糖腎上腺類皮質素受體之提高及阿 耳發胎兒蛋白分泌之抑制(參見齊等人,生命科學(1994年) 第54期第2099-2107頁)。先前所獲得之黃連資料已經顯示 ,糖腎上腺類皮質素所誘發的自體破壞之抑制與小篆鹼樣 生物驗係為強烈地相關(參見Miur a等人,生化藥理學(1997 年)第53期第13 15-1322頁)。經過反覆的分析之後,來自 任一檢驗的資料將被輸入演算法中,以產生基於數據化之 觀測資料、化學資料及與生物標識物次組有關的資料之一 測試藥草生物反應陣列。 一測试批次之品質將藉由比較針對上述之觀測值和次 組之分析比較測試藥草生物反應和標準黃連的藥草生物反 應陣列變項,其中間白素_2受體和NfkB之誘發、c_ki_ras2 基因表現之向下調控、有關HEP G2細胞糖腎上腺類皮質 素艾體增加和阿耳發胎兒胎白分泌之抑制之呈現(包含對 生長條件、來源、和小I驗植物驗之鑑定等所收集的資料) 係可預期此測試批次對於人類胚胎惡性瘤細胞株變為神經 元樣細胞之末端分化和地塞米松所誘發之自體破壞之一等 效價的生物反應作用如同被標準黃連所抑制者。基於此程 序’可以判定此測试批次是否具有與標準所具有者相似或 不同的品質。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) t----------訂---------. (請先閱讀背面之注意事項再填寫本頁) 69 1243210V. Explanation of the Invention (64) The biological response of the biological system will be judged using cells and the entire animal. The batches of the selected herbal composition will be exposed to specific cell types, including but not limited to: human 11 邛 G2 liver tumor cells, human embryo tumor cells, and thymocytes (between 〇 · 丨 _ 1〇〇 Mg / ml). For animal treatment, 0.1 mg to 2 g / kg of Coptis chinensis composition (i.e. Coptis chinensis) will be administered orally, intraperitoneally or subcutaneously. In order to determine the biological response of a biological system to standardized Coptis chinensis, human embryo tumor lines (NT2 / D1) were exposed to different, standard concentrations of Coptis chinensis and cells would be examined for differentiation into cells with neuron-like cell types ( Zhang et al., Journal of the Taiwan Medical Association (1991) No. 90 p. HM4). This test will be repeated to produce measurements and the analysis of the person as described in the examples will be completed. A second and independent determination of the biological response of a biological system to standard Coptis chinensis will be the effect of Coptis chinensis on the infestation caused by enterotoxic E. coli (ETEL). Patients with diarrhea due to enterotoxic E. coli will be treated with different concentrations of Coptis chinensis (eg 2 g / kg) and stool volume will be judged (see eg Rabbani GH, Dan Med BuU (1996) 43: 173-185 ). This test will be repeated to produce measurements and the analysis as described for the human being in Example 1 will be performed. The distribution group of any biological system is then input into the algorithm to generate a statistical value for the standard Coptis chinensis. The statistics will then be stored, preferably in the memory of a computer's processor 'for further operations. Finally, as in Example 1, these steps were repeated to generate a standard herbal bioreaction array of Coptis chinensis, where the bioreactor array of the herb produced was then used to predict biological activity and evaluate batch quality. With this method, the paper size is applicable to the Chinese National Standard (CNS) A4 specification (210 X 297 cm) (Please read the notes on the back before filling this page)-· I 丨 丨 h I 丨 —Order ---- IIII. Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 67 1243210 A7 B7 V. Description of the Invention (65) A standardized herbal bioreactor array can be generated and regularly updated. Example 10: Evaluation of a selected herbal composition of Coptis chinensis using a subgroup related to a specific biological response. In order to evaluate the quality of a selected test batch of Coptis chinensis composition, plant-related Data (such as: plant species, plant parts, geographical origin, growth conditions, processing methods, and storage conditions) are first collected. The herb composition is then subjected to chemical analysis that can be used to determine the chemical content of the composition (see also: Zhu M. Chinese Medicine Bulletin (1984) No. 9 pp. 63_64). Previously obtained data have shown that the differentiation of human embryonic malignant tumor cell lines into neuronal lobe cells is strongly related to the presence of alkaloids (see Zhang KS, Journal of the Taiwan Medical Association (1991) No. 90 No. 1). _14). This test batch was then exposed to a test cell containing a human embryonic malignant tumor cell line, NT2 / IM, at a concentration starting from a non-toxic concentration, which is determined to be a known technique. Information RNA was isolated from the exposed cells, which was then used as a substrate for hybridization reactions based on the monitoring of the performance of biochemical extracts using a microarray containing melanin_2 receptor and Nfk B (see: Qi et al. Humans, Life Science (1994), 54 (2) 99-2021); Yang et al., Schmidberger Schiak Pharmacology (1996), 354 (102-108); Miura Et al., Biochemical Pharmacology (1997) Issue: Zhang KS, Journal of the Taiwan Medical Association (1991) No. 90, page 10; 4; US Patent No. 5,556,752), and can be used to determine Down regulation of c_ Ki-ras2 gene expression in this cell. The previously obtained data of Coptis chinensis has shown that the human embryonic malignant tumor cell line has become a differentiation line of neuron-like cells (please read the precautions on the back before filling this page)! Appropriate ruled paper rule A4 for employees 'cooperatives printed by the Intellectual Property Bureau of the Ministry of Economic Affairs N (c quasi-standard country and country) 97 68 Printed by employees' cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 1243210 A7 ------ -B7_ 5. Description of the invention (66) is strongly related to the induction of mitogen probes and the down-regulation of c-Ki-ras2 gene expression (see Qi et al., Life Science (1994) No. 54 No. 2099-2017 As for biochemical biomarkers, Hep G2 cells were exposed to this test composition and the cells were tested for increased glucocorticoid receptors and inhibition of fetal protein secretion by Alfa (see Qi et al., Life Science (1994) No. 54, pp. 2099-2107). The previously obtained data of Coptis chinensis has shown that the inhibition of autologous destruction induced by glucocorticoids is strongly related to the berberine-like biological system (see Mi ur a et al., Biochemical Pharmacology (1997), No. 53, pp. 13 15-1322). After repeated analysis, data from any test will be input into the algorithm to generate data-based observations , Chemical data, and one of the data related to the biomarker sub-group to test the herb bio-response array. The quality of a test batch will be compared by comparing the observations for the above-mentioned observations with the analysis of the sub-group to compare the test bio-response and standard Coptis chinensis. Herb bioresponse array variants, including the induction of melanin_2 receptor and NfkB, down regulation of c_ki_ras2 gene expression, related to the increase of glucocorticoid corticoid artefacts in HEP G2 cells and secretion of fetal fetal leukocytes in Alfa The presence of inhibition (including data collected on growth conditions, origin, and identification of small plant test) is expected to be the test batch for the differentiation and termination of human embryonic malignant tumor cell lines into neuron-like cells One of the equivalent biological response effects of semexone-induced autologous destruction is the same as those inhibited by standard Coptis chinensis. Based on this procedure, it can be determined that this test batch is It has similar or different qualities to those of the standard. This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) t ---------- Order ------- -. (Please read the notes on the back before filling this page) 69 1243210

五、發明說明(67 ) 製成(柴胡、半夏、生薑、黃芩、大棗、:t蔘、人蔘和甘 草’相對重量蔘見表2)。V. Description of the invention (67) (Chaihu, Pinellia ternata, Ginger, Scutellaria baicalensis, Jujube, Jujube: t 蔘, mandarin duck and licorice 'relative weight (see Table 2).

貫施例11 ·利用兩和生物檢驗對小柴胡湯的評估 、為了評估三種來源之小柴胡湯的品質,兩種生物檢驗 被^用:1)細胞生長抑制及2)B型肝炎病毒由被感染的細 胞刀泌。小柴胡湯組成物係由6_7種藥草植物之混合物所 此三種“妙方”係源自新加坡、韓國或台灣。諸批次係 以藉由去氧核糖核酸定量或6型肝炎表面抗原(HbsAg)之 偵測所測定者來評估毒性及抑制B型肝炎病毒的能力(參見 •董等人,美國國家科學院報告(1991年)第88期第8495-8499頁)。 簡言之,一克之製劑被附加10毫升之水。其混合物被 煮30分鐘。其懸浮液於離心後被收集且被以一〇22微米濾 紙過濾。有兩種細胞種類被使用:a)分泌B型肝炎病毒的 2.2.15細胞(由G.艾斯教授慨為提供;參見··艾斯等人,美 國國家科學院報告(1987年)第84期第1〇〇5_1〇〇9頁)及匕) HepG2細胞(ATCC Cat#HB-8065)。1比50稀釋被運用於任 一檢驗。細胞生長抑制檢測被進行72小時。所有其他的程 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ---------^---------. (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 70 ο 2143 2 A7B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(68) 序皆如同被敘述於董等人,美國國家科學院報告(1991年) 第88期第8495-8499頁者被完成。利用此三批次的檢測之 結果係被呈現於表3。基於這些資料,台灣來源者將被擇 定為一標準藥草組成物,因為其低毒性搭配其降低分泌B 型肝炎病毒表面抗原(正比於病毒的釋放)超過半數之功效。 表3.小柴胡湯之生物檢測 來源 細胞生長抑制(%) B型肝炎病毒(被分泌)抑制百分比 新加坡 HepG2 2.2.15 DNA HBsAG 73 100 65 38 韓國 台灣~ 13 60 20 「42 0 42 0 47 表2和表3中所呈現的台灣藥草組成物的資料構成此藥 草組成物之標準化藥草生物反應陣列的起始資料。因此, 此資料組將初步地包含藥草組成物的來源、植物種類及任 一藥草組成物的相對量,和兩種生物反應(即細胞生長抑 制和由受感染的細胞之B型肝炎病毒分泌)。 利用在第1圖中之流程和在實施例丨和3中所載述的程 序,針對標準藥草組成物之植物相關資料、標識物和生物 反應之額外的資料可被收集。此額外的資料被加入起始標 準化藥草生物反應陣列以產生一擴增的標準化藥草生物反 應陣列。所產生的資料庫之適當的分析可如載述於詳細說 明和實施例中者被進行,以利確定與所感興趣的生物反應 最咼度相關或有關的變項之次組。批次藥草生物反應陣列 了利用描縿於第2圖中及實施例2和4之程序中的方法被、、办 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公1 ) t---------tT---------Avi. (請先閱讀背面之注意事項再填寫本頁) 71 1243210 A7 B7_ 五、發明說明(69 ) 定。 所產生的批次藥草生物反應陣列可與標準化藥草生物 反應比較,俾以預測此批次藥草組成物之生物反應。 實施例12 :藥草配製 藥草萃取物配製的標準化操作步驟係如下述:藥草粗 物質的成分以適當的比例被置於一有覆套的反應器中,且 在高的恆溫下被用水混合萃取。其固體物被以一 120目篩 從液體中分離。所產生的濾液被收集,然後在低壓下藉由 蒸發水分而被濃縮。濃縮液在高溫下被喷霧乾燥以產生顆 粒化粉末。此批物質隨後被配製成所需的劑型。 實施例13 :黃芩湯之評估 黃芩湯(HQT)係為一包含四種不同的藥草: Scutellariae(黃答)、Glycyrrhizae(甘草)、Paeonielactiflora pallus(白芍)和Fructus zizipho(大棗)(表4)之古老的中國植 物方劑。此配方在亞洲自從公元前300年以來已長期被用 來治療不同的腸胃疾病。 (請先閱讀背面之注意事項再填寫本頁) -裝-----r 訂 · 經濟部智慧財產局員工消費合作社印製 表4.傳統中醫處方黃芩湯之藥草成分 學名 俗名 傳統用途 Scutellariae Radix 黃芩 顱頭根 用於降低微血管通透性;消炎;治療腸 炎和痢疾;增值膽汁之分泌以治療黃疾 ;解痙治咳;驅蟲 Glycyrrhizae Radix (甘草) 甘草根 潤肺止咳;解痙止痛;調和諸藥;降火 解毒 Fructus Ziziphi 大棗 具有利尿和強壯功能 Paeonie lactiflora pallus radix 白芍根 用於鎮痛緩急;疏筋清血 72 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ^_ 表5.批次性質(黃芩湯) 性質 批次A 批次B 批次C 來源 台灣,順天 台灣,順天 台灣,順天 製備方法 標準 標準 煮30分鐘 植物部位 根 根 1243210 A7 _ B7 —------------ 五、發明說明(70 ) 生物和酵素檢測 簡吕之,1克之任一批次之黃芩湯(HQT)被附加1〇毫 升之水(1¾克/毫升)。其混合物係如簡列於表5中者被處理 。其上清液在離心後被收集並通過一〇22微米濾紙被過濾 。兩種細胞類型被用來測定任一批次之黃答湯的生物作用 :a) Jurkat T 細胞(ATCC cat#TIB-152)及 b)HepG2 細胞 (ATCC cat#HB_8065)。1比50稀釋被用於任—檢測。冷凍 細胞(107/毫升)被迅速地解凍於一攝氏37度水浴中。細胞 接著被稀釋於10毫升預熱過的培養基中(參見:生命科技 公司,型錄及參考指南,1998年至1999年,細胞培養節) ,繼之於1500rpm下離心5分鐘。其懸浮液隨後被倒掉且 其細胞在攝氏37度,5%二氧化碳下被培養於100毫升培養 基中。兩天後,其細胞被計數(约8X105/毫升,總共100毫 升)。 諸批次亦藉由去氧核糖核酸偵測來估計其抑制B型肝 炎病毒的能力(參見董等人,美國國家科學院報告U991年) 第88期第8495至8499頁)。簡言之,1克之製劑被附加10毫 升之水。其混合物被煮沸30分鐘。其懸浮液在離心後被收 集且通過一 0.22微米濾紙被過濾。分泌B型肝炎病毒的 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 裝-----^----訂---------. 經濟部智慧財產局員工消費合作社印製 73 l2432l〇 A7 B7 l、發明說明(71 )Implementation Example 11 · Evaluation of Xiao Chai Hu Tang using Lianghe biological test, in order to evaluate the quality of Xiao Chai Hu Tang from three sources, two biological tests were used: 1) cell growth inhibition and 2) hepatitis B virus Infected cells secrete. The composition of Xiao Chai Hu Tang is composed of a mixture of 6-7 herbs and plants. These three "magic formulas" are derived from Singapore, South Korea or Taiwan. The batches were evaluated by DNA quantification or detection of hepatitis 6 surface antigen (HbsAg) to assess toxicity and ability to inhibit hepatitis B virus (see Dong et al., National Academy of Sciences report ( (1991) 88 (8495-8499). Briefly, one gram of the preparation was added with 10 ml of water. The mixture was cooked for 30 minutes. The suspension was collected after centrifugation and filtered through 1022 micron filter paper. Two cell types are used: a) 2.2.15 cells that secrete hepatitis B virus (provided by Professor G. Ace; see Ace et al., National Academy of Sciences Report (1987) No. 84 (P. 105-10) and HepG2 cells (ATCC Cat # HB-8065). A 1:50 dilution is used for any inspection. The cytostatic assay was performed for 72 hours. All other paper sizes are in accordance with Chinese National Standard (CNS) A4 (210 X 297 mm) --------- ^ ---------. (Please read the note on the back first Please fill in this page again) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 70 ο 2143 2 A7B7 Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 5. The description of the invention (68) The sequence is as described in Dong et al. Report of the Chinese Academy of Sciences (1991) No. 88 pages 8495-8499 were completed. The results of the tests using these three batches are presented in Table 3. Based on these data, Taiwanese sources will be selected as a standard herbal composition because of its low toxicity combined with its ability to reduce the secretion of hepatitis B virus surface antigen (proportionate to the virus release) by more than half. Table 3. Inhibition of cell growth source (%) of Xiao Chai Hu Tang by Hepatitis B virus (secreted) inhibition percentage Singapore HepG2 2.2.15 DNA HBsAG 73 100 65 38 Taiwan Taiwan ~ 13 60 20 「42 0 42 0 47 Table The data of the Taiwan herb composition presented in 2 and Table 3 constitute the starting data for the standardized herb bioreaction array of this herb composition. Therefore, this data set will initially include the source of the herb composition, the plant species, and any The relative amounts of the herb composition, and the two biological responses (ie, cell growth inhibition and hepatitis B virus secretion from infected cells). Use the flow chart in Figure 1 and those described in Examples 丨 and 3 Process, additional data on plant-related data, markers, and biological responses to standard herb compositions can be collected. This additional data is added to the initial standardized herb bioresponse array to generate an expanded standardized herb bioresponse array An appropriate analysis of the generated database can be performed as described in the detailed description and examples to facilitate determination of reaction with the organism of interest The second group of the most relevant or related variables. The batch of herbal bioreactor arrays uses the method described in Figure 2 and the procedures of Examples 2 and 4, and the paper dimensions apply Chinese national standards. (CNS) A4 specifications (210 X 297 male 1) t --------- tT --------- Avi. (Please read the precautions on the back before filling this page) 71 1243210 A7 B7_ Fifth, the description of the invention (69). The generated batch bio-response array of herbs can be compared with the standardized bio-response of the herb, so as to predict the biological response of the batch of herbal composition. Example 12: Formulation of Herbs and Pharmaceutical Extracts The standardized operation steps are as follows: The crude herb ingredients are placed in a jacketed reactor at an appropriate ratio, and they are mixed and extracted with water at a high constant temperature. The solids are extracted from a 120 mesh sieve Separated from liquid. The resulting filtrate is collected and then concentrated by evaporation of water under low pressure. The concentrate is spray-dried at high temperature to produce a granulated powder. This batch of material is then formulated into the required dosage form Example 13: Evaluation of Huang Zhi Tang (HQT) is an ancient Chinese herbal formula containing four different herbs: Scutellariae (Yellow Answer), Glycyrrhizae (Glycyrrhiza uralensis), Paeonielactiflora pallus (White Juice), and Fructus zizipho (Jujube) (Table 4). This formula In Asia, it has been used to treat different gastrointestinal diseases for a long time since 300 BC. (Please read the precautions on the back before filling out this page.)-装 ----- r Order · Ministry of Economic Affairs Intellectual Property Bureau Staff Consumer Cooperatives Printed table 4. Traditional Chinese medicine prescription of Huangpi decoction Herb name Scientific name Traditional name Scutellariae Radix Scutellaria skull root is used to reduce microvascular permeability; anti-inflammatory; treat enteritis and dysentery; increase the secretion of bile to treat yellow disease; relieve spasm Cough; deworming Glycyrrhizae Radix (Glycyrrhiza uralensis) Glycyrrhizae Radix (Glycyrrhiza uralensis) Glycyrrhiza root Radicals and cough; Antispasmodic and analgesic; reconciling various medicines; Fructus Ziziphi jujube with diuretic and strong functions of reducing fire and detoxifying Paeonie lactiflora pallus radix Paeoniae root for analgesic and emergency; This paper size applies to China National Standard (CNS) A4 specifications (210 X 297 mm) ^ _ Table 5. Batch properties (Huangyao soup) Properties Batch A Batch B Batch C Source Taiwan, Suncheon Taiwan, Suncheon Taiwan, Suncheon Preparation Method Standard Standard Boil 30 minutes Plant parts Roots 1243210 A7 _ B7 —----------- -5. Description of the invention (70) Biological and enzyme detection Jian Luzhi, 1 g of any batch of Huang Qin Tang (HQT) is added with 10 ml of water (1¾ g / ml). The mixture was treated as outlined in Table 5. The supernatant was collected after centrifugation and filtered through 1022 micron filter paper. Two cell types were used to determine the biological effects of Huangda Tang in any batch: a) Jurkat T cells (ATCC cat # TIB-152) and b) HepG2 cells (ATCC cat # HB_8065). A 1:50 dilution is used for any-test. Frozen cells (107 / ml) were quickly thawed in a 37 ° C water bath. Cells were then diluted in 10 ml of pre-warmed culture medium (see: Life Technologies, Catalog and Reference Guide, 1998-1999, Cell Culture Section), followed by centrifugation at 1500 rpm for 5 minutes. The suspension was subsequently discarded and the cells were cultured in 100 ml of culture medium at 37 ° C and 5% carbon dioxide. After two days, their cells were counted (approximately 8X105 / ml, 100ml total). Batches have also been evaluated for their ability to inhibit hepatitis B virus by DNA detection (see Dong et al., National Academy of Sciences Report U991, 88, 8495-8499). Briefly, 1 gram of the preparation was added with 10 ml of water. Its mixture was boiled for 30 minutes. The suspension was collected after centrifugation and filtered through a 0.22 micron filter paper. The size of this paper that secretes hepatitis B virus is applicable to the Chinese National Standard (CNS) A4 (210 X 297 mm) (Please read the precautions on the back before filling this page) ---------. Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs 73 l2432l0A7 B7 l, Description of Invention (71)

HepG2.2.15細胞(由艾斯教授慨為提供;參見艾斯等人, 美國國家科學院報告(1987年)第84期第1〇〇5至1〇〇9頁)係 被用於本檢測中。1比50稀釋被用於任一檢測。細胞生長 抑制檢測被施行72小時。所有其他的程序如被描述於董等 人’美國國家科學院報告(1991年)第88期第8495至8499頁 中者被完成。 由於黃芩湯係以其對抗下痢的藥性而聞名,故石-葡 萄糖酸酸被檢測,黃芩湯萃取物被加入一包含〇.lniM酚酞 葡萄糖酸酯、70mM三羥甲基胺基甲烷一氫氯酸(Tris_ HCl)(pH6.8)和〇.8ng透析過的/5 -葡萄糖醛酸酶(來自大腸 桿菌,購自Sigma™)之三聯槽的96-槽檢測盤中,至最終 的體積為80微升。在攝氏37度培養2小時後,反應被以包 含0.2M甘胺酸和〇·2Μ氯化鈉(pH 10.4)之停止溶液200微升 終止’且其吸光度(〇D)被以一動態微盤讀取機在54〇11111波 長被監控。 利用此三批次之檢測結果係被呈現於表6。基於這些 資料,相對於批次黃芩湯C,黃芩湯來源A和B具有相對低 毒性搭配較高的抑制活性(即比黃芩湯A或B對HepG2細胞 約有高於5倍的毒性且對0 -葡萄糖醛酸酶有低於3.3倍的 抑制活性,參見表6)。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閲讀背面之注意事項再填寫本頁) 丨丨丨h丨丨訂---------. 經濟部智慧財產局員工消費合作社印製 74 經濟部智慧財產局員工消費合作社印製 1243210 A7 _B7_ 五、發明說明(72 ) 表6.三種黃芩湯製劑之生物檢測* 大腸桿菌 /3-葡萄糖醛酸酶 HepG2 Jurkat HBV; DNA 黃答湯A 0.6 1.50 0.76 無 黃芩湯B 0.7 1.6 0.81 ND 黃芩湯C 2.2 0.32 ND ND *代表IC5Q值 ND,未判定 :對照組百分比 黃芩湯對蛋白質表現的作用之評估 在藥物添加前HepG2細胞X 106)被接種於25厘米2燒 瓶中3.0毫升之RPMI-1640培養基内(參見生命科技公司, 型錄及參考指南,1998-1999年,細胞培養節)24小時。其 細胞被施以有或無藥草之處理,其中前者係分別以0.2毫 克/毫升或4毫克/毫升之最終濃度被添加,並於攝氏37度下 被培養24小時。其培養基被去除且其細胞被以冰的PBS清 洗兩次。其細胞被收集於1亳升之PBS内並於lOOOOrpm被 離心2分鐘,在冰上被以一含有50mM三羥甲基胺基甲烷 一氯(pH7.5)、0.2mM PMSF和10%甘油之緩衝劑萃取,繼 之以三個冷凍、解凍循環。在離心前氯化鉀以0.15M之最 終濃度被加入細胞溶解液中。其蛋白質濃度被測定且其細 胞萃取物依據蘭理(Laemmli)之方法(自然(1970年)第227期 第680至685頁)被電泳。西方轉印法係以標準的習知技藝 被施行,參見如山姆布魯克(Sambrook)等人(1989年)。所 使用的抗體係針對以下的蛋白質:拓普I ; Stat (20707); 周期素B1 (Cyclin Bl)、MAPK(抗體2)和Nm 23 HI。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 75 --------------^裝—l·——訂---------ΜΨ (請先閱讀背面之注音?事項再填寫本頁) 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(73 ) 第4圖揭示較高濃度的黃芩湯A或黃芩湯b分化性地影 響周期素B1 (Cyclin B1)胜肽之表現。 高效液相層析分析 樂卓批次係以一貝克曼ODS UltrasphereTM管柱(5微米 粒子,4.6亳米X 25厘米)藉由高效液相層析被分析且被以 一紫外光分光光度計(鉑金艾爾瑪)偵測。用於紫外光债測 之波長係於280nm和340nm被監測。其動相係以1毫升/分 鐘被推動且包含以如下述之梯度的溶劑A :水和溶劑B : 20%甲醇:1)前5分鐘溶劑為100%溶劑a ; 2)其次之1〇分鐘 溶劑改為10%溶劑A/90%溶劑B ; 3)其次之40分鐘溶劑改為 10%溶劑A/90%溶劑B。繼之以添加1〇〇%溶劑A5分鐘。其 高效液相層析標識物為黃芩苷和黃答素。 質譜儀分析 藥草萃取物係由來自鉑金艾爾瑪(PE)生物系統之 Mariner™ ESI-TOF質譜儀(MS)所分析。對照示踪物係利 用黃芩素及黃芩苷(兩種黃芩湯中之已知的活性成分)被產 生。 在水中及酸處理之批次的黃答湯樣品係被高效液相層 析及質譜儀所分析。雖然水處理的黃芩湯批次A和b具有 不同的高效液相層析及質譜儀踪跡,酸處理批次產生幾乎 相同的樣式(資料未提出)。 演算法 所收集的資料形成用於產生多變項常態分布組之多維 分析的一部分,以作為一判定生物活性和標準黃芩湯化學 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -----------裝-----^----訂---------Aww. (請先閱讀背面之注咅?事項再填寫本頁) 76 1243210 A7 -----------2Z________ 五、發明說明(74 ) 物質(高效液相層析及質譜儀)之間的基準線相關性,以及 起源/生長特性的手段。 實施例14 :各別成分 A.甘草HepG2.2.15 cells (provided by Professor Ace; see Ace et al., National Academy of Sciences Report (1987) No. 84, pages 105-109) were used in this test. A 1:50 dilution is used for any test. The cell growth inhibition test was performed for 72 hours. All other procedures were completed as described in Dong et al., National Academy of Sciences Report (1991), 88, 8495-8499. As Huanghuang Decoction is known for its anti-diarrheal drug properties, stone-gluconic acid was detected, and Huangzhi Decoction extract was added with a concentration of 0.1niM phenolphthalogluconate, 70mM trimethylolamine methane monohydrochloric acid (Tris_HCl) (pH 6.8) and 0.8 ng dialyzed / 5-glucuronidase (from E. coli, purchased from Sigma ™) in a 96-slot test dish with a triple volume to a final volume of 80 Slightly up. After 2 hours of incubation at 37 ° C, the reaction was terminated with 200 μl of a stop solution containing 0.2M glycine and 0.2M sodium chloride (pH 10.4) and its absorbance (OD) was determined by a dynamic microdisk The reader is monitored at a wavelength of 5401111. The test results using these three batches are presented in Table 6. Based on these data, compared with batch Huangpitang C, Huangpitang A and B have relatively low toxicity and higher inhibitory activity (ie, they are about 5 times more toxic to HepG2 cells than Huangpitang A or B and 0 -Glucuronidase has less than 3.3-fold inhibitory activity (see Table 6). This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) (Please read the precautions on the back before filling this page) 丨 丨 h 丨 丨 Order ---------. Economy Printed by the Employees 'Cooperatives of the Ministry of Intellectual Property Bureau 74 Printed by the Consumers' Cooperatives of the Ministry of Economics and Intellectual Property Bureau 1243210 A7 _B7_ V. Description of the invention (72) Table 6. Biological detection of three Huanghuang Tang preparations * HepG2 Jurkat HBV; DNA Huang Da Tang A 0.6 1.50 0.76 without Huang Zhi Tang B 0.7 1.6 0.81 ND Huang Zhi Tang C 2.2 0.32 ND ND * represents IC5Q value ND, not determined: the percentage of control group Huang Zhi Tang on protein performance is evaluated in the drug Before addition, HepG2 cells X 106) were seeded in 3.0 ml of RPMI-1640 medium in a 25 cm 2 flask (see Life Technology Corporation, Catalog and Reference Guide, 1998-1999, Cell Culture Section) for 24 hours. The cells were treated with or without herbs, of which the former was added at a final concentration of 0.2 mg / ml or 4 mg / ml, respectively, and cultured for 24 hours at 37 ° C. Its culture medium was removed and its cells were washed twice with iced PBS. The cells were collected in 1 liter of PBS and centrifuged at 1,000 rpm for 2 minutes. The cells were placed on ice with 50 mM trimethylolaminomethane monochloride (pH 7.5), 0.2 mM PMSF and 10% glycerol. Buffer extraction followed by three freeze and thaw cycles. Before the centrifugation, potassium chloride was added to the cell lysate at a final concentration of 0.15M. Its protein concentration was determined and its cell extracts were electrophoresed according to the Laemmli method (Nature (1970), 227, pp. 680-685). Western transfer law systems are implemented using standard know-how, see, for example, Sambrook et al. (1989). The antibodies used were directed against the following proteins: Top 1; Stat (20707); Cyclin B1 (Cyclin Bl), MAPK (Antibody 2), and Nm 23 HI. This paper size applies to China National Standard (CNS) A4 specification (210 X 297 mm) 75 -------------- ^ Packing--l · ——Order -------- -ΜΨ (Please read the phonetic on the back? Matters before filling out this page) 1243210 Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 B7 V. Description of the invention (73) Figure 4 reveals a higher concentration of Huang Zhi Tang A or Huang Zhi Tang b Differentially affects the performance of cyclin B1 (Cyclin B1) peptides. High Performance Liquid Chromatography (HPLC) analysis was performed on a Beckman ODS UltrasphereTM column (5 micron particles, 4.6 mm x 25 cm) by HPLC and analyzed by a UV spectrophotometer ( Platinum Elma) detection. The wavelengths used for UV light measurement are monitored at 280nm and 340nm. The mobile phase was pushed at 1 ml / min and contained a gradient of solvent A: water and solvent B: 20% methanol: 1) the first 5 minutes of the solvent was 100% solvent a; 2) the next 10 minutes Solvent was changed to 10% Solvent A / 90% Solvent B; 3) Secondly, the solvent was changed to 10% Solvent A / 90% Solvent B in 40 minutes. This was followed by the addition of 100% solvent A for 5 minutes. Its HPLC markers are baicalin and xanthophyll. Mass Spectrometer Analysis Herb extracts were analyzed by a Mariner ™ ESI-TOF mass spectrometer (MS) from a platinum Elma (PE) biological system. Control tracers were produced using baicalein and baicalin (both known active ingredients in baical decoction). Samples of Huangdatang in water and acid-treated batches were analyzed by HPLC and mass spectrometry. Although batches A and b of the water-treated Huangzhi soup had different HPLC and mass spectrometer traces, the acid-treated batches produced almost the same pattern (data not presented). The data collected by the algorithm form part of a multi-dimensional analysis used to generate a multivariate normal distribution group, as a determination of biological activity and standards (Li) ----------- install ----- ^ ---- order --------- Aww. (Please read the note on the back? Matters before filling out this page ) 76 1243210 A7 ----------- 2Z________ V. Description of the invention (74) Baseline correlation between substances (high performance liquid chromatography and mass spectrometer), and means of origin / growth characteristics. Example 14: Individual ingredients A. Licorice

Glycyirhizae Radix(甘草)之評估 甘草係有用於潤肺和袪咳,協助鬆弛痙攣和疼痛。用 於本實施例中之甘草批次的性質係被呈現於表7。 表7·批次性質(甘草) 性質 批次A 批次B 批次C ---—- 批•次D 植物名稱 甘草 甘草 甘草 來源 内蒙古 内蒙古 美國,金門 藥草中心 藥草中心 製備方法 _標準 標準 煮沸30分鐘 溫水,30分鐘 植物部位 根 根 - - 生物及酵素檢測 為了檢測藥草來源的品質,任一藥草萃取物懸浮液被 檢測且其分析係被重覆三次。對於一特定待被檢測的樣品 ,1克之藥草粉末被溶於一聚丙烯管中,1〇毫升之攝氏8〇 度去離子水(中性酸鹼值)中。此管隨被如表7中所簡列者 所培養,然後被離心以取得其懸浮液。諸批次之甘草被針 對 HepG2 細胞(ATCC Cat#HB-8065)或 Jurkat T 細胞(ATCC cat#TIB-152)或兩者作測試。細胞係如上述者被培養24小 時。 諸批次亦藉由去氧核糖核酸偵測來估計其抑制B型肝 炎病毒的能力(參見董等人,美國國家科學院報告(1991年) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 一裝Evaluation of Glycyirhizae Radix (Glycyrrhiza) Radix Glycyrrhizae is used to moisturize the lungs and cough, and to help relax spasms and pain. The properties of the licorice batches used in this example are presented in Table 7. Table 7 · Batch properties (Glycyrrhiza uralensis) properties Batch A Batch B Batch C ------ Batch • Times D Minutes of warm water, 30 minutes of plant parts and roots-Biological and enzyme testing To test the quality of herbal sources, any herb extract suspension was tested and its analysis was repeated three times. For a specific sample to be tested, 1 g of herbal powder was dissolved in a polypropylene tube and 10 ml of 80 ° C deionized water (neutral pH). This tube was then cultured as outlined in Table 7 and then centrifuged to obtain its suspension. Licorice was tested on HepG2 cells (ATCC Cat # HB-8065) or Jurkat T cells (ATCC cat # TIB-152) or both. Cell lines were cultured for 24 hours as described above. The batches also use DNA detection to estimate their ability to inhibit hepatitis B virus (see Dong et al., National Academy of Sciences report (1991). This paper applies Chinese National Standard (CNS) A4 specifications (210 X 297 mm) (Please read the notes on the back before filling this page)

丁 ϋ I ϋ · ϋ ·ϋ ϋ 1 ϋ -1 I I 經濟部智慧財產局員工消費合作社印製 77 1243210 A7 B7 五、發明說明(75 ) 第88期第8495至8499頁)。簡言之,1克之製劑被附加10毫 升之水。其混合物被煮沸30分鐘。其懸浮液在離心後被收 集且通過一 0.22微米濾紙被過濾。分泌B型肝炎病毒的 HepG2.2.15細胞(由艾斯教授慨為提供;參見艾斯等人, 美國國家科學院報告(1987年)第84期第1005至1009頁)係 被用於本檢測中。1比50稀釋被用於任一檢測。細胞生長 抑制檢測被施行72小時。所有其他的程序如被描述於董等 人,美國國家科學院報告(1991年)第88期第8495至8499頁 中者被完成。 再次地,/3 -葡萄糖醛酶被檢測不同的甘草萃取物被 加入一包含O.lmM酚酞葡萄糖醛酯、70Mm三羥甲基胺基 甲烷一氫氯酸(Tris-HCl)(pH6.8)和0.8ng透析過的/5 -葡萄 糖醛酶(來自大腸桿菌,購自Sigma™)之三聯槽的96-槽檢 測盤中,至最終的體積為80微升。 利用此二批次之諸檢測之結果係被呈現於表8。基於 這些資料,甘草批次A比甘草批次B對Jurkat細胞更具毒性 (約9倍)且為-/3 -葡萄糖醛酶之更有效的抑制劑(見表8)。 ------------------;----訂--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 表8_四種甘草製劑之生物檢測* β 大腸桿菌 -葡萄糖醛酸酶 HepG2 Jurkat HBV; DNA 甘草A 1.3 1.07 0.41 無 甘草B ND ND 3.6 ND 甘草C 2.1 ND ND ND 甘草D ND ND >2.0 53.8 *代表1〇50值 ND,未判定 |對照組百分比 78 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1243210 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(76) 表現檢測 為了檢測基因表現,Jurkat T細胞被以藥草萃取物處 理如下· Jurkat細胞(107/毫升)在一攝氏37度水浴中被快速 地解;東。其細胞接著被稀釋於1〇毫升之預熱過的培食基中 (參見生命科技公司,型錄及參考指南,1998-1999年,細 胞培養節),接著在1500rpm下離心5分鐘。其上清液隨後 被倒去且其細胞在攝氏3 7度,百分之5二氧化碳下被培養 於100毫升培養基中。兩天後,此細胞被計數(8X105/毫升 ’總共1 〇 〇毫升)。 其藥草製劑係如簡述於上者被製備(如:以2克之一藥 草粉末獲得20亳升之無菌溶液(〇·ι克/毫升)。其細胞以2.5 X10毫升之密度,1〇〇毫升/每燒瓶被分裝入3個燒瓶。檢 測係在有對照組(無萃取物),且1〇毫升之萃取物於1〇亳克 /¾升和1亳克/亳升之含量下被施行。再次地,毒性結果 被用來斷性一特定的萃取物為“高,,和“低,,濃度。在萃取物 添加後,在如以上所簡述之條件下,細胞培養被培養24小 時。此等細胞被計數且接著被收集於丨〇亳升離心管中。所 產的細胞團被以一核糖核酸分離方法處理以萃取核糖核酸 (參見,如:山姆布魯克等人,1989年於第7·3頁7·9頁)。 微陣列 微陣列列印係被施行如下: 基因選殖株係經由研究遺傳學(杭斯微耳,A2) (Research Genetics(Hunts Ville,AL))從IMA G E 集團圖蚩 館所獲得,且包含來自不同的組織的基因。大部分的選殊 (請先閱讀背面之注意事項再填寫本頁)Ding ϋ I ϋ · ϋ · ϋ ϋ 1 ϋ -1 I I Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs 77 1243210 A7 B7 V. Description of the Invention (75) 88th p. 8495-8499). Briefly, 1 gram of the preparation was added with 10 ml of water. Its mixture was boiled for 30 minutes. The suspension was collected after centrifugation and filtered through a 0.22 micron filter paper. HepG2.2.15 cells that secrete hepatitis B virus (provided by Professor Ace; see Ace et al., National Academy of Sciences Report (1987) No. 84, pages 1005 to 1009) were used in this test. A 1:50 dilution is used for any test. The cell growth inhibition test was performed for 72 hours. All other procedures were described as described in Dong et al., National Academy of Sciences Report (1991), 88, 8495-8499. Once again, / 3-glucosidase was detected. Different licorice extracts were added to a solution containing O.lmM phenolphthalein glucuronide and 70Mm tris-hydroxymethylaminomethane monohydrochloric acid (Tris-HCl) (pH 6.8). And 0.8 ng of dialyzed / 5-glucosidase (from E. coli, purchased from Sigma ™) in a 96-well test dish in a triple well to a final volume of 80 microliters. The results of the tests using these two batches are presented in Table 8. Based on these data, licorice batch A is more toxic (approximately 9 times) to Jurkat cells than licorice batch B and is a more effective inhibitor of-/ 3-glucosidase (see Table 8). ------------------ ; ---- Order --------- (Please read the notes on the back before filling this page) Intellectual Property of the Ministry of Economic Affairs Printed by the Consumer Cooperatives of the Bureau 8_Bioassay of four licorice preparations * β Escherichia coli-glucuronidase HepG2 Jurkat HBV; DNA Licorice A 1.3 1.07 0.41 Licorice-free B ND ND 3.6 ND Licorice C 2.1 ND ND ND Licorice D ND ND > 2.0 53.8 * Represents a value of 1,050 ND, not determined | Percentage of control group 78 This paper size is applicable to China National Standard (CNS) A4 (210 X 297 mm) 1243210 A7 B7 Employees ’Intellectual Property Bureau, Ministry of Economic Affairs Printed by the cooperative V. Description of the invention (76) Performance test In order to detect gene expression, Jurkat T cells were treated with herbal extracts as follows. Jurkat cells (107 / ml) were rapidly decomposed in a 37 ° C water bath; Dong. The cells were then diluted in 10 ml of pre-warmed culture medium (see Life Technology Corporation, Catalog and Reference Guide, 1998-1999, Cell Culture Section), followed by centrifugation at 1500 rpm for 5 minutes. The supernatant was subsequently decanted and the cells were cultured in 100 ml of culture medium at 37 ° C, 5% carbon dioxide. After two days, the cells were counted (8 × 105 / ml 'for a total of 1000 ml). The herb preparation is prepared as briefly described in the above (eg: 20 liters of sterile solution (0.05 g / ml) is obtained with 2 g of one herb powder. The cells are at a density of 2.5 x 10 ml, 100 ml / Each flask is divided into 3 flasks. The test is performed in the presence of a control group (without extracts) and 10 ml of extracts at a content of 10 g / ¾ liter and 1 g / liter. Again, the toxicity results were used to determine the concentration of a particular extract as "high, and" low. After the extract was added, the cell culture was cultured for 24 hours under the conditions as briefly described above. These cells were counted and then collected in a 100-liter centrifuge tube. The resulting cell mass was processed by a ribonucleic acid separation method to extract the ribonucleic acid (see, for example, Sambrook et al., 1989. Pages 7 · 3 and 7 · 9). Microarrays and microarray printing lines were implemented as follows: Genetic selection lines were obtained from IMA via Research Genetics (Hunts Ville, AL) Obtained from the Ge Group Library and contains genes from different organizations. Points special election (please read the back of the precautions to fill out this page)

a—· _1 I I ϋ I · 79 1243210 A7 五、發明說明(77 ) 株已部分被定序且由基因銀行(GenBank)之dbEST資料庫 可作為己表現的序列標籤。包含pBluescript質體之選殊株 在施用加財龍膜上之前利用市面上可獲得的引子被分別地 培養及放大(陳等人,基因組學(1998年)第51期第313_324 頁)。大約10ng之任一已放大的標的利用一 pC(個人電腦) 控制的整列系統被塗在一帶正電的耐龍膜上。利用一24一 針整列工具約略有8500點可被安置在一片尺寸為35乘55毫 米之耐龍膜上。 互補去氧核糖核酸與膜雜交反應 一微克之任一信息核酸樣品(核糖核酸係以如概述於 前者被分離)利用隨機引發的反轉錄反應被以生物素和/或 異羥基毛地黃毒苔配基所標定。被標定的樣品被以鹼處理 且在施用於雜交反應前所產生之標定好的核酸被沈澱。利 用該標定好的探針,膜雜交反應和清洗被施行,如被揭露 於陳等人之報告(1998年)中者。為了以二重色調(即生物 素和異羥基毛地黃毒苷配基)偵測膜上之點,/3 _半乳糖苷 酶-錯合的抗生蛋白鏈菌素(Streptavidin)(Strept_Gal)和鹼 性磷酸酶-錯合異羥基毛地黃毒苔配基抗體(anti_Dig_Ap) 被運用。經過顯色後,利用一影像化工具之影像數位化被 運用(如一平板式掃描器或數位化相機)。數量化測量係由 利用測量每一點的原始顏色成分之積分密度、進行此積分 密度資料之迴歸分析並將統計的外顯值設定為分化式表現 的基因。 (請先閱讀背面之注意事項再填寫本頁)a— · _1 I I ϋ I · 79 1243210 A7 V. Description of the invention (77) The strain has been partially sequenced and can be used as the expressed sequence tag by the dbEST database of GenBank. Selected strains containing pBluescript plastids were separately cultured and amplified using commercially available primers prior to application on Cicailong membranes (Chen et al., Genomics (1998) 51, pp. 313_324). Approximately 10ng of any enlarged target is controlled by a pC (Personal Computer) controlled whole column system and is coated on a positively charged Nylon film. Approximately 8,500 points can be placed on a piece of Nylon film with a size of 35 by 55 millimeters using a 24-pin full-row tool. Complementary DNA and membrane hybridization reaction. One microgram of any information nucleic acid sample (the ribonucleic acid is isolated as outlined in the former). Randomly initiated reverse transcription reaction is matched with biotin and / or isohydroxy digitalis Base calibration. The calibrated sample is treated with an alkali and the calibrated nucleic acid produced before being applied to the hybridization reaction is precipitated. Using the calibrated probe, membrane hybridization reactions and washing are performed, as disclosed in the report of Chen et al. (1998). In order to detect dots on the membrane in a dual tone (ie, biotin and isoxygenin), the / 3-galactosidase-conjugated streptavidin (Streptavidin) and alkali Phosphatase-conjugated isohydroxy foxglove poison ligand antibody (anti_Dig_Ap) was used. After color development, image digitization using an imaging tool is applied (such as a flatbed scanner or digital camera). Quantitative measurement is performed by measuring the integral density of the original color component at each point, performing a regression analysis of the integral density data, and setting the statistically explicit value as the gene with differential expression. (Please read the notes on the back before filling this page)

裝·![!訂·!------ 經濟部智慧財產局員工消費合作社印製Outfit! [! Order ·! ------ Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs

1243210 A7 B7 五、發明說明(78) 樣品1,2及甘草(ST117)之基因表現資料 刀別對應於冬蟲夏草H(STG27)和甘草之萃取物 的卒取物1,2和6係由以下之方法被檢測:諸批次利用 JurkatT細胞被評估其毒性。其萃取物係以 如實施例6中所 概述者被製m^5xiG5/毫升之密度添w毫升的 rkat、、、田胞#細胞被分裝入2續細胞培養盤中。檢測係 以對妝組(無卒取物,及如所述之5種濃度之萃取物(參見 表9)被實施。細胞培養檢測之高和低濃度係介於…亳克/ 毫升和〇·〇5毫克/亳升(即每毫升_草萃取物之毫克乾重)之 間,視萃聚物對細胞的毒性而被變自。對於某些樣品而言 ,10¾克/¾升之毒性係為所謂的“高毒性,,而“低毒性,,濃 度就被往下調整,不過各極端間至少有一位數的級距被維 持著。例如,對於甘草(ST117),其“高,,為〇·5毫克/毫升而 其“低”為0.05毫克/毫升(見表9)。在萃取物添加後,在如 實施例所述之條件下,細胞培養被培養24小時。其細胞被 計數且所產生的資料被表列以呈現萃取物毒性。所產生的 資料被表示於表9中。 ---——-----裝-----:----訂--------- (請先閱讀背面之注咅?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 81 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 1243210 A7 B7 發明說明(79) 表9·不同藥草萃取物溶液下之存活細胞數目1243210 A7 B7 V. Description of the invention (78) Gene expression data of samples 1, 2 and licorice (ST117) The cuts correspond to the extracts 1, 2 and 6 of Cordyceps sinensis H (STG27) and licorice extract. The method was tested: batches were evaluated for toxicity using JurkatT cells. The extract was prepared as described in Example 6 at a density of ^ 5xiG5 / ml and wml of rkat ,,, and cell # cells were divided into 2 continuous cell culture plates. The test was performed on a makeup set (without strokes, and 5 concentrations of extracts as described (see Table 9). The high and low concentrations of cell culture tests were between 亳 g / ml and 0 · 〇5 mg / 亳 liter (ie dry weight of milligrams per milliliter of grass extract), depending on the toxicity of the extractive polymer to the cell. For some samples, the toxicity of 10¾g / ¾liter For the so-called "high toxicity, and" low toxicity, "the concentration is adjusted downwards, but at least a one-digit step between the extremes is maintained. For example, for licorice (ST117), 0.5 mg / ml and its "low" was 0.05 mg / ml (see Table 9). After the extract was added, the cells were cultured for 24 hours under the conditions described in the examples. The cells were counted and The data generated are tabulated to show the toxicity of the extracts. The data generated are shown in Table 9. --------------- install -----: ---- order ---- ----- (Please read the note on the back? Matters before filling out this page) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 81 This paper is applicable to China Standard (CNS) A4 size (210 x 297 mm) 1243210 A7 B7 Description of invention (79) Table 9 · Number of viable cells in different herb extract solutions

注意:以=1為…的毫升孤小時培養後’ 操作步驟: 1.將1毫升之5 X 105/毫升Jurkat細胞加入24槽培養盤中 2·製備12種藥草萃取物溶液並滅菌 係描 (請先閱讀背面之注音?事項再填寫本頁)Note: After solitary hours of culture with = 1 as the operation steps: 1. Add 1 ml of 5 X 105 / ml Jurkat cells to a 24-well culture plate 2. Prepare 12 herb extract solutions and sterilize the lines ( (Please read the Zhuyin on the back? Matters before filling out this page)

升 經濟部智慧財產局員工消費合作社印製 在任一分析中,144 X96基因(即13,824基因被分析(資 料未現)且與對照組相較約有100基因表現顯著的差別。其 中有些基因被向上調控而其它則被向下調控。與對照組之 差異的程度係視特地的細胞所被暴露之藥草組成物的相對 量而改變。在C1(對照處理)和η和L(藥草)項下之數目代表 扣除月厅、值後所表現之4吕息核糖核酸的強度(表1 〇)。盆某 因標號係被編碼於陣列AD中,其所被追溯至一特定的基 因銀行(GenBank)選殖株。其表現之水準可由被c除 而被判疋。在任一藥草處理過的樣品中只有13,824基因中 之一小部分表現出顯著的變人,亦即,向上、向下或不變 (見表10)。 ^-----^^---------一 【適用中國國家標準(CNS)A4規格(210 X 297公釐) 1243210 A7 B7 五、發明說明(80) <80035〉 <74,108> <74,012> <73,132> <72,101〉 <72o14> <7αο1> <69,107> <68,064〉 <62,117> <62,084〉 <62,§> Α1,11δ> <59,142> <59,135> <58,087> <57,016> <56,088> <56,060> <55,琴 <54,134〉 <53,04S> <53,023〉 Α織KIAA— 4^—驟*种觫输淼 I fi.f .fs I 3-露-3--®^^-糞 A ##取咖13屮一 蠢i曰 a織 ^Nt-tfIa屮 3^t^i^ Μ,^^€β, ^ A織 KIAA878_g13HV.l^«^»> 辦觫鯓la i ^ 00β ΚΓΜ,Ν,ΡΡ 薤奇身麻方沐 #1' #2 . ti 会,030>累8^3^蓄今素 βθν $ - i s <89,083〉叶一AJM盡鷂铖 I 濫衲处塒 HLA-ACHLA-A28,-B40,-CW3) <87083〉 <85,129>^M±MSE16 <85_112> <84075〉 <83,129> A8.0SV <82,027> 01 Sg-Bk 55.29 89.55 80.68 85.33 99.48 90.64 3523 89.56 118.83 6023 65.11 9627 44.91 652 34.68 109.86 46.96 4.37 60.86 3792 224 106.71 U3 97.11 89.52 13.03 60.85 77.72 71J1 5677 8126 0 0 025 6776 m Sg-Bk 00.55 9829 61.91 50.% 109.46 72.12 60.82 77.54 108· 15 47.87 9001 99.% 4623 77.2560s 10338 25.76 i P55 31.41 127 94.67 0 71.92 59·97 15.48 9023 46.86 16.47 5266 9128 43.58 0 0 R98 1LSI 7.15 7P26 46.13 37.75 105.62 92.75 48.87 77.9 — 34.96 66.74 1093 25.19 68s 57.73 82.35 1835 SI 3523 26.12 5.31 83.98 0 73_16 54.11 47.75 I 7633 44.61 59.53 92.08 3947 4300 0 4233 2h Sg-Bk 46.74 84003 59.86 b325 56.68 3797 44.04 66·1 75.84 37_41 66.3 81.88 7821 602 24.61 85.97 0.54 42.87 bi.39 82.82 021 8139 13.55 4201 66.86 27.71 9301 64.43 39.51 59.6 36.86 53.67 43.47 33.47 38.48 2L Sg-Bk 38.07 93003 29.64 25.54 67.54 7008 29.71 59.44 64s 9.84 64.44 8766 40.75 6621 48.93 625 17.87 22.76 40.65 28.64 2.5 61.45 0.58 78.94 43.05 27·86 38,17 22.52 66.89 16.89 70.09 46.42 823 0 66.52 6H sg_Bk 29.21 36Ό2 46.16 37_5 35.65 48.47 2825 43.37 55.8 4400 39.3 4832 37.48 51.52 4234 61.91 127 20.64 1636 36.95 42 77 32.81 83.94 65.65 2322 86.39 56.78 50.43 7287 7174 40 :32.61 0 2724 6L Sg-Bk 3P82 89OV3 32.35 49.82 7578 S6 5933 42.97 6627 46.5 78.37 53.87 42.49 70.19 65.02 3144 17.51 3S1 18.7 50·55 41.64 4100 17.71 96.87 34.92 1S8 312 63.4 35.52 6028 70.47 65.93 9.74 0.53 3724 0 0221074 0.154639 §7599 0.767353 0.597211 —22 P795675 172637 P865788 0.9S124 0.794787 138243 1.03833 192 l_il6 1.756632 0.941016 0.548552 3.450801 0222642 0.123 0·566964 0.887171 0 0.740603 0.669906 L188Q28 1.482827 ai34 0229675 0.927603 1.135614Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs in any analysis, 144 X96 genes (ie, 13,824 genes were analyzed (data not shown) and there were significant differences in about 100 genes compared to the control group. Some of these genes were up Regulation and others are down-regulated. The degree of difference from the control group varies depending on the relative amount of the herb composition to which the specific cells are exposed. Under C1 (control treatment) and η and L (herb) The number represents the intensity of the 4 RNAs after deducting the month hall and value (Table 10). The basin number is coded in the array AD, and it is traced back to a specific gene bank (GenBank) selection. Plants. The level of performance can be judged by dividing by c. Only a small portion of 13,824 genes in any herb-treated sample showed significant changes, that is, upward, downward, or unchanged ( (See Table 10). ^ ----- ^^ --------- 1 [Applicable to China National Standard (CNS) A4 specification (210 X 297 mm) 1243210 A7 B7 V. Description of the invention (80) < 80035> < 74,108 > < 74,012 > < 73,132 > < 72, 101〉 < 72o14 > < 7αο1 > < 69,107 > < 68,064〉 < 62,117 > < 62,084〉 < 62, § > Α1,11δ > < 59,142 > < 59,135 > < 58,087 > < 57,016 > < 56,088 > < 56,060 > < 55, harp < 54,134〉 < 53,04S > < 53,023> 织 woven KIAA— 4 ^ —emergency input Miao I fi.f .fs I 3- 露 -3--® ^^-粪 A ## 取 咖啡 13 屮 一 傻 i 曰 a 织 ^ Nt-tfIa 屮 3 ^ t ^ i ^ Μ, ^^ € β , ^ Awoven KIAA878_g13HV.l ^ «^» > 觫 鯓 la i ^ 00β ΚΓΜ, Ν, ΡΡ 薤 奇 身 麻 方 沐 # 1 '# 2. Ti will, 030 > tired 8 ^ 3 ^^ 今 素βθν $-is < 89,083> Ye Yi AJM does everything I do: HLA-ACHLA-A28, -B40, -CW3) < 87083> < 85,129 > ^ M ± MSE16 < 85_112 > < 84075> < 83,129 > A8.0SV < 82,027 > 01 Sg-Bk 55.29 89.55 80.68 85.33 99.48 90.64 3523 89.56 118.83 6023 65.11 9627 44.91 652 34.68 109.86 46.96 4.37 60.86 3792 224 106.71 U3 97.11 89.126.83 3.126. 0 0 025 6776 m Sg-Bk 00.55 9829 61.91 50.% 109.46 72.12 60.82 77.54 108 · 15 47.87 9001 99.% 4623 77.25 60s 10338 25.76 i P55 31.41 127 94.67 0 71.92 59 · 97 15.48 9023 46.86 16.47 5266 9128 43.58 0 0 R98 1LSI 7.15 7P26 46.13 37.75 105.62 92.75 48.87 77.9 — 34.96 66.74 1093 25.19 68s 57.73 82.35 1835 SI 5523.98. I 7633 44.61 59.53 92.08 3947 4300 0 4233 2h Sg-Bk 46.74 84003 59.86 b325 56.68 3797 44.04 66 · 1 75.84 37_41 66.3 81.88 7821 602 24.61 85.97 0.54 42.87 bi.39 82.82 021 8139 13.55 4201 66.86 27.71 53.167.69 9301 649.6 33.47 38.48 2L Sg-Bk 38.07 93003 29.64 25.54 67.54 7008 29.71 59.44 64s 9.84 64.44 8766 40.75 6621 48.93 625 17.87 22.76 40.65 28.64 2.5 61.45 0.58 78.94 43.05 27 · 86 38,17 22.52 66.89 16.89 70.21 46.42 64.2 28.6 0823 37_5 35.65 48.47 2825 43.37 55.8 4400 39.3 4832 37.48 51.52 4234 61.91 127 20.64 1636 36.95 42 77 32.81 83.94 65.65 2322 86.39 56.78 50.43 7287 7174 40: 32.61 0 2724 6L Sg-Bk 3P82 89OV3 32.35 49.82 49.72 78.82 79.72 78.78 70.19 65.02 3144 17.51 3S1 18.7 5 0 · 55 41.64 4100 17.71 96.87 34.92 1S8 312 63.4 35.52 6028 70.47 65.93 9.74 0.53 3724 0 0221074 0.154639 §7599 0.767353 0.597211 —22 P795675 172637 P865788 0.9S124 0.794787 138243 1.03833 192 l_il6 1.756632 0.941016 0 0460 602 0.548552 3.906 192 l_il6 L188Q28 1.482827 ai34 0229675 0.927603 1.135614

1H 0 0.624705 3._2 0.65456 0.982115 0.622089 1.17 1.133153 0.129318p7i S71765 0.4424 1.061721 —79 1.38717 01 0.993436 0.58S2 1035 1.135348 0.5609 125 L664648 0.74959 0.390758 —67 0.57887 Pil9 2370536 0.786993 0 0753s1H 0 0.624705 3._2 0.65456 0.982115 0.622089 1.17 1.133153 0.129318p7i S71765 0.4424 1.061721 —79 1.38717 01 0.993436 0.58S2 1035 1.135348 0.5609 125 L664648 0.74959 0.390758 —67 0.57887 Pil9 2370536 0.786993 0 0753s

1L 經濟部智慧財產局員工消費合作社印製 133.88 0.567887 0 0.9817 0 0.40287 212 0.549587 P845361 0.947292 0— P6240480.1s 041891 125871 0.738053 P638223 P621119 S8277 0.85i 1.713 0.13 0_7i 0.782541 0224446 90010069 0.548636 —72 ai5 0.762721 —5 P4326Q2 0746872 1 1.528513 0.829002 0.55— 1.04985 0.453606 ai551 L§795 0367397 0299309 0.67893 0.773169 015 P663689 0.539342 0.174 0.98971 P910564 Pi7 loil 1.4109 0.629437 0.380537 52082300 0.667926 0.755274 nil P57586 0.513274 0.81_ 0— 2b2243 P62728 02897500 0.932785 §7516 0.973296 s_5 0.402233 0.572137 0.43947 S4363 P534753 0.801873 0.484256 0.469578 0743815 0.603594 0.501922 0.834558 a_84 122877 0.563535 aB_ 4.723112 0268814 P97442 10075 P721582 290354 0.864381 0.733356 1.782041 1.419721 071 0.703249 12836 0.882845 0. 557424 1. §893 P400967 0.583851 0.761761 0— Li76 0.47979 0.557687 0.772041 1203655 0.559572 0.9461 M 1076534 1.874856 0295285 S72871 6.89016 0.307263 133307 18.5— 0391716 15.67257 0.997529 039008 1272448 P512736 P815749 0.495328 L06_ ai6 51927 241351 i2 236388 —8 121270 510863 645239 47526 509520 —7 328351 28_ 1122— 2h 2L 囊:rnf s1L Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 133.88 0.567887 0 0.9817 0 0.40287 212 0.549587 P845361 0.947292 0— P6240480.1s 041891 125871 0.738053 P638223 P621119 S8277 0.85i 1.713 0.13 0_7i 0.782541 0224446 90010069 0.548636 —72 ai5 0.76272 — 5 P4326 1.528513 0.829002 0.55— 1.04985 0.453606 ai551 L§795 0367397 0299309 0.67893 0.773169 015 P663689 0.539342 0.174 0.98971 P910564 Pi7 loil 1.4109 0.629437 0.380537 52082300 0.667926 0.755274 nil P57586 0.513274 0.43 736 07293 0.3735 0.93 735 0.93 736 0.933785 0.93785 0.932785 0.469578 0743815 0.603594 0.501922 0.834558 a_84 122877 0.563535 aB_ 4.723112 0268814 P97442 10075 P721582 290354 0.864381 0.733356 1.782041 1.419721 071 0.703249 12836 0.882845 0. 557424 1. §893 P400967 0.5 M S5 1.957 765 0.7765 1 0.7572 0.67 0.7572 0.6720 1 726 672 18.5— 0391716 15.67257 0.997529 039008 127 2448 P512736 P815749 0.495328 L06_ ai6 51927 241351 i2 236388 —8 121270 510863 645239 47526 509520 —7 328351 28_ 1122— 2h 2L Capsule: rnf s

6H6H

6L 504540 013392 51 1188706 72215 118548 115134 172767 1184183 lli 17i 1172135 1172266 37502 45672 79342 5S992 21759 铖5> #6濮啉4ia(Hr»>轎挪ffflst赛(cl)盆rrrr批命駟翁¾¾踝洳i£7JC^errrr^ 裝-----^----訂----- (請先閱讀背面之注意事項再填寫本頁) $ 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 83 1243210 A7 B7 五、發明說明(si) <52,135> <47,055>>菜^1蠢 <46,097> <45,100> 翁 HM^I3>L5 <44,103> 繁蠢 <43o39> <43o35> 14-3-3 蛴卧塒 TAU <43o19> <42,099> Δ9,118> 報&細衲D> <3987> 郵4 趣突與^φ¥#1屮-δ <18,097> I蠢 厶5,096> <34,143〉 <30,102> $障難孫*f 赛逾ΓΠ>Ρ48 <30033〉 <29o5s> 繫蠢 Λ9ο35> <28,104> 兹|蜗处813 <28035〉 <27,119> <27,097>>^^2燕*#tiBr-3(A織) <25,126>>§ 刈蠢 <25,106> <24,098> AJMIT蘇雖辦D>(SAP65tl^—^* 种幡筠* 会,071>奪^70+隻養1 <23,126> Af <22o13> 當§0 屮 4B <22,— 3_露_3丨歲^餐—囊> 4926 2.02 00.65 0008 38.53 3426 26_15 _ 55.86 86.86 7248 3S5 0 426 9.46 11.81 10L51 4735 6123 21.98 7841 113 70.49 25.77 60.19 0 71.46 0 i 42.93 61_9 2426 63_92 5Λ8 5.13 61.8 83.17 46.81 0 P17 0 31.69 35.95 33.6 54.36 1 23.18 10.4 33.73 0 034 24.06 6.94 8161 24.52 2.99 8.91 54,15' 23.1 3032 i 5712 0 35.93 0 24.53 2203 48.3 欠 25.43 58.19 1.1 1.93 Φ.95 5784 44.4 52.06 0.45 0.21 1945 32.49 26.3 70.27 2P83 3623 23.38 36.83 02 2.83 15.82 23.82 89.86 0 25.05 SI 7936 16.06 65.13 0 86.66 0 51.86 0 926 29.88 4141 2100 61.1 S.08 δ 41.52 3900 沐0(¾) 72.95 55.5 S3 6.03 38.99 1431 44.14 0 43.8 56.1 _1 63.19 55.86 48.59 75.43 91.53 11.68 17.8 18.14 12·Ί6 Ζ7.59 12.83 61 51.56 S7 1278 3728 i 26s 25.48 80.14 16.65 2188 71.4 23.2 32.88 30.61 16.93 53.54 2401 29.56 40_5 S5 3439 17.18 33.65 59.85 3324 46.47 5S9 37.19 1.37 1127 39.75 4827 1.66 7622434 67.76 4039 91.26 58009 56.18 3728 50.86 6627 54.71 1111 3PO99 1435 32.99 49.11 40.04 4433 24.16 2486 39.88 30.59 80.57 2.9 4.51 42.7 46.33 40.12 0 63.21 22.36 3825 0.79 59.36 30.86 3126 70.5 11.82 1299 3.47 4036 2.59 225 2200 6.13 I 37.19 27.03 1746 28.52 16·52 4907 2705 6101 0 3035 5·6 1L64 il 53.2 5176 4329 80.86 4L06 42.28 15.99 48.43 7.47 9.67 4436 1PO51 79.82 3529 40.4 22.99 61.59 47.49 36.52 18.54 58.47 5.97 36.54 1.1 3α2 30.53 51003 46.77 68.86 5.53 18.73 2i 35.49 經濟部智慧財產局員工消費合作社印製 0.95iP90134 1.480918 0 25.77228 19.4703 0.019653 0.052§ 4.507514 0 i7 525909 0.822476 0_5il 1.136777 1.049329 0.948336 l_16i 1284895 1.85736 2.136138 P7i5P975837 LM7493 0.322592 0.372897 0.209094 0266866 0.41708 0208842 01 0322572 0380657 1.115041 1217521 2016529 0.079812 0_i9 8.751174 254334 —04 2756871 0.5876300201 6785775 0.813811 P885233 0225397 P517846 0P489968 012 0.13 0.499918 0.405369 0.641947 2.435851 oil 1012116 0376693 P846154 a58_ 2283883 0.430132 0.923961 0.243723 o.i 0 2322468 0.948995 1.439774 0.772055 0.502799 0.725721 0.157711 1.527397 0.575588 4.732877 0.513161Pil7 1.578383 0.781583 0J01292 L474313 1.048228 §8599 2315746 0.910357 0.955882 0.795682 0212355 1.945946 178 0376218 0243665 719 P808252 0·671845 0.372006 p69i 0.47— 0.481424 1.126675 1.283191 0.616119 2985149 —31 2772277 1.654335 4421965 1.345665 0 897727 0011364 1.45§8 1.540618 1.380742 1.844425 0.900759 1.5108 1.858126 1.655449 1.27073 0.979031 i p34i 02116 073— 0.146903 £49551 Pi76 P177014P047875 0.13 1.704463 1334215 1.600992 1.8i7 0.528169 2269953 2.693446 2.40148 4.18 i822P51 L567316 0.703379 0.885923 a786326 0.694403 0.785428 0.745301 0276498 0.44145 0.659807 1.092357 0794359 1.045951 0.516516 0.363729 0.785487 1259707 asi 1.73956 0.477373 0.696127 0.5— 1289872 l.i7 0.71 01 1.013624 0.971424 0.430311 0.561433P511335 1.515567 1.504359 l_i8 o.i 0.579082P711158 0.951373 0.644265 0.837318 1.53i 1260923 1.927865 1036765 1260482 1.077284 2.337838P559846 2119 2.797271 G.879142 1651072 a7_ 0.690939 0.324272 0.53385 0.557052 0.426716 286222 624420 529138 5— 2i 511591 5U410 2i 592919 11 488154 86102 84335 123764 23643 81665 1185901 723779 712549 26i 117Q289 612365 82236 38798 81491 595769 994662 li2 68744 427843 42714 274769 255134 416946 298187 5i 563866 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 84 ------.----裝----l·---訂---------Aw. (請先閱讀背面之注意事項再填寫本頁) 1243210 A7B7 五、發明說明(82) 27.02 22.09 <20103〉 1.45 <19,098> AJi 目 <18,103>^—^I]>L5 31.47 <18,084>>ii^蠢 54_61 <17,103〉繁蠢 0 <17,097> 繁義 1.52 <17,f 92.72 , 〇 ms 0.79 <15,112> 16.47 <14,103> 寒蠢 2161 <14011〉·墓# 4742 <13,114> A織掏馨2—蠢翠芝 20.64 <12,i AJMNAD :餐坤處窠NDi 76.78 <12,1 lv40.04 <11,135〉 9034 A1U05V 翁|_处13 827 <11053〉Spain ->冰»織12 10.48 <10,136>¾¾攝?谗捧雖 74.34 <10,101>>§^1蠢 13.65 <09,136> 澌裏# 59_82 <09,11? 2塒1商蜗In'桊蛇冷雜一 173 Aslv 80.14 <08,138> 4L57 <08,132> 6722 <08,122> AJMDRAKH—蹇等辦皭繁 3201 <08,05> 69_58 <08055〉 19.5 <07,111> 30.8 <07s7>>§2雜難 4.57 <06,135〉 71.42 <06,102>>奪蠢擻 39.82 β§ν 4.43 <06,034>^nrIIhLS 0 2219 15.17 126 1438 21.13 75.17 0 21 73.27 0.92 33.86 17.33 0 0.79 3007 46.16 0 1.21 103.64 0 0.7 11007 3S8 68.28 192 76.11 46.34 87.88 Is 1400 90.94 13.97 87.16 48.92 9622 69.53 103.65 47.74 84.49 22.83 48.75 901 I 32.57 421 0 74.98 39.66 52.94 78.6 79.5 33.% 37.77 69.79私一.3 38.06 46.52 55.67 38·71 5126 64.5 77.78 80.49 36.82 15.69 83.18 47.57 77.34 55.32 80.4 7327 90.56 63.02 90.5 27.87 73.84 4132 li 67.74 38.95 0 19.17 ΡΟ67 28.97 27.18 6001 2.87 11.59 Φ35 1.84 8.28 22.98 38.45 516 3234 5— 4607 8722 25.87 8.87 74.85 26.68 83.51 35.56 77 Μ 8126 I 35.64 68.91 34.66 5131 00.83 lolfe 46Ό4 16·6 33.93 洳 10¾) 56007 32.97 2724 8.3 0.73 N5 27.47 74.37 3·64 3.43 68.85 6.67 0.89 2822 35·52 5003 2027 53.7 69.51 60.79 3L97 47ΟΝ3 54.35 36.05 6924 45.73 7605 59.49 76.85 32·48 89.98 48.86 55>.76 22.9 93.72 59.07 15005 Ο 33_86 35.84 903 3125 43.29 56·43 9.87 14.35 S.14 1L18 16.63 2143 50.43 5224 27.7 6.92 55.69 8728 47.1 28.91 65.41 40·14 71.68 6003 82.81 66·73 81.15 46005 94.96 5Ρ43 6829 2156 942 5713 32.59 Ο Ο 0.707347 1240855 0.735344 0.671996 0.875228 1.374625 I 1.742443 225 1.098063 —7 l_58i 2.412139 L1I5 1.452971 1·529902 Ρ725086 ai33 154 L450325 0.706783 1.577709 0.904822 α—4 Ρ886076 0.720704 1Ό93082 1.439899 0.93i 0.991274 1.157343 097277 1.885127 1.412214 1223298 1.023443 1457038 2.827746 12_9 1.6726 1.541952 1.491409 1214286 1.17_ 1.582792 S71554 Li56 Ρ817931 0139 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 48.17722 2824529 2016298 0.816322 —27 0.840063 1.942557 0.890967 4.452237 L497137 1.118913 3.484982 1292879 3.197688 1.83244 1762569 1.347218 i76 oil 1429231 2.397403 —575 1.439373 1.701155 8J92325 048101 1.395264 1.3— 1.130325 L5i 0.651732 Li99 0.965464 3.128174 Pi74 L00686 1.954579 1396021 2.055491 0.966309 1.954775 1315531 l_li ai71 1.777436 1.665909 1.932166 1.41 1.156203 3.747178 1.126582 1.713418 I 105504 P982074 0.611 1.736014 0.672902 186578 4.544847 07311 2.641026 L157472 2643353 0.948964 1,43108 U43261 L0_3 1293188 2.505641 1.94026 II 1.312237 1.483425 3.577878 2105063 1.36187 1.826512 1.15 1342054 0128 1.390859 P966128 5.695284 2758588 0.8790076 2940659 1.198261 3.469942 1033317 1.144 120723 1.463605 1.36476 2.586154 2217208 5.155361 1318958 1434706 7356659 1.381579 0.796053 24.84868 7.625 2256579 9.1789 0.790229 1.117774 07526% 0.747951 0.742558 0.178 0.821244 0.686736 0.868966 019 0.671433 1.376488 1253146 Ρ784518 Ο Ρ606521 0.955513 0.845266 —7 3.394296 27.35172 2.975829 2.497617 1.455777 1.22S07 0.867813 5.97931 1.62S3 0.86368 183 —142 0375736 0.503448 0702642 0.872895 1.3618300 1 1.622454 6.227586 1.756605 1375596 1033327 一 -----^----訂--------- 29970 _90 53078 53i6L 504540 013392 51 1188706 72215 118548 115134 172767 1184183 lli 17i 1172135 1172266 37502 45672 79342 5S992 21759 铖 5 ># 6 濮 岭 4ia (Hr »> Carlo ffflst race (cl) basin rrrr life order ¾¾ ankle 洳 i £ 7JC ^ errrr ^ Pack ----- ^ ---- Order ----- (Please read the precautions on the back before filling out this page) 297 mm) 83 1243210 A7 B7 V. Description of the invention (si) < 52,135 > < 47,055 > > Dish ^ 1 Stupid < 46,097 > < 45,100 > Weng HM ^ I3 > L5 < 44,103 > Stupid < 43o39 > < 43o35 > 14-3-3 Tau Tau < 43o19 > < 42,099 > Δ9,118 > Report & Fine D > < 3987 > Post 4 Fun and ^ φ ¥ # 1 屮 -δ < 18,097 > I 厶 5,096 > < 34,143〉 < 30,102 > $ 障 难 孙 * f Saiyo ΓΠ > P48 < 30033〉 < 29o5s > 蠢 9ο35 > < 28,104 > | < 25,106 > < 24,098 > AJMIT Souban D > (SAP65tl ^ — ^ * species 幡 筠 * Yes, 071 > Win 70+ only 1 < 23,126 > Af < 22o13 > When §0 屮 4B < 22, — 3_ 露 _3 丨 years old ^ Meal-bag> 4926 2.02 00.65 0008 38.53 3426 26_15 _ 55.86 86.86 7248 3S5 0 426 9.46 11.81 10L51 4735 6123 21.98 7841 113 70.49 25.77 60.19 0 71.46 0 i 42.93 61_9 2426 63_92 5Λ8 5.13 61.8 83.17 46.81 0 P17 0 31.69 35.95 33.6 54.36 1 23.18 10.4 24.73 33.06 24.06 33.73 8.91 54,15 '23.1 3032 i 5712 0 35.93 0 24.53 2203 48.3 25.43 58.19 1.1 1.93 Φ.95 5784 44.4 52.06 0.45 0.21 1945 32.49 26.3 70.27 2P83 3623 23.38 36.83 02 2.83 15.82 23.82 89.86 0 25.05 SI 7936 16.06 65.13 0 86.66 0 51.86 0 926 29.88 4141 2100 61.1 S.08 δ 41.52 3900 Mu0 (¾) 72.95 55.5 S3 6.03 38.99 1431 44.14 0 43.8 56.1 _1 63.19 55.86 48.59 75.43 91.53 11.68 17.8 18.14 12 · Ί6 Z7.59 12.83 61 51.56 S7 1278 3728 i 26s 25.48 80.14 16.65 2188 71.4 23.2 32.88 30.61 16.93 53.54 2401 29.56 40_5 S5 3439 17.18 33.65 59.85 3324 46.47 5S9 37.19 1.37 1127 39.75 4827 1.66 7622434 67.76 4039 91.26 58009 56.18 3728 50.86 6627 54.71 1111 3PO99 1435 32.99 49.11 40.04 4433 24.16 2486 39.88 30.59 80.57 2.9 4.51 42.7 46.33 40.12 0 63.21 22.36 3825 0.79 59.36 30.86 3126 70.5 11.82 1299 3.47 4036 2.59 225 2200 6.13 I 37.19 2705.60 1746 5.6 1L64 il 53.2 5176 4329 80.86 4L06 42.28 15.99 48.43 7.47 9.67 4436 1PO51 79.82 3529 40.4 22.99 61.59 47.49 36.52 18.54 58.47 5.97 36.54 1.1 3α2 30.53 51003 46.77 68.86 5.53 18.73 2i 35.49 Intellectual Property Agency of the Ministry of Economic Affairs and Consumer Affairs Co., Ltd.5. 1.480918 0 25.77228 19.4703 0.019653 0.052§ 4.507514 0 i7 525909 0.822476 0_5il 1.136777 1.049329 0.948336 l_16i 1284895 1.85736 2.136138 P7i5P975837 LM7493 0.322592 0.372897 0.209094 0225 850 0 P1 850 0 1 1867 01000 175041 1 2751 1751 0.499918 0.405369 0.641947 2.435851 oil 1012116 0376693 P846154 a58_ 2283883 0.430132 0.923961 0.243723 oi 0 2322468 0.9 48995 1.439774 0.772055 0.502799 0.725721 0.157711 1.527397 0.575588 4.732877 0.513161Pil7 1.578383 0.781583 0J01292 L474313 1.048228 §8599 2315746 0.910357 0.955882 0.795682 0212355 1.945946 178 0376218 0243 1.65 1.697 2654 1654 1.65 654 1654-1675-0.465 1.45§8 1.540618 1.380742 1.844425 0.900759 1.5108 1.858126 1.655449 1.27073 0.979031 i p34i 02116 073— 0.146903 £ 49551 Pi76 P177014P047875 0.13 1.704463 1334215 1.600992 1.8i7 0.528169 2269953 2.693446 0 359 0589 589 0589 589 0859285 1859326 1786326 0.8786 285 1259707 asi 1.73956 0.477373 0.696127 0.5— 1289872 l.i7 0.71 01 1.013624 0.971424 0.430311 0.561433P511335 1.515567 1.504359 l_i8 oi 0.579082P711158 0.951373 0.644265 0.837318 1.53i 1260923 1.927865 1036765 1260482 1.077284 2.33783872 G559846 2119 2.119 2.797 _ 0.690939 0.324272 0.53385 0.557052 0.426716 286222 624420 529138 5— 2i 511591 5U410 2i 592919 11 488154 86102 84335 123764 23643 81665 1185901 723779 712549 26i 117Q289 612365 82236 38798 81491 595769 994662 li2 68744 427 642 642 636 642 636 642 636 642 636 636 636 636 636 456 Standard (CNS) A4 specification (210 X 297 mm) 84 ------.---- installation ---- l · --- order --------- Aw. (Please first Read the notes on the back and fill in this page) 1243210 A7B7 V. Description of the invention (82) 27.02 22.09 < 20103> 1.45 < 19,098 > AJi item < 18,103 > ^-^ I] > L5 31.47 < 18,084 > > ii ^ Stupid 54_61 < 17,103> Stupid 0 < 17,097 > Stupid 1.52 < 17, f 92.72, 〇ms 0.79 < 15,112 > 16.47 < 14,103 > Cold Stupid 2161 < 14011> Tomb # 4742 < 13,114 > A weaving sweet 2-Stupid Cuizhi 20.64 < 12, i AJMNAD: Restaurant Kunji 窠 NDi 76.78 < 12,1 lv40.04 < 11,135〉 9034 A1U05V Weng__ place 13 827 < 11053> Spain-> Ice »Weaving12 10.48 < 10,136 > Although holding 74.34 < 10,101 > > § ^ 1 stupid 13.65 < 09,136 > Bali # 59_82 < 09,11? 2 埘 1 commercial snail In 'Viper cold mixed one 173 Aslv 80.14 < 08,138 > 4L57 < 08,132 > 6722 < 08,122 > AJMDRAKH— 蹇 and other offices 3201 < 08,05 > 69_58 < 08055> 19.5 < 07,111 > 30.8 < 07s7 > > §2 Miscellaneous 4.57 < 06,135> 71.42 < 06,102 > > 擞 39.82 β§ν 4.43 < 06,034 > ^ nrIIhLS 0 2219 15.17 126 1438 21.13 75.17 0 21 73.27 0.92 33.86 17.33 0 0.79 3007 46.16 0 1.21 103.64 0 0.7 11007 3S8 68.28 192 76.11 46.34 87.88 Is 1400 90.94 13.97 87.16 48.92 9622 69.53 103.65 47.74 84.49 22.83 48.75 901 I 32.57 421 0 74.98 39.66 52.94 78.6 79.5 33.% 37.77 69.79 Private one.3 38.06 46.52 55.49 36.69 38.69 83.18 47.57 77.34 55.32 80.4 7327 90.56 63.02 90.5 27.87 73.84 4132 li 67.74 38.95 0 19.17 ΡΟ67 28.97 27.18 6001 2.87 11.59 Φ35 1.84 8.28 22.98 38.45 516 3234 5— 4607 8722 25.87 8.87 74.85 26.68 58.6 88.6 51.91.46Ό4 16 · 6 33.93 洳 10¾) 56007 32.97 2724 8.3 0.73 N5 27.47 74.37 3.64 3.43 68.85 6.67 0.89 2822 35 · 52 5003 2027 53.7 69.51 60.79 3L97 47 ON3 54.35 36.05 6924 45.73 7605 59.49 76.85 32 · 48 89.98.98 48.86 48.86 22.9 93.72 59.07 15005 〇 33_86 35.84 903 3125 43.29 56 · 43 9.87 14.35 S.14 1L18 16.63 2143 50.43 5224 27.7 6.92 55.69 8728 47.1 28.91 65.41 40 · 14 71.68 6003 82.81 66 · 73 81.15 46005 94.96 5PP43 6829 2156 942 5713 0.707347 1240855 0.735344 0.671996 0.875228 1.374625 I 1.742443 225 1.098063 —7 l_58i 2.412139 L1I5 1.452971 1 · 529902 P725086 ai33 154 L450325 0.706783 1.577709 0.904822 α—4 P886076 1.2409 1.41 412 1.41 421 1.417 343 1.274343 1 297 123 929 142 _ 1.582792 S71554 Li56 Ρ817931 0139 (Please read the precautions on the back before filling this page) Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs 48.17722 2824529 2016298 0.816322 —27 0.840063 1.942557 0.890967 4.45223 7 L497137 1.118913 3.484982 1292879 3.197688 1.83244 1762569 1.347218 i76 oil 1429231 2.397403 —575 1.439373 1.701155 8J92325 048101 1.395264 1.3— 1.130325 L5i 0.651732 Li99 0.965464 3.128174 Pi74 L00686 1.7471 1.577775 115631 115631 115631 115631 115631 115631 115631 1156312 115631 115631 115631 115631 115631 115631 115631 138631 115631 115631 159631 159631 159631 1615 1531 1962 1.736014 0.672902 186578 4.544847 07311 2.641026 L157472 2643353 0.948964 1,43108 U43261 L0_3 1293188 2.505641 1.94026 II 1.312237 1.483425 3.577878 2105063 1.36187 1.826512 1.15 1342054 0128 1.390859 1.96061 1.615618 1 683 618 156 162 618 156 156 1 682 618 2256579 9.1789 0.790229 1.117774 07526% 0.747951 0.742558 0.178 0.821244 0.686736 0.868966 019 0.671433 1.376488 1253146 P784518 〇 P606521 0.955513 0.845266 —7 3.394296 27.35172 2.975829 2.497617 1.455777 1.22S07 0.867813 5.97931 1.62S3 0.86368 183 1,420,375,736 0,702,642 0.503448 1.622454 6.227586 1.756605 0.872895 1.3618300 1 13755961033327 ^ ---- ----- a book --------- 29970 _90 53078 53i

382766 562992 562928 248687 549382 512336 549224 327474 50753 547624 308754 49967 546545 32672一義一 325580 49373 51i 31866 544957 510323 613442 5S836 4788 S511 632480 66427 308580 3i 6111M 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 85 1243210 A7 B7 五、發明說明(83 ) Λο^.— 0 31.71 0 会,134V 3— 54.62 46.61 会,106> 幾蜗卟>黹>诔 15.74 23.81 21.94 <03,140〉 5608 8S3 6129 <03,099> 22.97 18.57 12_1 <02,111>>罃蠢獬 > 综拿|1.5斗聲轰11>34.89 23.63 25 2136 34.84 23.95 <mo58>pIISIA^l^-c4^c-12i^60.68 53.35 73.26 搔氺116 0 71.8 4674 93_1 52.83 77.41 53.14 S.56 0 58.82 21.94 7404 23.48 28.84 45.66 5S8 0 64003 56.63 74.42 53.26 56.6 40.67 72001 0 64.43 55.12 81.16 41.55 6036 51.53 91.71 1.399436 1.512706 L575071 0.808446 0.677271 L631086 0.87i 1·1 1.393901 i903 0.526774 0.7165300 —5 1207317 S9611 2.969504 1.660128 2.299956 2218687 2.487828 1030982 1.507046 1.393901 1320257 1.0_3 0.826598 2.13764 P932432 1.66103 3.5i 1327033 2.318677 1.622241 1.904026 1 L650781 1501906 L447218 1.808881 173i 2.412453 1.511371382766 562992 562928 248687 549382 512336 549224 327474 50753 547624 308754 49967 546545 32672 Yiyi 325580 49373 51i 31866 544957 510323 613442 5S836 4788 S511 632480 66427 308580 3i 6111M This paper applies the Chinese National Standard (CNS) A4 standard (210 X) 85 1243210 A7 B7 V. Description of the invention (83) Λο ^ .— 0 31.71 0 meeting, 134V 3— 54.62 46.61 meeting, 106 > snail porch > 黹 > 诔 15.74 23.81 21.94 < 03,140> 5608 8S3 6129 < 03,099 > 22.97 18.57 12_1 < 02,111 > > Stupid 獬 > Synthetic | 1.5 Dou Heng 11 > 34.89 23.63 25 2136 34.84 23.95 < mo58 > pIISIA ^ l ^ -c4 ^ c-12i ^ 60.68 53.35 73.26 搔 氺 116 0 71.8 4674 93_1 52.83 77.41 53.14 S.56 0 58.82 21.94 7404 23.48 28.84 45.66 5S8 0 64003 56.63 74.42 53.26 56.6 40.67 72001 0 64.43 55.12 81.16 41.55 6036 51.53 91.71 1.399436 1.512706 L575071 1.8631 0.808446 0.808446 0.6 i903 0.526774 0.7165300 —5 1207317 S9611 2.969504 1.660128 2.299956 2218687 2.487828 1030982 1.507046 1.393901 1320257 1.0_3 0.826598 2.13764 P932432 1.66103 3.5i 1327033 2.318677 1.622241 1.904026 1 L650781 1501906 L447218 1.808881 173i 2.412453 1.511371

530672 285979 31309 624595 42281 45327 567287 I (請先閱讀背面之注意事項再填寫本頁) mm— ϋ I 一一口、I I ...I ϋ ϋ I » 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 86 l2432l〇 A7 B7 五、 發明說明(84 ) 以此方式,吾人可以探討特定的基因表現與一細胞對 氣、低(L)或高⑻量之-藥草組成物之暴露的相關係。以 此方式所鐘定之基因中有許多編碼在已知代謝或生化途徑 有重要性之蛋白質。這些蛋白質中有許多對於某些生理、 理要項具有直接或間接的作用。因此,此方法允 許一藥草組成物之一特定的遺傳指紋與其陣列生物作用之 聯結。此等聯結可被用來剖析或特徵化_藥草組成物,以 達到οσ貝控制和品質確認以及評估藥理或毒理學性質之目 的。在一藥草配方中之初級和次級藥草的角色亦可藉此方 法被檢測。 南效液相層析分析 其 藥草批次係以一貝克曼〇DS UhrasphereTM管柱(5微米 粒子,4.6亳米X25厘米)藉由高效液相層析被分析且被以 一糸外光分光光度計(鉑金艾爾瑪y偵測。用於紫外光偵測 之波長係於280nm和34〇nm被監測。其動相係以i毫升/分 鐘被推動且包含以如下述之梯度的溶劑A :水和溶劑B ·· 20%甲醇:1)前5分鐘溶劑為1〇〇%溶劑a ; 2)其次之ι〇分鐘 溶劑改為10%溶劑A/90%溶劑B ; 3)其次之4〇分鐘溶劑改為 10%溶劑A/90%溶劑B。繼之以添加1〇〇%溶劑A5分鐘。 高效液相層析標識物係為甘草甜素。 演算法 維 學 所收集的資料形成用於產生多變項常態分布組之多 分析的一部分,以作為一判定生物活性和標準黃芩湯化 物質(高效液相層析及質譜儀)之間的基準線相闕性,以及 本紙張尺度適用中國國家標準(CNS)A4規格(21〇7^97公髮) 87 - 1243210 A7530672 285979 31309 624595 42281 45327 567287 I (Please read the precautions on the back before filling out this page) mm— ϋ I one-on-one, II ... I ϋ ϋ I »This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) 86 l2432l0A7 B7 V. Explanation of the invention (84) In this way, we can explore specific gene expression and a cell's air-to-air, low (L), or high-amount-herb composition Exposed relationship. Many of the genes identified in this way encode proteins that are important in known metabolic or biochemical pathways. Many of these proteins have direct or indirect effects on certain physiological and rationale items. Therefore, this method allows the association of a particular genetic fingerprint of a herb composition with the biological effects of its array. These associations can be used to analyze or characterize the herb composition for the purposes of σσ control and quality assurance, as well as evaluation of pharmacological or toxicological properties. The role of primary and secondary herbs in a herb formula can also be tested in this way. The HPLC analysis of the herb batch was performed on a Beckman ØDS UhrasphereTM column (5 micron particles, 4.6 mm x 25 cm) by HPLC and analyzed by a spectrophotometer. (Platinum Elma y detection. The wavelengths used for ultraviolet light detection are monitored at 280nm and 34nm. The mobile phase is driven at 1 ml / min and contains a solvent A with a gradient as follows: water And solvent B · 20% methanol: 1) the first 5 minutes of the solvent is 100% of the solvent a; 2) the next 10 minutes of the solvent is changed to 10% of the solvent A / 90% of the solvent B; 3) the next 40 minutes The solvent was changed to 10% solvent A / 90% solvent B. This was followed by the addition of 100% solvent A for 5 minutes. The HPLC identification system was glycyrrhizin. The data collected by the algorithm dimensionality forms part of the multi-analysis used to generate the multivariate normal distribution group, as a benchmark for determining biological activity and standard Huanghua Tanghua substances (high performance liquid chromatography and mass spectrometer) Linearity, and this paper size applies Chinese National Standard (CNS) A4 specifications (21〇7 ^ 97 issued) 87-1243210 A7

五、發明說明(85 ) 起源/生長特性的手段。 B.黃答 黃芩之評估 、^"被^現有用於降低微血管通透性和發炎。它亦 可被用來治療腸炎和病疾,增進膽汁分泌以、冶療黃殖、緩 解肌肉痙·攣/σ療咳啦以及驅蟲。被使用於本實施例之黃 答批次的特性被表示於表丨【。 表11·批次特性(黃芩) 特性 批次A 批次B 批次C 批次D 植物名稱 黃答 黃芩 黃芩 黃芩 來源 山西省 美國,金門 藥草中心 美國,金門 藥草中心 美國,波士頓 製備方法 標準H 煮彿30分鐘 煮沸30分鐘 煮沸,2小時 植物部位 根 根—' - - (請先閱讀背面之注咅?事項再填寫本頁) ▼裝 經濟部智慧財產局員工消費合作社印製 生物及酵素檢測 簡吕之’ 1克之任一配製之黃芩萃取物被附加1〇毫克 之水(1亳克/毫升)。其混合物係如簡列於表丨丨中者被處理 。其上清液在離心後被收集並通過一0.22微米濾紙被過濾 。諸批次之黃芩針對HepG2細胞(ATCC cat#HB_8065)或 Jurkat細胞(ATCC cat#I7B-152)或兩者被測試。1比50稀釋 被用於任一檢測。細胞被培養24小時悉如上述者。 諸批次亦藉由去氧核糖核酸偵測來估計其抑制B型肝 炎病毒的能力(參見董等人,美國國家科學院報告(1991年) 第88期第8495至8499頁)。簡言之,1克之製劑被附加10毫 升之水。其混合物被煮沸3〇分鐘。其懸浮液在離心後被收 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 88 l·---訂------ 1243210 A7 B7 五、發明說明(86 ) 集且通過一 0.22微米濾紙被過濾。分泌B型肝炎病毒的 HepG2.2.15細胞(由艾斯教授慨為提供;參見艾斯等人, 美國國家科學院報告(1987年)第84期第1005至1009頁)係 被用於本檢測中。1比50稀釋被用於任一檢測。細胞生長 抑制檢測被施行72小時。所有其他的程序如被描述於董等 人,美國國家科學院報告(1991年)第88期第8495至8499頁 中者被完成。 至於yS -葡萄糖醛酸酶,不同的黃芩萃取物被加入一 包含O.lmM酚酞葡萄糖醛酯、70 mM三羥甲基胺基甲烷一 氫氯酸(Tris-HCl)(pH6.8)和0.8ng透析過的/3 _葡萄糖酸酸 酶(來自大腸桿菌,購自Sigma™)之三聯槽的96·槽檢測盤 中,至最終的體積為80微升。在攝氏37度培養2小時後, 反應被以包含0.2M甘胺酸和0.2M氯化鈉(ρΗΙΟ.4)之停止溶 液200微升終止,且其吸光度(0D)被以一動態微盤讀取機 在540nm波長被監控。 利用此三批次之檢測的結果被呈現於表12中。 ----Γ---*----裝-----^----訂--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 表12.黃芩之四種製劑之生物檢測* 大腸桿菌 yg-葡萄糖醛酸酶 HepG2 Jurkat HBV; DNA 黃芩A 1.5 0.33 0.45 無 黃芩B 1.8 ND ND ND 黃芩C 0.3 ND ND ND 黃芩D ND 0.65 ND 27.5 *代表IC5Q值 ND,未判定 對照組百分比 89 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 1243210 A7 ____B7___ 五、發明說明(87 ) 黃芩對蛋白質表現之作用的評估 在藥物添加前HepG2細胞(1 X 1〇6)被接種於25厘米2燒 瓶中3.0毫升之rpmI-1640培養基内(參見生命科技公司, 型錄及參考指南,1998-1999年,細胞培養節)24小時。其 細胞被施以有或無藥草之處理,其中前者係分別以〇.2毫 克/毫升或4毫克/毫升之最終濃度被添加,並於攝氏37度下 被培養24小時。其培養基被去除且其細胞被以冰的pBS清 洗兩次。其細胞被收集於1毫升之pBS内並於⑺⑼^㈣被 離〜2分4里,在冰上被以一含有5 〇mM三經甲基胺基甲烧 氣(ρΗ7·5)、〇_2mM PMSF和10%甘油之緩衝劑萃取,繼 之以二個冷凍、解凍循環。在離心前氯化鉀以〇15M之最 終濃度被加入細胞溶解液中。其蛋白質濃度被測定且其細 胞萃取物依據蘭理(Laemmli)之方法(自然(1970年)第227期 第680至685頁)被電泳。西方轉印法係以標準的習知技藝 被施行,參見如山姆布魯克(Sambr〇〇k)等人(1989年)。所 使用的抗體係針對以下的蛋白質:拓普〗;Stat (2〇7〇7); 周期素B1 (Cyclin Bl)、MAPK(抗體2)和Nm 23 H1。 第4圖揭示黃芩批次八和B並未分化性地影響被溶解於 西方轉印膜上的多胜類之表現。 高效液相層析分析 藥草批次係以一貝克曼〇DS Ultrasphere™管柱(5微米 粒子,4.6亳米X25厘米)藉由高效液相層析被分析且被以 一紫外光分光光度計(鉑金艾爾瑪)偵測。用於紫外光偵測 之波長係於280nm和34〇nm被監測。其動相係以}毫升/分 (請先閱讀背面之注意事項再填寫本頁) f -----^----訂----V. Description of the invention (85) Means of origin / growth characteristics. B. Huang A. Huang's evaluation was used to reduce microvascular permeability and inflammation. It can also be used to treat enteritis and diseases, increase bile secretion, cure yellow colon, relieve muscle spasms, cramps / σ cure cough, and deworming. The characteristics of the yellow answer batches used in this example are shown in Table 丨 [. Table 11 · Batch characteristics (Scutellaria baicalensis) Characteristics Batch A Batch B Batch C Batch D Plant name Huangda Scutellaria baicalensis Scutellaria baicalensis Source Shanxi Province United States, Golden Gate Herb Center United States, Golden Gate Herb Center United States, Boston Preparation Method Standard H Cook Buddha boil for 30 minutes, boil for 30 minutes, 2 hours for plant parts— '--(Please read the note on the back? Matters before filling out this page) ▼ Install the printed biological and enzyme test briefs of the Employees ’Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs Lu Zhi '1 g of any formulated scutellaria baicalensis extract was added with 10 mg of water (1 g / ml). The mixture is processed as briefly listed in the table. The supernatant was collected after centrifugation and filtered through a 0.22 micron filter paper. Batches of Scutellaria baicalensis were tested against HepG2 cells (ATCC cat # HB_8065) or Jurkat cells (ATCC cat # I7B-152) or both. A 1:50 dilution is used for any test. Cells were cultured for 24 hours as described above. Batches have also been evaluated for their ability to inhibit hepatitis B virus by DNA detection (see Dong et al., National Academy of Sciences Report (1991) 88 (8495-8499). Briefly, 1 gram of the preparation was added with 10 ml of water. The mixture was boiled for 30 minutes. The suspension was collected after centrifugation. The paper size is in accordance with the Chinese National Standard (CNS) A4 (210 X 297 mm) 88 l · --- order ----- 1243210 A7 B7 V. Description of the invention (86) Collect and filter through a 0.22 micron filter paper. HepG2.2.15 cells that secrete hepatitis B virus (provided by Professor Ace; see Ace et al., National Academy of Sciences Report (1987) No. 84, pages 1005 to 1009) were used in this test. A 1:50 dilution is used for any test. The cell growth inhibition test was performed for 72 hours. All other procedures were described as described in Dong et al., National Academy of Sciences Report (1991), 88, 8495-8499. As for yS-glucuronidase, different extracts of Scutellaria baicalensis were added with a phenol glucuronide ester containing O.lmM, 70 mM Tris-HCl (pH 6.8) and 0.8 ng dialyzed / 3-glucosidase (from E. coli, purchased from Sigma ™) in a triple-well 96-well test dish with a final volume of 80 microliters. After 2 hours incubation at 37 ° C, the reaction was terminated with 200 μl of a stop solution containing 0.2M glycine and 0.2M sodium chloride (ρΗΙ10.4), and its absorbance (OD) was read on a dynamic microdisk The machine is monitored at a wavelength of 540nm. The results of the tests using these three batches are presented in Table 12. ---- Γ --- * ---- install ----- ^ ---- order --------- (Please read the precautions on the back before filling this page) Ministry of Economy Wisdom Printed by the Employees' Cooperatives of the Property Bureau 12. Bioassay of the four preparations of Scutellariae黄 芩 D ND 0.65 ND 27.5 * Represents the IC5Q value ND, the percentage of the control group is not determined 89 This paper size is applicable to the Chinese National Standard (CNS) A4 specification (210 X 297 mm) Printed by the Intellectual Property Bureau Staff Consumer Cooperatives of the Ministry of Economy 1243210 A7 ____B7___ V. Description of the invention (87) Evaluation of the effect of Scutellaria baicalensis on protein performance Prior to drug addition, HepG2 cells (1 X 106) were seeded into 3.0 ml of rpmI-1640 medium in a 25 cm 2 flask (see Life Science and Technology Corporation, Catalog and Reference Guide, 1998-1999, Cell Culture Festival) 24 hours. The cells were treated with or without herbs, of which the former was added at a final concentration of 0.2 mg / ml or 4 mg / ml, respectively, and cultured at 37 ° C for 24 hours. Its medium was removed and its cells were washed twice with iced pBS. The cells were collected in 1 ml of pBS and separated for 2 minutes and 4 minutes on ice. The cells were burned on ice with 50 mM tris (methyl) methylamine gas (ρΗ7.5), 〇_ 2mM PMSF and 10% glycerol buffer extraction followed by two freeze and thaw cycles. Before the centrifugation, potassium chloride was added to the cell lysate at a final concentration of 0.15M. Its protein concentration was determined and its cell extracts were electrophoresed according to the Laemmli method (Nature (1970), 227, pp. 680-685). Western transfer law systems are implemented using standard techniques, see, for example, Sambrok et al. (1989). The anti-system used was directed against the following proteins: TOP; Stat (2007); cyclin B1 (Cyclin Bl), MAPK (antibody 2), and Nm 23 H1. Figure 4 reveals that Scutellaria baicalensis B. and B. did not differentiately affect the performance of the multiple species that were dissolved on the western transfer film. The HPLC analysis of the herb batch was performed on a Beckman ODS Ultrasphere ™ column (5 micron particles, 4.6 mm x 25 cm) by HPLC and analyzed by a UV spectrophotometer ( Platinum Elma) detection. The wavelengths used for UV detection are monitored at 280nm and 34nm. Its dynamic phase is} ml / min (please read the precautions on the back before filling this page) f ----- ^ ---- Order ----

ο 2143 2 Α7Β7 五、發明說明(88) 鐘被推動且包含以如下述之梯度的溶劑A :水和溶劑B : ' 聽甲醇:丨)前5分鐘溶劑為⑽%溶劑A; 2)其次之1〇分梦 溶劑改為溶劑Α/90%溶劑Β ; 3)其次之4〇分鐘溶劑改: 職容劑Α/9〇%溶劑Β。繼之以添加刚%溶劑Α5分鐘。其 高效液相層析標識物為黃芩苷和黃芩素。 在水中及I處理的樣品H批次被以高效液相層析 分析。水及酸處理的批次本質上無法區分。 演算法 所收集的資卿成用於產以變項m布組之多維 分析的-部分,以作為一判定生物活性和標準黃答湯化學 物質(高效液相層析及質譜儀)之間的基準線相關性,以及 起源/生長特性的手段。 c.白芍 白芍之評估 白苟係被用於鎮壓和緩解疼痛。它亦聞名於疏筋和、主 血。被用於本實施例中之白苟批次的性質被表示於表^ 表13.批次性質(白芍) 性質 批次A 批次B 植物名稱 白芍 白芍 來源 安徽省 美國,波士頓 製備方法 標準 煮沸2小時~ 植物部位 根 —---Λ 簡言之’1克之任-配製之白与萃取物被添加10毫升 本紙張尺度翻中國國家標準(CNS)A4規格(21G X 297公釐Τ (請先閱讀背面之注意事項再填寫本頁} ▼裝·----r---訂---- 經濟部智慧財產局員工消費合作社印製 91 1243210 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(89 ) 之水(1毫克/毫升)。其混合物係如簡述於表13中者被處理 。其上清液在離心後被收集,並通過一0.22微米濾紙被過 遽。諸批次之白3針對HepG2細胞(ATCC cat#HB-8065)或ο 2143 2 Α7Β7 V. Description of the invention (88) The clock is pushed and contains a solvent A with a gradient as follows: water and solvent B: 'Listen to methanol: 丨) The solvent is ⑽% solvent A in the first 5 minutes; 2) followed by 10 minutes dream solvent was changed to solvent A / 90% solvent B; 3) followed by 40 minutes solvent change: capacity agent A / 90% solvent B. This was followed by the addition of rigid% solvent A for 5 minutes. Its HPLC markers are baicalin and baicalein. Batch H of sample treated in water and I was analyzed by high performance liquid chromatography. Water and acid treated batches are essentially indistinguishable. The collected by the algorithm was used for multi-dimensional analysis of the variable m cloth group, which was used to determine the biological activity and standard Huang Da Tang chemicals (high performance liquid chromatography and mass spectrometer). Baseline correlation, and means of origin / growth characteristics. c. Evaluation of Baiji Baiji is used to suppress and relieve pain. It is also known for sparse tendons and blood. The properties of the Baigou batches used in this example are shown in Table ^ Table 13. Batch properties (Baiyu) Properties Batch A Batch B Plant name Baizhi Baizhi Source Boston, Anhui, USA Preparation method Standard boiling for 2 hours ~ Plant parts roots --- Λ In short '1g of any-white and extracts are added 10ml This paper is scaled to Chinese National Standard (CNS) A4 (21G X 297mm T (Please read the precautions on the back before filling out this page} ▼ Installation -------- r --- Order ---- Printed by the Employee Consumption Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs 91 1243210 Preparation of A7 B7 V. Description of the invention (89) water (1 mg / ml). The mixture was treated as briefly described in Table 13. The supernatant was collected after centrifugation and passed through a 0.22 micron filter paper. Pass. The batches of White 3 are directed against HepG2 cells (ATCC cat # HB-8065) or

Jurkat細胞(ATCC cat#IB-152)或兩者被測試。1比50稀釋 被用於任一檢測。細胞如前述者被培養24小時。 諸批次亦藉由去氧核糖核酸偵測來估計其抑制B型肝 炎病毒的能力(參見董等人,美國國家科學院報告(1991年) 第88期第8495至8499頁)。簡言之,1克之製劑被附加10毫 升之水。其混合物被煮彿3 0分鐘。其懸浮液在離心後被收 集且通過一 0.22微米滤紙被過濾、。分泌b型肝炎病毒的 HepG2.2· 15細胞(由艾斯教授慨為提供;參見艾斯等人, 美國國家科學院報告(1987年)第84期第1005至1009頁)係 被用於本檢測中。1比50稀釋被用於任一檢測。細胞生長 抑制檢測被施行72小時。所有其他的程序如被描述於董等 人’美國國家科學院報告(1991年)第88期第8495至8499頁 中者被完成。 不同的白芍萃取物被加入一包含O.lmM酚酞葡萄糖醛 酯、70mM三羥甲基胺基甲烷一氫氯酸(Tris_HCl)(pH6.8) 和0.8ng透析過的/5 -葡萄糠醛酸酶(來自大腸桿菌,購自 Sigma™)之三聯槽的96-槽檢測盤中,至最終的體積為80 微升。在攝氏37度培養2小時後,反應被以包含0.2M甘胺 酸和0.2M氣化鈉(ρΗΙΟ.4)之停止溶液200微升終止,且其 吸光度(0D)被以一動態微盤讀取機在540nm波長被監控。 其結果被揭示於表14中。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 92 --------^----裝-----^----訂--------- (請先閱讀背面之注意事項再填寫本頁) 1243210 五、發明說明(9〇 表14.兩種白芍製劑的生物檢測:1ί^〇2 Jurkat 汐-葡萄糖酸酸酶Jurkat cells (ATCC cat # IB-152) or both were tested. A 1:50 dilution is used for any test. Cells were cultured for 24 hours as previously described. The batches were also evaluated for their ability to inhibit hepatitis B virus by DNA detection (see Dong et al., National Academy of Sciences Report (1991) 88 (8495-8499). Briefly, 1 gram of the preparation was added with 10 ml of water. The mixture was boiled for 30 minutes. The suspension was collected after centrifugation and filtered through a 0.22 micron filter paper. HepG2.2 · 15 cells that secrete hepatitis B virus (provided by Professor Ace; see Ace et al., National Academy of Sciences Report (1987) No. 84, pages 1005 to 1009) were used for this test in. A 1:50 dilution is used for any test. The cell growth inhibition test was performed for 72 hours. All other procedures were completed as described in Dong et al., National Academy of Sciences Report (1991), 88, 8495-8499. Different Paeonia lactiflora extracts were added with a phenol glucuronide, 70 mM Tris_HCl (pH 6.8) and 0.8 ng dialyzed / 5-granulofuric acid Enzyme (from E. coli, purchased from Sigma ™) in a triple-well 96-well test dish to a final volume of 80 μl. After 2 hours incubation at 37 ° C, the reaction was terminated with 200 microliters of a stop solution containing 0.2M glycine and 0.2M sodium gasification (ρΗΙ 10.4), and its absorbance (OD) was read on a dynamic microdisk The machine is monitored at a wavelength of 540nm. The results are shown in Table 14. This paper size applies to China National Standard (CNS) A4 specification (210 X 297 mm) 92 -------- ^ ---- install ----- ^ ---- order ----- ---- (Please read the precautions on the back before filling out this page) 1243210 V. Description of the invention (9〇 Table 14. Biological detection of two kinds of Paeonia lactiflora preparations: 1ί ^ 〇2 Jurkat Xi-Gluconidase

HBV *代表IC5Q值 ND,未判定 對照組百分比 經濟部智慧財產局員工消費合作社印製 高效液相色層分析 藥草批次係以一貝克曼0DS Ultrasphere™管柱(5微米 粒子,4.6亳米X25厘米)藉由高效液相層析被分析且被以 一紫外光分光光度計(鉑金艾爾瑪)偵測。用於紫外光偵測 之波長係於280nm和34〇nm被監測。其動相係以工毫升/分 鐘被推動且包含以如下述之梯度的溶劑A :水和溶劑b : 20%甲醇:1)前5分鐘溶劑為100%溶劑a ; 2)其次之ι〇分鐘 溶劑改為10%溶劑A/90%溶劑B ; 3)其次之40分鐘溶劑改為 10%溶劑A/90%溶劑B。繼之以添加100%溶劑A5分鐘。其 高效色層分析標識物為芍藥苷。 白苟批次被以高效液相色層法分析悉如第5圖中所揭 示者。 藥草批次係以一貝克曼ODS Ultrasphere™管柱(5微 粒子,4.6宅求X 2 5厘米)精由兩效液相層析被分析且被 I外光分光光度計(翻金艾爾瑪)偵測。用於紫外光偵 之波長係於280nm和340nm被監測。其動相係以!毫升/名 鐘被推動且包含以如下述之梯度的溶劑A :水和溶劑B 20%甲醇:1)前5分鐘溶劑為100%溶劑A ; 2)其次之1〇分 米 以 測HBV * stands for IC5Q value ND, without determining the percentage of the control group. High-performance liquid chromatographic analysis printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs. Cm) were analyzed by high performance liquid chromatography and detected by a UV spectrophotometer (Platinum Elma). The wavelengths used for UV detection are monitored at 280nm and 34nm. Its mobile phase is pushed at cc / min and contains a solvent A: water and solvent b: 20% methanol: 1) the first 5 minutes of the solvent is 100% of the solvent a; 2) the second minute Solvent was changed to 10% Solvent A / 90% Solvent B; 3) Secondly, the solvent was changed to 10% Solvent A / 90% Solvent B in 40 minutes. This was followed by the addition of 100% solvent A for 5 minutes. Its efficient chromatographic marker is paeoniflorin. The Bai Gou batch was analyzed by high performance liquid chromatography as shown in Figure 5. Herb batches were analyzed by two-effect liquid chromatography with a Beckman ODS Ultrasphere ™ column (5 microparticles, 4.6 cm X 2 5 cm) and analyzed by an external light spectrophotometer (turned gold Elma) Detect. The wavelengths used for UV detection are monitored at 280nm and 340nm. It ’s dynamic! Ml / minute is pushed and contains a solvent A with water and solvent B in a gradient as follows: 20% methanol: 1) the first 5 minutes of the solvent is 100% solvent A; 2) the second 10 dm is measured

* ^ ------------- (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 93 1243210 A7* ^ ------------- (Please read the notes on the back before filling out this page) This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) 93 1243210 A7

經濟部智慧財產局員工消費合作社印製 五、發明說明(91 ) 溶劑改為10%溶劑A/90%溶劑B ; 3)其次之4〇分鐘溶劑改為 10%溶劑A/90%溶劑B。繼之以添加1〇〇%溶劑A5分鐘。 D.大棗 大棗之評估 大棗已被用於利尿性質和強壯作用。被用於本實施例 之诸大棗批次的特性係被表示於表1 5中。 表15·批次性質(大棗) 性質 批次A 批次B 批次C 植物名稱 大棗 大棗 大棗 來源 河北省 美國,金門 藥草中心 美國,金門 藥草中心 製備方法 ^標準 煮沸30分鐘 &水,30分鐘 植物部位 果實 - - 生物及酵素檢測 簡言之’ 1克之任一配製之大棗萃取物被添加1〇毫升 之水(1毫克/亳升)。其混合物係如簡述於表丨5中者被處理 。其上清液在離心後被收集,並通過一〇·22微米濾紙被過 濾、。諸批次之大棗針對HepG2細胞(ATCC cat#HB-8065)或 Jurkat細胞(ATCC cat#IB-152)或兩者被測試。1比50稀釋 被用於任一檢測。細胞被培養24小時悉如前述者。 諸批次亦藉由去氧核糖核酸偵測來估計其抑制B型肝 炎病毒的能力(參見董等人,美國國家科學院報告(丨991年) 第88期第8糾5至8499頁)。簡言之,1克之製劑被附加1〇亳 升之水。其混合物被煮沸30分鐘。其懸浮液在離心後被收 集且通過一 0.22微米濾紙被過濾。分泌b型肝炎病毒的 本紙張尺度適用中國國家標準(CNS)A4規格(21〇 χ 297公釐) 94 illflIt — — — — -----r---^ ·11111111 i (請先閲讀背面之注意事項再填寫本頁) 1243210 經濟部智慧財產局員工消費合作社印製 A7 五、發明說明(92)Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs. 5. Description of the invention (91) Solvent was changed to 10% Solvent A / 90% Solvent B; 3) The next 40 minutes was changed to 10% Solvent A / 90% Solvent B. This was followed by the addition of 100% solvent A for 5 minutes. D. Jujube Jujube Jujube Jujube has been used for diuretic properties and strengthening effects. The characteristics of the jujube batches used in this example are shown in Table 15. Table 15 · Batch properties (Jujube) Nature Batch A Batch B Batch C Plant name Jujube Jujube Jujube Source Hebei Jinmen Herb Center United States, Jinmen Herb Center Preparation method ^ Standard boiling 30 minutes & Water, fruits of plant parts for 30 minutes-biological and enzyme test Briefly, 1 gram of any prepared jujube extract is added with 10 ml of water (1 mg / ml). The mixture is treated as briefly described in Table 5. The supernatant was collected after centrifugation and filtered through a 10.22 micron filter paper. Batches of jujube were tested against HepG2 cells (ATCC cat # HB-8065) or Jurkat cells (ATCC cat # IB-152) or both. A 1:50 dilution is used for any test. Cells were cultured for 24 hours as described above. The batches also used DNA detection to estimate their ability to inhibit hepatitis B virus (see Dong et al., National Academy of Sciences Report (丨 991), 88, pp. 8-8499). Briefly, 1 gram of the preparation was added with 10 liters of water. Its mixture was boiled for 30 minutes. The suspension was collected after centrifugation and filtered through a 0.22 micron filter paper. The size of this paper that secretes hepatitis B virus is applicable to the Chinese National Standard (CNS) A4 (21〇χ 297 mm) 94 illflIt — — — — ----- r --- ^ · 11111111 i (Please read the back first Please note this page and fill in this page again) 1243210 Printed by the Consumer Cooperative of the Intellectual Property Bureau of the Ministry of Economic Affairs A7 V. Description of Invention (92)

HepG2.2.15細胞(由艾斯教授慨為提供;參見艾斯等人, 美國國家科學院報告(1987年)第84期第】〇〇5至1〇〇9頁)係 被用於本檢測中。1比5〇稀释被用於任一檢測。細胞生長 抑制檢測被施行72小時。所有其他的程序如被描述於董等 人,美國國豕科學院報告(1991年)第88期第8495至8499頁 中者被完成。 不同的大棗卒取物被加入一包含〇.lmM酚酞葡萄糖醛 酯、70 mM二羥甲基胺基曱烷一氫氯酸(Tris_HC1)(pH6 8) 和0.8ng透析過的冷-葡萄糖醛酸酶(來自大腸桿菌,購自 Sigma™)之三聯槽的96_槽檢測盤中,至最終的體積為8〇 微升。在攝氏37度培養2小時後,反應被以包含0.2M甘胺 酸和0.2M氣化鈉(pH 10.4)之停止溶液2〇〇微升終止,且其 <吸光度(OD)被以一動態微盤讀取機在54〇nm波長被監控。 其結果被呈現於表16中。 表16.大棗之三種製劑的生物檢測* 大腸桿菌 冷-葡萄糖醛酸酶 HepG2 Jurkat HBV: DNA 大棗A 1.2 1.5 5.1 無 大棗B ND >2.0 ND 52.3 大棗c 2.5 ND ND ND *代表IC5。值 ::對照組百分比 ND,未判定 局效液相層析 藥草批次係以一貝克曼〇DS Ultrasphere™管柱(5微米 粒子,4.6毫米X25厘米)藉由高效液相層析被分析且被以 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 95 -裝-----^—訂---------. (請先閱讀背面之注意事項再填寫本頁) 1243210HepG2.2.15 cells (provided by Professor Ace; see Ace et al., National Academy of Sciences Report (1987) No. 84, pp. 005 to 109) were used in this test. A 1 to 50 dilution was used for either assay. The cell growth inhibition test was performed for 72 hours. All other procedures were described as described in Dong et al., National Academy of Sciences Report (1991), 88, 8495-8499. Different jujube extracts were added with 0.1 mM phenolphthalein glucuronide, 70 mM dimethylolaminopanehydrochloric acid (Tris_HC1) (pH 6 8) and 0.8 ng dialyzed cold-glucosaldehyde Acidase (from E.coli, purchased from Sigma ™) in a 96-well 96-well test dish with a triple well to a final volume of 80 microliters. After 2 hours incubation at 37 ° C, the reaction was terminated with 200 μl of a stop solution containing 0.2M glycine and 0.2M sodium gasification (pH 10.4), and its < absorbance (OD) was changed with a dynamic The microdisk reader is monitored at a wavelength of 54nm. The results are presented in Table 16. Table 16. Biological detection of three preparations of jujube * E. coli cold-glucuronidase HepG2 Jurkat HBV: DNA Jujube A 1.2 1.5 5.1 Jujube B ND > 2.0 ND 52.3 Jujube c 2.5 ND ND ND * Representative IC5. Value: Control group percentage ND. Undetermined LC LC batches were analyzed by high performance liquid chromatography on a Beckman ØDS Ultrasphere ™ column (5 micron particles, 4.6 mm x 25 cm). Applicable to Chinese paper standard (CNS) A4 (210 X 297 mm) at this paper size 95 -pack ----- ^-order ---------. (Please read the notes on the back first (Fill in this page again) 1243210

經濟部智慧財產局員工消費合作社印製 五、發明說明(93) 一紫外光分光光度計(鉑金艾爾瑪)偵測。用於紫外光偵測 之波長係於280mn和34〇nm被監測。其動相係以i毫升/分 鐘被推動且包含以如下述之梯度的溶劑A :水和溶劑B : 20%甲醇:1)前5分鐘溶劑為100%溶劑a ; 2)其次之分鐘 溶劑改為10%溶劑A/90%溶劑B ; 3)其次之4〇分鐘溶劑改為 10%溶劑A/90%溶劑B。繼之以添加100%溶劑A5分鐘。大 棗之高效液相層析標識物為棗酸和環·腺苷單磷酸。 大棗批次被由高效液相色層分析悉如第6圖中所揭示 者。 /、 演算法 所收集的資料形成用於產生多變項常態分布組之多維 分析的一部分,以作為一判定生物活性和標準黃芩湯化學 物質(高效液相層析及質譜儀)之間的基準線相關性,以及 起源/生長特性的手段。 以上之洋細說明僅為了解之清晰而設並且務須了解由 此並無不必要的限制,因為對熟習此項技藝者而言,變更 將為顯而易見者。 儘管本發明已連同其中之特定的實施例被描述,須明 白的是其堪為進一步的變更且本發明意圖涵蓋大體上遵循 本务明之原理的本發明之任何的變異、用途或調整且包含 諸如落在本發明所屬之技藝之習知或慣例上的實務和可被 應用於本文先前所載述之必須的特徵和遵循在申請專利範 圍内之本發明的新發展。 本紙張尺度義 ----*1;--^-------- l·---訂--------- & (請先閱讀背面之注意事項再填寫本頁) 96Printed by the Consumer Cooperatives of the Intellectual Property Bureau of the Ministry of Economic Affairs. 5. Description of the Invention (93) A UV spectrophotometer (Platinum Elma) detection. The wavelengths used for UV detection are monitored at 280mn and 34nm. The mobile phase is pushed at 1 ml / min and contains a solvent A: water and solvent B: 20% methanol with a gradient as follows: 1) the first 5 minutes of the solvent is 100% of the solvent a; 2) the second minute of the solvent change 10% solvent A / 90% solvent B; 3) followed by 40 minutes solvent changed to 10% solvent A / 90% solvent B. This was followed by the addition of 100% solvent A for 5 minutes. The HPLC markers of jujube are date acid and cyclic adenosine monophosphate. Jujube batches were analyzed by HPLC chromatography as disclosed in Figure 6. / 、 The data collected by the algorithm form part of a multidimensional analysis used to generate a multivariate normal distribution group, as a benchmark for determining biological activity and standard Huangqintang chemicals (high performance liquid chromatography and mass spectrometer) Line correlation, and means of origin / growth characteristics. The above detailed description is only for clarity of understanding and it must be understood that there are no unnecessary restrictions, because for those skilled in the art, the change will be obvious. Although the invention has been described in connection with specific embodiments thereof, it should be understood that it can be further modified and that the invention is intended to cover any variations, uses, or adaptations of the invention that generally follow the principles of the present invention and includes such Practices that fall on the knowledge or practice of the technology to which this invention pertains may be applied to the necessary features previously described herein and to follow new developments of the invention within the scope of the patent application. Dimensions of this paper ---- * 1;-^ -------- l · --- Order --------- & (Please read the notes on the back before filling in this (Page) 96

Claims (1)

六、申請專利範圍 第089HM268號專利申靖幸由咬 j T明累申凊專利範圍修正本 I 一種用於評估一筚草组成 ;日』·94年5月 同的藥草組成物或是實Iπ 玄相 一 飞疋貝貝上與之相同的藥草組成物之 的等效性之品質管制方法,其中該藥草組 匕3有何生自一或多種全株植物或植物部分的多 種化學組份,該品質管制方法包含: 化批 次; a.選擇-藥草組成物之—製備物來供作為該標準 b·藉由下歹,J來特徵化一有關於該標準化批次的藥草生 物反應(HBR)陣列: 、 將特徵化生物系統活體外地暴露給該標準化 批次,與該特徵化生物系統之一未處理對照組作 比較以檢定一區分性的基因表現輪廓,以及獲得 -有關於該標準化批次的基因表現變化的陣 列;以及 ϋ.將步驟b⑴中所得到的基因表現變化陣列健存 至一標準化的HBR陣列内; c.藉由下列來特徵化一有關於該測試批次的藥草生物 反應(HBR)陣列: 1•將步驟b⑴中所使用的特徵化生物系統活體外 地暴露給該測試批次,與該特徵化生物系統之一 未處理對照組作比較以檢定區分性的基因表現 輪廓’以及獲得一有關於該測試批次的基因表現 1243210 /、、申晴專利範圍 變化陣列;以及 Π.將步驟C⑴中所得到的基因表?見變化 至—測試HBR陣列内; 存 d.藉由比較基因表現強度與基因表現型式來評估該炉 準化職陣列與該測試職陣列之間的量化相似 度數值;以及 ^利用㈣d巾所得到的相似度數值㈣估該測試批 次與該標準化批次的等效性,以達品質管制之目的。 2·如申請專利範圍第旧的方法,其中該特徵化生物系統 係選自於由下列所構成之群組··經分離之細胞、經分離 之組織、經分離之器官,以及其它形式之活體外分析。 3·如申請專利範圍第"員的方法,其中基因表現轉錄地發 生。 4·如申請專利範圍第1項的方法,其中該量化相似度數值 係使用該標準化HBR陣列與該測試HBR陣列的常態化 數值而被估算出。 -98-Sixth, the scope of application for patent No. 089HM268 patent application Jing Xing is composed of bite j T Minglei application patent scope amendment I a type used to evaluate the composition of a yarrow grass; the same herb composition or real Iπ in May 1994 A quality control method for the equivalence of the same herb composition on the Hida Babe, wherein the herb group 3 has multiple chemical components derived from one or more whole plants or plant parts, the The quality control method includes: a batch; a. Selection-herb composition-preparation for use as the standard b. By yoke, J to characterize a biological response (HBR) to the standardized batch Array: Exposing the characterizing biological system to the standardized batch in vitro, comparing it with an untreated control group of the characterizing biological system to test a distinguishing gene expression profile, and obtaining-related to the standardized batch Array of gene expression change; and ϋ. Save the array of gene expression change obtained in step b⑴ into a standardized HBR array; c. Characterize a correlation by The Herbal Biological Response (HBR) array of the test batch: 1 • Expose the characteristic biological system used in step b⑴ to the test batch in vitro and compare it with one of the untreated control groups of the characteristic biological system to compare Test the distinguishing gene expression profile 'and obtain an array of gene expression 1243210 /, Shen Qing patent range change arrays related to the test batch; and Π. Change the gene table obtained in step C⑴ to see to test HBR Within the array; storing d. Evaluating the quantitative similarity value between the furnace standardization array and the test array by comparing the gene expression intensity and the gene expression pattern; and ^ estimating the similarity value obtained using the ㈣d towel The equivalence between the test batch and the standardized batch for quality control purposes. 2. The oldest method as claimed in the patent application, wherein the characteristic biological system is selected from the group consisting of: isolated cells, isolated tissues, isolated organs, and other forms of living organisms Outside analysis. 3. A method as described in the patent application, in which the gene expression occurs transcribed. 4. The method according to item 1 of the patent application range, wherein the quantized similarity value is estimated using the normalized values of the standardized HBR array and the test HBR array. -98-
TW089104268A 1999-10-22 2000-03-09 A quality control method for assessing herbal compositions TWI243210B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/024851 WO2000024934A1 (en) 1998-10-23 1999-10-22 Phytomics: a genomic-based approach to herbal compositions

Publications (1)

Publication Number Publication Date
TWI243210B true TWI243210B (en) 2005-11-11

Family

ID=37025328

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089104268A TWI243210B (en) 1999-10-22 2000-03-09 A quality control method for assessing herbal compositions

Country Status (1)

Country Link
TW (1) TWI243210B (en)

Similar Documents

Publication Publication Date Title
TWI275792B (en) Matrix methods for quantitatively analyzing and assessing the properties of botanical samples
US20030207270A1 (en) Phytomics: a genomic-based approach to herbal compositions
Li et al. Identification of bioactive compounds and potential mechanisms of kuntai capsule in the treatment of polycystic ovary syndrome by integrating network pharmacology and bioinformatics
Zhou et al. Systems pharmacology uncovers the mechanisms of anti-asthma herbal medicine intervention (ASHMI) for the prevention of asthma
KR100470379B1 (en) Phytomics: a genomic-based approach to herbal compositions
KR20030017459A (en) Phytomics: a genomic-based approach to herbal compositions
Lin et al. Systematic elucidation of the bioactive alkaloids and potential mechanism from Sophora flavescens for the treatment of eczema via network pharmacology
Wen et al. Correlation analysis between genetic and chemical differences of Nardostachys jatamansi from different habitats in Ganzi Tibetan Autonomous Prefecture, Sichuan Province, China
Uddin et al. Amaranthus viridis modulates anti-hyperglycemic pathways in hemi-diaphragm and improves glycogenesis liver function in rats
TWI243210B (en) A quality control method for assessing herbal compositions
Wang et al. Effect of Huangqin Tang on colonic gene expression in rats with ulcerative colitis
JP5984882B2 (en) Method for quantifying skin changes caused by six indecent nuisances, and screening method for skin improving substances using the same
Song et al. Anti-inflammatory effects of Capparis ecuadorica extract in phthalic-anhydride-induced atopic dermatitis of IL-4/Luc/CNS-1 transgenic mice
Bao et al. Exploring anti-type 2 diabetes mellitus mechanism of gegen qinlian decoction by network pharmacology and experimental validation
Wang et al. Investigation of the mechanism of periploca forrestii against rheumatoid arthritis with network pharmacology-based analysis
CN112843049A (en) Application of composition in preparing medicine for inhibiting gastric cancer cell proliferation based on regulation of CDKs and SMAD6 genes
AU2005201751A1 (en) Phytomics: a genomic-based approach to herbal compositions
Wang et al. New insights of low-temperature plasma effects on seeds germination of Platycodon grandiflorum
Kumar Ayurveda Renaissance–Quo Vadis?
CN113827669B (en) Traditional Chinese medicine composition for treating acute lung injury/acute respiratory distress syndrome and application thereof
Zhang et al. Gel-forming Mucins in Oviductus Ranae Contribute to Swelling Capacity by iTRAQ Proteomics Analysis
Wang et al. Effects of plant density on alfalfa (Medicago sativa L.) seed yield in western Heilongjiang areas
Ren et al. Network pharmacology-based prediction of underlying mechanisms of Glycyrrhiza uralensis Fisch and Anglica sinensis (Oliv.) Diels in the treatment of breast cancer
CN116574797A (en) Construction method and application of anti-osteoporosis zebra fish biomarker and anti-osteoporosis zebra fish model of American ginseng
Zhang et al. Mechanisms of action of Shizhenqing granules for eczema treatment: Network pharmacology analysis and experimental validation

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees